

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12833 A2**

(51) International Patent Classification<sup>7</sup>: C12P 7/00

(21) International Application Number: PCT/US00/22874

(22) International Filing Date: 18 August 2000 (18.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/149,534 18 August 1999 (18.08.1999) US

(71) Applicants (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94303 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EMPTAGE, Mark [US/US]; 2822 Landon Drive, Wilmington, DE 19810 (US). HAYNIE, Sharon [US/US]; 529 Spruce Street,

Philadelphia, PA 19106 (US). LAFFEND, Lisa [US/US]; 2 Mount Vernon Drive, Claymont, DE 19703 (US). PUCCI, Jeff [US/US]; 925 Page Mill Road, Palo Alto, CA 94303 (US). WHITED, Greg [US/US]; 304 South Road, Belmont, CA 94002 (US).

(74) Agent: FLOYD, Linda, Axamethy; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States (national): BR, CA, CN, ID, IN, JP, KR, MX, SG, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE BIOLOGICAL PRODUCTION OF 1,3-PROPANEDIOL WITH HIGH TITER

A2



**WO 01/12833** (57) Abstract: The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an *E. coli* transformed with the *Klebsiella pneumoniae* dha regulon genes *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3*, and *orfZ*, all these genes arranged in the same genetic organization as found in wild type *Klebsiella pneumoniae*. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (*dhaT*). The dramatically improved process relies on the presence in *E. Coli* of a gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropi-aldehyde to 1,3-propanediol.

TITLEPROCESS FOR THE BIOLOGICAL PRODUCTION  
OF 1,3-PROPANEDIOL WITH HIGH TITERFIELD OF INVENTION

5 This invention comprises process for the bioconversion of a fermentable carbon source to 1,3-propanediol by a single microorganism.

BACKGROUND

1,3-Propanediol is a monomer having potential utility in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds.

10 A variety of chemical routes to 1,3-propanediol are known. For example ethylene oxide may be converted to 1,3-propanediol over a catalyst in the presence of phosphine, water, carbon monoxide, hydrogen and an acid, by the catalytic solution phase hydration of acrolein followed by reduction, or from compounds such as glycerol, reacted in the presence of carbon monoxide and hydrogen over 15 catalysts having atoms from group VIII of the periodic table. Although it is possible to generate 1,3-propanediol by these methods, they are expensive and generate waste streams containing environmental pollutants.

It has been known for over a century that 1,3-propanediol can be produced from the fermentation of glycerol. Bacterial strains able to produce 20 1,3-propanediol have been found, for example, in the groups *Citrobacter*, *Clostridium*, *Enterobacter*, *Ilyobacter*, *Klebsiella*, *Lactobacillus*, and *Pelobacter*. In each case studied, glycerol is converted to 1,3-propanediol in a two step, enzyme catalyzed reaction sequence. In the first step, a dehydratase catalyzes the conversion of glycerol to 3-hydroxypropionaldehyde (3-HPA) and water, 25 Equation 1. In the second step, 3-HPA is reduced to 1,3-propanediol by a NAD<sup>+</sup>-linked oxidoreductase, Equation 2. The 1,3-propanediol is not metabolized further and, as a result,



accumulates in the media. The overall reaction consumes a reducing equivalent in the form of a cofactor, reduced β-nicotinamide adenine dinucleotide (NADH), which is oxidized to nicotinamide adenine dinucleotide (NAD<sup>+</sup>).

35 In *Klebsiella pneumonia*, *Citrobacter freundii*, and *Clostridium pasteurianum*, the genes encoding the three structural subunits of glycerol dehydratase (*dhaB1-3* or *dhaB, C and E*) are located adjacent to a gene encoding a specific 1,3-propanediol oxidoreductase (*dhaT*) (see Figure 1). Although the

genetic organization differs somewhat among these microorganisms, these genes are clustered in a group which also comprises *orfX* and *orfZ* (genes encoding a dehydratase reactivation factor for glycerol dehydratase), as well as *orfY* and *orfW* (genes of unknown function). The specific 1,3-propanediol oxidoreductases (5 *dhaT*'s) of these microorganisms are known to belong to the family of type III alcohol dehydrogenases; each exhibits a conserved iron-binding motif and has a preference for the NAD<sup>+</sup>/NADH linked interconversion of 1,3-propandiol and 3-HPA. However, the NAD<sup>+</sup>/NADH linked interconversion of 1,3-propandiol and 3-HPA is also catalyzed by alcohol dehydrogenases which are not specifically 10 linked to dehydratase enzymes (for example, horse liver and baker's yeast alcohol dehydrogenases (E.C. 1.1.1.1)), albeit with less efficient kinetic parameters. Glycerol dehydratase (E.C. 4.2.1.30) and diol [1,2-propanediol] dehydratase (E.C. 4.2.1.28) are related but distinct enzymes that are encoded by distinct genes. Diol dehydratase genes from *Klebsiella oxytoca* and *Salmonella typhimurium* are 15 similar to glycerol dehydratase genes and are clustered in a group which comprises genes analogous to *orfX* and *orfZ* (Daniel et al., *FEMS Microbiol. Rev.* 22, 553 (1999); Toraya and Mori, *J. Biol. Chem.* 274, 3372 (1999); GenBank AF026270).

The production of 1,3-propanediol from glycerol is generally performed 20 under anaerobic conditions using glycerol as the sole carbon source and in the absence of other exogenous reducing equivalent acceptors. Under these conditions, in e.g., strains of *Citrobacter*, *Clostridium*, and *Klebsiella*, a parallel pathway for glycerol operates which first involves oxidation of glycerol to dihydroxyacetone (DHA) by a NAD<sup>+</sup>- (or NADP<sup>+</sup>-) linked glycerol 25 dehydrogenase, Equation 3. The DHA, following phosphorylation to dihydroxyacetone phosphate (DHAP) by a DHA kinase (Equation 4),



30 becomes available for biosynthesis and for supporting ATP generation via e.g., glycolysis. In contrast to the 1,3-propanediol pathway, this pathway may provide carbon and energy to the cell and produces rather than consumes NADH.

In *Klebsiella pneumoniae* and *Citrobacter freundii*, the genes encoding the 35 functionally linked activities of glycerol dehydratase (*dhaB*), 1,3-propanediol oxidoreductase (*dhaT*), glycerol dehydrogenase (*dhaD*), and dihydroxyacetone kinase (*dhaK*) are encompassed by the *dha* regulon. The *dha* regulon, in *Klebsiella pneumoniae* and *Citrobacter freundii*, also encompasses a gene

encoding a transcriptional activator protein (*dhaR*). The *dha* regulons from *Citrobacter* and *Klebsiella* have been expressed in *Escherichia coli* and have been shown to convert glycerol to 1,3-propanediol.

Neither the chemical nor biological methods described above for the production of 1,3-propanediol are well suited for industrial scale production since the chemical processes are energy intensive and the biological processes are limited to relatively low titer from the expensive starting material, glycerol. These drawbacks could be overcome with a method requiring low energy input and an inexpensive starting material such as carbohydrates or sugars, or by increasing the metabolic efficiency of a glycerol process. Development of either method will require the ability to manipulate the genetic machinery responsible for the conversion of sugars to glycerol and glycerol to 1,3-propanediol.

Biological processes for the preparation of glycerol are known. The overwhelming majority of glycerol producers are yeasts but some bacteria, other fungi and algae are also known. Both bacteria and yeasts produce glycerol by converting glucose or other carbohydrates through the fructose-1,6-bisphosphate pathway in glycolysis or the Embden Meyerhof Parnas pathway, whereas, certain algae convert dissolved carbon dioxide or bicarbonate in the chloroplasts into the 3-carbon intermediates of the Calvin cycle. In a series of steps, the 3-carbon intermediate, phosphoglyceric acid, is converted to glyceraldehyde 3-phosphate which can be readily interconverted to its keto isomer dihydroxyacetone phosphate and ultimately to glycerol.

Specifically, the bacteria *Bacillus licheniformis* and *Lactobacillus lycopersica* synthesize glycerol, and glycerol production is found in the halotolerant algae *Dunaliella sp.* and *Asteromonas gracilis* for protection against high external salt concentrations. Similarly, various osmotolerant yeasts synthesize glycerol as a protective measure. Most strains of *Saccharomyces* produce some glycerol during alcoholic fermentation, and this can be increased physiologically by the application of osmotic stress. Earlier this century commercial glycerol production was achieved by the use of *Saccharomyces* cultures to which "steering reagents" were added such as sulfites or alkalis. Through the formation of an inactive complex, the steering agents block or inhibit the conversion of acetaldehyde to ethanol; thus, excess reducing equivalents (NADH) are available to or "steered" towards DHAP for reduction to produce glycerol. This method is limited by the partial inhibition of yeast growth that is due to the sulfites. This limitation can be partially overcome by the use of alkalis that create excess NADH equivalents by a different mechanism. In this practice,

the alkalis initiated a Cannizarro disproportionation to yield ethanol and acetic acid from two equivalents of acetaldehyde.

5       The gene encoding glycerol-3-phosphate dehydrogenase (DAR1, GPD1) has been cloned and sequenced from *S. diastaticus* (Wang et al., *J. Bact.* 176, 7091-7095 (1994)). The DAR1 gene was cloned into a shuttle vector and used to transform *E. coli* where expression produced active enzyme. Wang et al. (*supra*) recognize that DAR1 is regulated by the cellular osmotic environment but do not suggest how the gene might be used to enhance 1,3-propanediol production in a recombinant microorganism.

10      Other glycerol-3-phosphate dehydrogenase enzymes have been isolated: for example, sn-glycerol-3-phosphate dehydrogenase has been cloned and sequenced from *Saccharomyces cerevisiae* (Larason et al., *Mol. Microbiol.* 10, 1101 (1993)) and Albertyn et al. (*Mol. Cell. Biol.* 14, 4135 (1994)) teach the cloning of GPD1 encoding a glycerol-3-phosphate dehydrogenase from *Saccharomyces cerevisiae*. Like Wang et al. (*supra*), both Albertyn et al. and Larason et al. recognize the osmo-sensitivity of the regulation of this gene but do not suggest how the gene might be used in the production of 1,3-propanediol in a recombinant microorganism.

15      As with G3PDH, glycerol-3-phosphatase has been isolated from *Saccharomyces cerevisiae* and the protein identified as being encoded by the GPP1 and GPP2 genes (Norbeck et al., *J. Biol. Chem.* 271, 13875 (1996)). Like the genes encoding G3PDH, it appears that GPP2 is osmosensitive.

20      Although a single microorganism conversion of fermentable carbon source other than glycerol or dihydroxyacetone to 1,3-propanediol is desirable, it has been documented that there are significant difficulties to overcome in such an endeavor. For example, Gottschalk et al. (EP 373 230) teach that the growth of most strains useful for the production of 1,3-propanediol, including *Citrobacter freundii*, *Clostridium autotrophicum*, *Clostridium butylicum*, and *Klebsiella pneumoniae*, is disturbed by the presence of a hydrogen donor such as fructose or glucose. Strains of *Lactobacillus brevis* and *Lactobacillus buchneri*, which produce 1,3-propanediol in co-fermentations of glycerol and fructose or glucose, do not grow when glycerol is provided as the sole carbon source, and, although it has been shown that resting cells can metabolize glucose or fructose, they do not produce 1,3-propanediol (Veiga DA Cunha et al., *J. Bacteriol.*, 174, 1013 (1992)).  
25      Similarly, it has been shown that a strain of *Ilyobacter polytropus*, which produces 1,3-propanediol when glycerol and acetate are provided, will not produce 1,3-propanediol from carbon substrates other than glycerol, including fructose and

5 glucose (Steib et al., *Arch. Microbiol.* 140, 139 (1984)). Finally, Tong et al. (*Appl. Biochem. Biotech.* 34, 149 (1992)) taught that recombinant *Escherichia coli* transformed with the *dha* regulon encoding glycerol dehydratase does not produce 1,3-propanediol from either glucose or xylose in the absence of exogenous glycerol.

10 Attempts to improve the yield of 1,3-propanediol from glycerol have been reported where co-substrates capable of providing reducing equivalents, typically fermentable sugars, are included in the process. Improvements in yield have been claimed for resting cells of *Citrobacter freundii* and *Klebsiella pneumoniae* DSM 4270 co-fermenting glycerol and glucose (Gottschalk et al., *supra*; and Tran-Dinh et al., DE 3734 764); but not for growing cells of *Klebsiella pneumoniae* ATCC 25955 co-fermenting glycerol and glucose, which produced no 1,3-propanediol (I-T. Tong, Ph.D. Thesis, University of Wisconsin-Madison (1992)). Increased yields have been reported for the cofermentation of glycerol 15 and glucose or fructose by a recombinant *Escherichia coli*; however, no 1,3-propanediol is produced in the absence of glycerol (Tong et al., *supra*). In these systems, single microorganisms use the carbohydrate as a source of generating NADH while providing energy and carbon for cell maintenance or growth. These disclosures suggest that sugars do not enter the carbon stream that 20 produces 1,3-propanediol.

Recently, however, the conversion of carbon substrates, other than glycerol or dihydroxyacetone, to 1,3-propanediol by a single microorganism that expresses a dehydratase enzyme has been described (U.S. 5,686,276; WO 9821339; WO 9928480; and WO 9821341 (US 6013494)). A specific 25 deficiency in the biological processes leading to the production of 1,3-propanediol from either glycerol or glucose has been the low titer of the product achieved via fermentation; thus, an energy-intensive separation process to obtain 1,3-propanediol from the aqueous fermentation broth is required. Fed batch or batch fermentations of glycerol to 1,3-propanediol have led to final titers of 65 g/L 30 by *Clostridium butyricum* (Saint-Amans et al., *Biotechnology Letters* 16, 831 (1994)), 71 g/L by *Clostridium butyricum* mutants (Abbad-Andaloussi et al., *Appl. Environ. Microbiol.* 61, 4413 (1995)), 61 g/L by *Klebsiella pneumoniae* (Homann et al., *Appl. Microbiol. Biotechnol.* 33, 121 (1990)), and 35 g/L by *Citrobacter freundii* (Homann et al., *supra*). Fermentations of glucose to 1,3-propanediol that 35 exceed the titer obtained from glycerol fermentations have not yet been disclosed.

The problem that remains to be solved is how to biologically produce 1,3-propanediol, with high titer and by a single microorganism, from an

inexpensive carbon substrate such as glucose or other sugars. The biological production of 1,3-propanediol requires glycerol as a substrate for a two-step sequential reaction in which a dehydratase enzyme (typically a coenzyme B<sub>12</sub>-dependent dehydratase) converts glycerol to an intermediate,  
5 3-hydroxypropionaldehyde, which is then reduced to 1,3-propanediol by a NADH- (or NADPH) dependent oxidoreductase. The complexity of the cofactor requirements necessitates the use of a whole cell catalyst for an industrial process that utilizes this reaction sequence for the production of 1,3-propanediol.

#### SUMMARY OF THE INVENTION

10 Applicants have solved the stated problem and the present invention provides for bioconverting a fermentable carbon source directly to 1,3-propanediol at significantly higher titer than previously obtained and with the use of a single microorganism. Glucose is used as a model substrate and *E. coli* is used as the model host. In one aspect of this invention, recombinant *E. coli* expressing a group of genes (comprising genes that encode a dehydratase activity, a dehydratase reactivation factor, a 1,3-propanediol oxidoreductase (*dhaT*), a glycerol-3-phosphate dehydrogenase, and a glycerol-3-phosphatase) convert glucose to 1,3-propanediol at titer that approaches that of glycerol to 1,3-propanediol fermentations.  
15  
20 In another aspect of this invention, the elimination of the functional *dhaT* gene in this recombinant *E. coli* results in a significantly higher titer of 1,3-propanediol from glucose. This unexpected increase in titer results in improved economics, and thus, an improved process for the production of 1,3-propanediol from glucose.  
25 Furthermore, the present invention may be generally applied to include any carbon substrate that is readily converted to 1) glycerol, 2) dihydroxyacetone, 3) C<sub>3</sub> compounds at the oxidation state of glycerol (e.g., glycerol 3-phosphate), or 4) C<sub>3</sub> compounds at the oxidation state of dihydroxyacetone (e.g., dihydroxyacetone phosphate or glyceraldehyde 3-phosphate). The production of  
30 1,3-propanediol in the *dhaT* minus strain requires a non-specific catalytic activity that converts 3-HPA to 1,3-propanediol. Identification of the enzyme(s) and/or gene(s) responsible for the non-specific catalytic activity that converts 3-HPA to 1,3-propanediol will lead to production of 1,3-propanediol in a wide range of host microorganisms with substrates from a wide range of carbon-containing  
35 substrates. It is also anticipated that the use of this non-specific catalytic activity that converts 3-HPA to 1,3-propanediol will lead to an improved process for the

production of 1,3-propanediol from glycerol or dihydroxyacetone, by virtue of an improved titer and the resulting improved economics.

This activity has been isolated from *E. coli* as a nucleic acid fragment encoding a non-specific catalytic activity for the conversion of 3-

5 hydroxypropionaldehyde to 1,3-propanediol, as set out in SEQ ID NO:58 or as selected from the group consisting of:

- (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence of SEQ ID NO:57;
- (b) an isolated nucleic acid fragment that is substantially similar to 10 an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence of SEQ ID NO:57;
- (c) an isolated nucleic acid fragment encoding a polypeptide of at least 387 amino acids having at least 80% with the amino acid sequence of SEQ ID NO:57;
- 15 (d) an isolated nucleic acid fragment that hybridizes with (a) under hybridization conditions of 0.1X SSC, 0.1% SDS, 65 °C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS; and
- (d) an isolated nucleic acid fragment that is complementary to (a), 20 (b), (c), or (d). Alternatively, the nonspecific catalytic acitivity is embodieed in the polypeptide as set out in SEQ ID NO:57.

A chimeric gene may be constructed comprising the isolated nucleic acid fragment described above operably linked to suitable regulatory sequences. This chimeric gene can be used to transform microorganisms selected from the group 25 consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Salmonella*, *Bacillus*, *Aerobacter*, *Streptomyces*, *Escherichia*, and *Pseudomonas*. *E. coli* is the 30 preferred host.

Accordingly, the present invention provides a recombinant microorganism, useful for the production of 1,3-propanediol comprising: (a) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (b) at least one gene encoding a polypeptide having glycerol-3-phosphatase 35 activity; (c) at least one gene encoding a polypeptide having a dehydratase activity; (d) at least one gene encoding a dehydratase reactivation factor; (e) at least one endogenous gene encoding an non-specific catalytic activity sufficient to

convert 3-hydroxypropionaldehyde to 1,3-propanediol, wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase is present. The preferred embodiment is a recombinant microorganism (preferably *E. coli*) where no *dhaT* gene is present. Optionally, the recombinant microorganism may comprise

5 mutations (e.g., deletion mutations or point mutations) in endogenous genes selected from the group consisting of: (a) a gene encoding a polypeptide having glycerol kinase activity; (b) a gene encoding a polypeptide having glycerol dehydrogenase activity; and (c) gene encoding a polypeptide having triosephosphate isomerase activity.

10 In another embodiment the invention includes a process for the production of 1,3-propanediol comprising:(a) contacting, under suitable conditions, a recombinant *E. coli* comprising a *dha* regulon and lacking a functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity with at least one carbon source, wherein the carbon source is selected from the group consisting of

15 monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates; and (b) optionally recovering the 1,3-propanediol produced in (a).

The invention also provides a process for the production of 1,3-propanediol from a recombinant microorganism comprising: (a) contacting the recombinant microorganism of the present invention with at least one carbon

20 source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and (b) optionally recovering the 1,3-propanediol produced in (a).

Similarly the invention intends to provide a process for the production of 1,3-propanediol from a recombinant microorganism comprising:

25 (a) contacting a recombinant microorganism with at least one carbon source, said recombinant microorganism comprising:

(i) at least one gene encoding a polypeptide having a dehydratase activity;

(ii) at least one gene encoding a dehydratase reactivation factor;

30 (iii) at least one endogenous gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol; wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase is present;

said carbon source selected from the group consisting of glycerol and dihydroxyacetone, wherein 1,3-propanediol is produced and;

35 (b) optionally recovering the 1,3-propanediol produced in (a).

Yet another aspect of the invention provides for the co-feeding of the carbon substrate. In this embodiment for the production of 1,3-propanediol, the steps are: (a) contacting a recombinant *E. coli* with a first source of carbon and with a second source of carbon, said recombinant *E. coli* comprising: (i) at least one exogenous gene encoding a polypeptide having a dehydratase activity; (ii) at least one exogenous gene encoding a dehydratase reactivation factor; (iii) at least one exogenous gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol, wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli* and wherein said first carbon source is selected from the group consisting of glycerol and dihydroxyacetone, and said second carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates, and (b) the 1,3-propanediol produced in (a) is optionally recovered. The co-feed may be sequential or simultaneous. The recombinant *E. coli* used in a co-feeding embodiment may further comprise: (a) a set of exogenous genes consisting of (i) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (ii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and (iii) at least one subset of genes encoding the gene products of *dhaR*, *orfY*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3* and *orfZ*, and (b) a set of endogenous genes, each gene having a mutation inactivating the gene, the set consisting of: (i) a gene encoding a polypeptide having glycerol kinase activity; (ii) a gene encoding a polypeptide having glycerol dehydrogenase activity; and (iii) a gene encoding a polypeptide having triosephosphate isomerase activity.

Useful recombinant *E. coli* strains include recombinant *E. coli* strain KLP23 comprising: (a) a set of two endogenous genes, each gene having a mutation inactivating the gene, the set consisting of: (i) a gene encoding a polypeptide having a glycerol kinase activity; and (ii) a gene encoding a polypeptide having a glycerol dehydrogenase activity; (b) at least one exogenous gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (c) at least one exogenous gene encoding a polypeptide having glycerol-3-phosphatase activity; and (d) a plasmid pKP32 and a recombinant *E. coli* strain RJ8 comprising: (a) set of three endogenous genes, each gene having a mutation inactivating the gene, the set consisting of: (i) a gene encoding a polypeptide having a glycerol kinase activity; (ii) a gene encoding a polypeptide having a glycerol dehydrogenase activity; and (iii) a gene encoding a polypeptide having a triosephosphate isomerase activity.

Other useful embodiments include recombinant *E. coli* comprising: (a) a set of exogenous genes consisting of: (i) at least one gene encoding a polypeptide having a dehydratase activity; (ii) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (iii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and (iv) at least one gene encoding a dehydratase reactivation factor; and (b) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol; wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli*.

Another embodiment is a recombinant *E. coli* comprising: (a) a set of exogenous genes consisting of (i) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (ii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and (iii) at least one subset of genes encoding the gene products of *dhaR*, *orfY*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3* and *orfZ*, and (b) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol, wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli*. This embodiment also includes a process using a recombinant *E. coli* further comprising a set of endogenous genes, each gene having a mutation inactivating the gene, the set consisting of: (a) a gene encoding a polypeptide having glycerol kinase activity; (b) a gene encoding a polypeptide having glycerol dehydrogenase activity; and (c) a gene encoding a polypeptide having triosephosphate isomerase activity.

This embodiment still further includes a process for the bioproduction of 1,3-propanediol comprising: (a) contacting under suitable conditions the immediately disclosed recombinant *E. coli* with at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and (b) optionally recovering the 1,3-propanediol produced in (a).

And also includes a further process for the bioproduction of 1,3-propanediol comprising: (a) contacting the recombinant *E. coli* of the immediately disclosed embodiments that further comprise: (i) at least one exogenous gene encoding a polypeptide having a dehydratase activity; (ii) at least one exogenous gene encoding a dehydratase reactivation factor; (iii) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol, with at least one carbon source selected from

the group consisting of glycerol and dihydroxyacetone, and (b) optionally recovering the 1,3-propanediol produced in (a).

BRIEF DESCRIPTION OF THE DRAWINGS,  
SEQUENCE DESCRIPTIONS, AND BIOLOGICAL DEPOSITS

5       The invention can be more fully understood from the following detailed description, Figures, the accompanying sequence descriptions, and biological deposits that form parts of this application.

Figure 1 presents the gene organization within the sequence of the *dha* regulon subclone pHK28-26.

10      Figure 2 presents a graph of the extracellular soluble protein (g/L) compared between two fermentations runs essentially as described in Example 7 using a constant feed of vitamin B<sub>12</sub>. In one case, solid lines, the strain used was KLP23/pAH48/pKP32. In the other case, dashed lines, the strain used was KLP23/pAH48/pDT29.

15      Figure 3 presents a graph of the cell viability [(viable cells/mL)/OD550] compared between two fermentations runs essentially as described in Example 7 using a constant feed of vitamin B<sub>12</sub>. In one case (solid lines), the strain used was KLP23/pAH48/pKP32. In the other case (dashed lines), the strain used was KLP23/pAH48/pDT29.

20      Figure 4 presents a graph of the yield of glycerol from glucose compared between two fermentations runs essentially as described in Example 7, but in the absence of vitamin B<sub>12</sub> or coenzyme B<sub>12</sub>. In one case (solid lines), the strain used was KLP23/pAH48/pKP32. In the other case (dashed lines), the strain used was KLP23/pAH48/pDT29.

25      Figure 5 is a flow diagram illustrating the metabolic conversion of glucose to 1,3-propanediol.

Figure 6 is a 2D-PAGE membrane blot with the soluble protein fraction extracted from a band showing endogenous *E. coli* oxidoreductase activity (non-specific catalytic activity) on a native gel.

30      The 68 sequence descriptions and the sequence listing attached hereto will comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures – the Sequence Rules") and will be consistent with World Intellectual Property Organization (WIPO) Standard ST2.5 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administration Instructions). The Sequence

Descriptions contain the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IYUB standards described in *Nucleic Acids Res.* 13, 3021-3030 (1985) and in the *Biochemical Journal* 219, 345-373 (1984) which are herein incorporated by reference.

5 SEQ ID NO:1 contains the nucleotide sequence determined from a 12.1 kb EcoRI-SalI fragment from pKP1 (cosmid containing DNA from *Klebsiella pneumoniae*), subcloned into pIBI31 (IBI Biosystem, New Haven, CT), and termed pHK28-26. Table 1 further details genes, corresponding base pairs  
 10 identified within SEQ ID NO:1, and associated functionality. See also Example 1.

SEQ ID NO:57 contains the nucleotide sequence determined for *yqhD*.

Applicants have made the following biological deposits under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure:

15 SEQ ID NO:58 contains the amino acid sequence determined for *YahD*.

	<u>Depositor Identification Reference</u>	<u>Int'l Depository Designation</u>	<u>Date of Deposit</u>
20	Transformed <i>E. coli</i> DH5 $\alpha$ containing a portion of the <i>Klebsiella</i> genome encoding the glycerol dehydratase enzyme	ATCC 69789	18 April 1995
25	transformed <i>E. coli</i> DH5 $\alpha$ containing cosmid pKP4 containing a portion of <i>Klebsiella</i> genome encoding a diol dehydratase enzyme	ATCC 69790	18 April 1995
30	<i>E. coli</i> MSP33.6	ATCC 98598	25 November 1997
	<i>glpK</i> mutant <i>E. coli</i> RJF10m	ATCC 98597	25 November 1997

The deposit(s) will be maintained in the indicated international depository for at least 30 years and will be made available to the public upon the grant of a patent disclosing it. The availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.

As used herein, "ATCC" refers to the American Type Culture Collection international depository located 10801 University Blvd., Manassas, VA 20110-2209 U.S.A. The "ATCC No." is the accession number to cultures on deposit with the ATCC.

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for an improved process for bioconverting a fermentable carbon source directly to 1,3-propanediol using a single microorganism. The method is characterized by improved titer, yield, and cell 5 viability as well as a decrease in cell lysis during fermentation.

The present invention is based, in part, upon the observation that 1,3-propanediol fermentation processes comprising 1,3-propanediol oxidoreductase (dhaT) are characterized by high levels of 3HPA and other aldehydes and ketones in the medium, which is correlated to a decrease in cell 10 viability. The present invention is also based, in part, upon the unexpected finding that the model host, *E. coli*, is capable of converting 3-HPA to 1,3-propanediol by an endogenous non-specific catalytic activity capable of converting 3-hydroxypropionaldehyde to 1,3-propanediol. The present invention is further based, in part, upon the unexpected finding that an *E. coli* fermentation 15 process comprising this non-specific catalytic activity and lacking a functional dhaT results in increased cell viability during fermentation and provides for higher titers and/or yields of 1,3-propanediol than a fermentation process comprising a functional dhaT.

In one aspect, glycerol is a model substrate, the host microorganism has a 20 mutation in wild-type dhaT such that there is no 1,3-propanediol oxidoreductase activity and comprises a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol. In another aspect, glucose is a model substrate and recombinant *E. coli* is a model host. In this aspect, *E. coli* comprises an endogenous non-specific catalytic activity sufficient to convert 25 3-hydroxypropionaldehyde to 1,3-propanediol. In one embodiment, the non-specific catalytic activity is an alcohol dehydrogenase.

In one aspect, the present invention provides a recombinant *E. coli* expressing a group of genes comprising (a) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; (b) at least one 30 gene encoding a polypeptide having glycerol-3-phosphatase activity; (c) at least one gene encoding a polypeptide having a dehydratase activity; (d) at least one gene encoding a dehydratase reactivation factor; and (e) at least one endogenous gene encoding an non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol; use of this microorganism converts glucose 35 to 1,3-propanediol at a high titer. In another aspect of this invention, the elimination of the functional dhaT gene in this recombinant *E. coli* provides an

unexpectedly higher titer of 1,3-propanediol from glucose than previously attained.

The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of a recombinant microorganism comprising a host *E. coli* transformed with the *Klebsiella pneumoniae* *dha* regulon genes *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3*, and *orfZ*, all these genes arranged in the same genetic organization as found in wild type *Klebsiella pneumoniae*. The titer obtained for the fermentation process is significantly higher than any titer previously reported for a similar fermentation. This improvement relies on the use of the plasmid pDT29 as described in Example 6 and Example 7.

In another aspect of the present invention, a further improved process for the production of 1,3-propanediol from glucose is achieved using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to a process using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor, and also a functional *dhaT*. The dramatically improved process relies on an endogenous gene encoding a non-specific catalytic activity, expected to be an alcohol dehydrogenase, which is present in *E. coli*.

The dramatic improvement in the process is evident as an increase in 1,3-propanediol titer as illustrated in Examples 7 and 9. The improvement in the process is also evident as a decrease in cell lysis as determined by the extracellular soluble protein concentration in the fermentation broth. This aspect of the invention is illustrated in Figure 2. Additionally, the improvement in the process is evident as prolonged cell viability over the course of the fermentation. This aspect of the invention is illustrated in Figure 3. Furthermore, the improvement in the process is also evident as an increase in yield. In *E. coli* expressing a 1,3-propanediol oxidoreductase (*dhaT*) (for example, *E. coli* KLP23 transformed with the plasmid pDT29), glycerol can be metabolized to a product other than 3-HPA. In direct contrast, in *E. coli* not expressing a 1,3-propanediol oxidoreductase (*dhaT*) (for example, *E. coli* KLP23 transformed with the plasmid pKP32), glycerol is not metabolized to a product other than 3-HPA. That this cryptic pathway is attributable to the presence or absence of a functional *dhaT* is demonstrated by the lower yield of glycerol from glucose as illustrated in Figure 4.

As used herein the following terms may be used for interpretation of the claims and specification.

The terms "glycerol-3-phosphate dehydrogenase" and "G3PDH" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). *In vivo* G3PDH may be NADH; NADPH; or FAD-dependent. When specifically referring to a cofactor specific glycerol-3-phosphate dehydrogenase, the terms "NADH-dependent glycerol-3-phosphate dehydrogenase", "NADPH-dependent glycerol-3-phosphate dehydrogenase" and "FAD-dependent glycerol-3-phosphate dehydrogenase" will be used. As it is generally the case that NADH-dependent and NADPH-dependent glycerol-3-phosphate dehydrogenases are able to use NADH and NADPH interchangeably (for example by the gene encoded by *gpsA*), the terms NADH-dependent and NADPH-dependent glycerol-3-phosphate dehydrogenase will be used interchangeably. The NADH-dependent enzyme (EC 1.1.1.8) is encoded, for example, by several genes including GPD1 (GenBank Z74071x2), or GPD2 (GenBank Z35169x1), or GPD3 (GenBank G984182), or DAR1 (GenBank Z74071x2). The NADPH-dependent enzyme (EC 1.1.1.94) is encoded by *gpsA* (GenBank U321643, (cds 197911-196892) G466746 and L45246). The FAD-dependent enzyme (EC 1.1.99.5) is encoded by GUT2 (GenBank Z47047x23), or *glpD* (GenBank G147838), or *glpABC* (GenBank M20938) (see WO 9928480 and references therein, which are herein incorporated by reference).

The terms "glycerol-3-phosphatase", "sn-glycerol-3-phosphatase", or "d,l-glycerol phosphatase", and "G3P phosphatase" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol-3-phosphate and water to glycerol and inorganic phosphate. G3P phosphatase is encoded, for example, by GPP1 (GenBank Z47047x125), or GPP2 (GenBank U18813x11) (see WO 9928480 and references therein, which are herein incorporated by reference).

The term "glycerol kinase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol and ATP to glycerol-3-phosphate and ADP. The high-energy phosphate donor ATP may be replaced by physiological substitutes (e.g., phosphoenolpyruvate). Glycerol kinase is encoded, for example, by GUT1 (GenBank U11583x19) and *glpK* (GenBank L19201) (see WO 9928480 and references therein, which are herein incorporated by reference).

The term "glycerol dehydrogenase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol to dihydroxyacetone (E.C. 1.1.1.6) or glycerol to glyceraldehyde (E.C. 1.1.1.72). A polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol to dihydroxyacetone is also referred to as a "dihydroxyacetone reductase". Glycerol dehydrogenase may be dependent upon NADH (E.C. 1.1.1.6), NADPH (E.C. 1.1.1.72), or other cofactors (e.g., E.C. 1.1.99.22). A NADH-dependent glycerol dehydrogenase is encoded, for example, by *gldA* (GenBank U00006) (see WO 9928480 and references therein, which are herein incorporated by reference).

5           The term "dehydratase enzyme" or "dehydratase" will refer to any enzyme activity that catalyzes the conversion of a glycerol molecule to the product 3-hydroxypropionaldehyde. For the purposes of the present invention the dehydratase enzymes include a glycerol dehydratase (E.C. 4.2.1.30) and a diol dehydratase (E.C. 4.2.1.28) having preferred substrates of glycerol and

10          1,2-propanediol, respectively. Genes for dehydratase enzymes have been identified in *Klebsiella pneumoniae*, *Citrobacter freundii*, *Clostridium pasteurianum*, *Salmonella typhimurium*, and *Klebsiella oxytoca*. In each case, the dehydratase is composed of three subunits: the large or "α" subunit, the medium or "β" subunit, and the small or "γ" subunit. Due to the wide variation in gene

15          nomenclature used in the literature, a comparative chart is given in Table 1 to facilitate identification. The genes are also described in, for example, Daniel et al. (*FEMS Microbiol. Rev.* 22, 553 (1999)) and Toraya and Mori (*J. Biol. Chem.* 274, 3372 (1999)). Referring to Table 1, genes encoding the large or "α" subunit of glycerol dehydratase include *dhaB1*, *gldA* and *dhaB*; genes encoding the medium or "β" subunit include *dhaB2*, *gldB*, and *dhaC*; genes encoding the small or "γ" subunit include *dhaB3*, *gldC*, and *dhaE*. Also referring to Table 1, genes

20          encoding the large or "α" subunit of diol dehydratase include *pduC* and *pddA*; genes encoding the medium or "β" subunit include *pduD* and *pddB*; genes encoding the small or "γ" subunit include *pduE* and *pddC*.

25          30

Table I : Comparative chart of gene names and GenBank references for dehydratase and dehydratase linked functions.

GENE FUNCTION:							
	regulatory	unknown	reactivation	1,3-PD dehydrogenase	unknown		
	gene	base pairs	gene	base pairs	gene	base pairs	gene
<b>ORGANISM (GenBank Reference)</b>							
<i>K. pneumoniae</i> (SEQ ID NO.:1)	<i>dhaR</i>	2209-4134	<i>orfW</i>	4112-4642	<i>orfX</i>	4643-4996	<i>dhaT</i>
<i>K. pneumoniae</i> (U30903)			<i>orf2c</i>	7116-7646	<i>orf2b</i>	6762-7115	<i>dhaT</i>
<i>K. pneumoniae</i> (U60992)					<i>gdrB</i>		
<i>C. freundii</i> (U09771)	<i>dhaR</i>	3746-5671	<i>orfW</i>	5649-6179	<i>orfX</i>	6180-6533	<i>dhaT</i>
<i>C. pasteurianum</i> (AF051373)							
<i>C. pasteurianum</i> (AF006034)			<i>orfW</i>	210-731	<i>orfX</i>	1-196	<i>dhaT</i>
<i>S. typhimurium</i> (AF026270)					<i>pduH</i>	8274-8645	
<i>K. oxytoca</i> (AF017781)					<i>ddrB</i>	2063-2440	
<i>K. oxytoca</i> (AF051373)							
GENE FUNCTION:							
			dehydratase, $\alpha$	dehydratase, $\beta$	dehydratase, $\gamma$		reactivation
	gene	base pairs	gene	base pairs	gene	base pairs	gene
<b>ORGANISM (GenBank Reference)</b>							
<i>K. pneumoniae</i> (SEQ ID NO.:1)	<i>dhaB1</i>	7044-8711	<i>dhaB2</i>	8724-9308	<i>dhaB3</i>	9311-9736	<i>orfZ</i>
<i>K. pneumoniae</i> (U30903)	<i>dhaB1</i>	3047-4714	<i>dhaB2</i>	2450-2890	<i>dhaB3</i>	2022-2447	<i>dhaB4</i>
<i>K. pneumoniae</i> (U60992)	<i>glcA</i>	121-1788	<i>glcB</i>	1801-2385	<i>glcC</i>	2388-2813	<i>gdrA</i>
<i>C. freundii</i> (U09771)	<i>dhaB</i>	8556-10223	<i>dhaC</i>	10235-10819	<i>dhaE</i>	10822-11250	<i>orfZ</i>
<i>C. pasteurianum</i> (AF051373)	<i>dhaB</i>	84-1748	<i>dhaC</i>	1779-2318	<i>dhaE</i>	2333-2773	<i>orfZ</i>
<i>C. pasteurianum</i> (AF006034)							
<i>S. typhimurium</i> (AF026270)	<i>pduC</i>	3557-5221	<i>pduD</i>	5232-5906	<i>pduE</i>	5921-6442	<i>pduG</i>
<i>K. oxytoca</i> (AF017781)							<i>ddrA</i>
<i>K. oxytoca</i> (AF051373)	<i>pddA</i>	121-1785	<i>pddB</i>	1796-2470	<i>pddC</i>	2485-3006	

Glycerol and diol dehydratases are subject to mechanism-based suicide inactivation by glycerol and some other substrates (Daniel et al., *FEMS Microbiol. Rev.* 22, 553 (1999)). The term “dehydratase reactivation factor” refers to those proteins responsible for reactivating the dehydratase activity. The terms 5 “dehydratase reactivating activity”, “reactivating the dehydratase activity” or “regenerating the dehydratase activity” refers to the phenomenon of converting a dehydratase not capable of catalysis of a substrate to one capable of catalysis of a substrate or to the phenomenon of inhibiting the inactivation of a dehydratase or the phenomenon of extending the useful half-life of the dehydratase enzyme *in* 10 *vivo*. Two proteins have been identified as being involved as the dehydratase reactivation factor (see WO 9821341 (US 6013494) and references therein, which are herein incorporated by reference; Daniel et al., *supra*; Toraya and Mori, *J. Biol. Chem.* 274, 3372 (1999); and Tobimatsu et al., *J. Bacteriol.* 181, 4110 (1999)). Referring to Table 1, genes encoding one of the proteins include *orfZ*, 15 *dhaB4*, *gdrA*, *pduG* and *ddrA*. Also referring to Table 1, genes encoding the second of the two proteins include *orfX*, *orf2b*, *gdrB*, *pduH* and *ddrB*.

The terms “1,3-propanediol oxidoreductase”, “1,3-propanediol dehydrogenase” or “DhaT” refer to the polypeptide(s) responsible for an enzyme activity that is capable of catalyzing the interconversion of 3-HPA and 20 1,3-propanediol provided the gene(s) encoding such activity is found to be physically or transcriptionally linked to a dehydratase enzyme in its natural (i.e., wild type) setting; for example, the gene is found within a *dha* regulon as is the case with *dhaT* from *Klebsiella pneumonia*. Referring to Table 1, genes encoding a 1,3-propanediol oxidoreductase include *dhaT* from *Klebsiella pneumoniae*, 25 *Citrobacter freundii*, and *Clostridium pasteurianum*. Each of these genes encode a polypeptide belonging to the family of type III alcohol dehydrogenases, exhibits a conserved iron-binding motif, and has a preference for the NAD<sup>+</sup>/NADH linked interconversion of 3-HPA and 1,3-propanediol (Johnson and Lin, *J. Bacteriol.* 169, 2050 (1987); Daniel et al., *J. Bacteriol.* 177, 2151 (1995); and Leurs et al., *FEMS Microbiol. Lett.* 154, 337 (1997)). Enzymes with similar physical properties have 30 been isolated from *Lactobacillus brevis* and *Lactobacillus buchneri* (Veiga da Dunha and Foster, *Appl. Environ. Microbiol.* 58, 2005 (1992)).

The term “*dha* regulon” refers to a set of associated genes or open reading frames encoding various biological activities, including but not limited to a 35 dehydratase activity, a reactivation activity, and a 1,3-propanediol oxidoreductase. Typically a *dha* regulon comprises the open reading frames *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3*, and *orfZ* as described herein.

The term "non-specific catalytic activity" refers to the polypeptide(s) responsible for an enzyme activity that is sufficient to catalyze the interconversion of 3-HPA and 1,3-propanediol and specifically excludes 1,3-propanediol oxidoreductase(s). Typically these enzymes are alcohol dehydrogenases. Such 5 enzymes may utilize cofactors other than NAD<sup>+</sup>/NADH, including but not limited to flavins such as FAD or FMN. A gene(s) for a non-specific alcohol dehydrogenase(s) is found, for example, to be endogenously encoded and functionally expressed within the microorganism *E. coli* KLP23.

The terms "function" or "enzyme function" refer to the catalytic activity of 10 an enzyme in altering the energy required to perform a specific chemical reaction. It is understood that such an activity may apply to a reaction in equilibrium where the production of either product or substrate may be accomplished under suitable conditions.

The terms "polypeptide" and "protein" are used interchangeably. 15 The terms "carbon substrate" and "carbon source" refer to a carbon source capable of being metabolized by host microorganisms of the present invention and particularly carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof.

The terms "host cell" or "host microorganism" refer to a microorganism 20 capable of receiving foreign or heterologous genes and of expressing those genes to produce an active gene product.

The terms "foreign gene", "foreign DNA", "heterologous gene" and "heterologous DNA" refer to genetic material native to one organism that has 25 been placed within a host microorganism by various means. The gene of interest may be a naturally occurring gene, a mutated gene, or a synthetic gene.

The terms "transformation" and "transfection" refer to the acquisition of new genes in a cell after the incorporation of nucleic acid. The acquired genes may be integrated into chromosomal DNA or introduced as extrachromosomal 30 replicating sequences. The term "transformant" refers to the product of a transformation.

The term "genetically altered" refers to the process of changing hereditary material by transformation or mutation.

The terms "recombinant microorganism" and "transformed host" refer to 35 any microorganism having been transformed with heterologous or foreign genes or extra copies of homologous genes. The recombinant microorganisms of the present invention express foreign genes encoding glycerol-3-phosphate

dehydrogenase (GPD1), glycerol-3-phosphatase (GPP2), glycerol dehydratase (*dhaB1*, *dhaB2* and *dhaB3*), dehydratase reactivation factor (*orfZ* and *orfX*), and optionally 1,3-propanediol oxidoreductase (*dhaT*) for the production of 1,3-propanediol from suitable carbon substrates. A preferred embodiment is an 5 *E. coli* transformed with these genes but lacking a functional *dhaT*. A host microorganism, other than *E. coli*, may also be transformed to contain the disclosed genes and the gene for the non-specific catalytic activity for the interconversion of 3-HPA and 1,3-propanediol, specifically excluding 1,3-propanediol oxidoreductase(s) (*dhaT*).

10 "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding) and following (3' non-coding) the coding region. The terms "native" and "wild-type" refer to a gene as found in nature with its own regulatory sequences.

15 The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, produces an amino acid sequence. It is understood that the process of encoding a specific amino acid sequence includes DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of 20 the protein encoded by the DNA sequence. It is therefore understood that the invention encompasses more than the specific exemplary sequences.

The term "isolated" refers to a protein or DNA sequence that is removed from at least one component with which it is naturally associated.

25 An "isolated nucleic acid molecule" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid molecule in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

30 "Substantially similar" refers to nucleic acid molecules wherein changes in one or more nucleotide bases result in substitution of one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. "Substantially similar" also refers to nucleic acid molecules wherein changes in one or more nucleotide bases do not affect the ability of the nucleic acid molecule to mediate alteration of gene expression by antisense or 35 co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid molecules of the instant invention (such as deletion or insertion of one or more nucleotide bases) that do not substantially affect the functional

properties of the resulting transcript vis-à-vis the ability to mediate alteration of gene expression by antisense or co-suppression technology or alteration of the functional properties of the resulting protein molecule. The invention encompasses more than the specific exemplary sequences.

5 For example, it is well known in the art that alterations in a gene which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded protein are common. For the purposes of the present invention substitutions are defined as exchanges within one of the following five groups:

10 1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr (Pro, Gly);  
2. Polar, negatively charged residues and their amides: Asp, Asn, Glu, Gln;  
3. Polar, positively charged residues: His, Arg, Lys;  
15 4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val (Cys); and  
5. Large aromatic residues: Phe, Tyr, Trp.

Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue (such as glycine) or a more hydrophobic residue (such as valine, leucine, or isoleucine).  
20 Similarly, changes which result in substitution of one negatively charged residue for another (such as aspartic acid for glutamic acid) or one positively charged residue for another (such as lysine for arginine) can also be expected to produce a functionally equivalent product.

In many cases, nucleotide changes which result in alteration of the  
25 N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein.

Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Moreover, the skilled artisan recognizes that substantially similar sequences  
30 encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 °C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS), with the sequences exemplified herein. Preferred substantially similar nucleic acid fragments of the instant invention are those nucleic acid fragments whose DNA sequences are at least 80% identical to  
35 the DNA sequence of the nucleic acid fragments reported herein. More preferred nucleic acid fragments are at least 90% identical to the DNA sequence of the nucleic acid fragments reported herein. Most preferred are nucleic acid fragments

that are at least 95% identical to the DNA sequence of the nucleic acid fragments reported herein.

A nucleic acid fragment is "hybridizable" to another nucleic acid fragment, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the 5 nucleic acid fragment can anneal to the other nucleic acid fragment under the appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989), particularly 10 Chapter 11 and Table 11.1 therein (entirely incorporated herein by reference). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a  $T_m$  of 55 °, can be used, e.g., 5X SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5X 15 SSC, 0.5% SDS. Moderate stringency hybridization conditions correspond to a higher  $T_m$ , e.g., 40% formamide, with 5X or 6X SSC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the 20 nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridization decreases in the following order: RNA:RNA, DNA:RNA, 25 DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (see Sambrook et al., *supra*, 9.50-9.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). In one 30 embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferable a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least 30 nucleotides. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration may be 35 adjusted as necessary according to factors such as length of the probe.

A "substantial portion" refers to an amino acid or nucleotide sequence which comprises enough of the amino acid sequence of a polypeptide or the

nucleotide sequence of a gene to afford putative identification of that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al., *J. Mol. Biol.* 215:403-410 (1993); see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 20-30 contiguous 5 nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid molecule comprising the primers. Accordingly, a “substantial 10 portion” of a nucleotide sequence comprises enough of the sequence to afford specific identification and/or isolation of a nucleic acid molecule comprising the sequence. The instant specification teaches partial or complete amino acid and nucleotide sequences encoding one or more particular proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or 15 a substantial portion of the disclosed sequences for the purpose known to those skilled in the art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

The term “complementary” describes the relationship between nucleotide 20 bases that are capable to hybridizing to one another. For example, with respect to DNA, adenine is complementary to thymine and cytosine is complementary to guanine. Accordingly, the instant invention also includes isolated nucleic acid molecules that are complementary to the complete sequences as reported in the accompanying Sequence Listing as well as those substantially similar nucleic acid 25 sequences.

The term “percent identity”, as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, 30 as the case may be, as determined by the match between strings of such sequences. “Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in: *Computational*

*Molecular Biology*; Lesk, A. M., Ed.; Oxford University Press: New York, 1988; *Biocomputing: Informatics and Genome Projects*; Smith, D. W., Ed.; Academic Press: New York, 1993; *Computer Analysis of Sequence Data, Part I*; Griffin, A. M. and Griffin, H. G., Eds.; Humana Press: New Jersey, 1994; *Sequence Analysis in Molecular Biology*; von Heinje, G., Ed.; Academic Press: New York, 1987; and *Sequence Analysis Primer*; Gribskov, M. and Devereux, J., Eds.; Stockton Press: New York, 1991. Preferred methods to determine identity are designed to give the largest match between the sequences tested.

Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG Pileup program found in the GCG program package, using the Needleman and Wunsch algorithm with their standard default values of gap creation penalty=12 and gap extension penalty=4 (Devereux et al., *Nucleic Acids Res.* 12:387-395 (1984)), BLASTP, BLASTN, and FASTA (Pearson et al., *Proc. Natl. Acad. Sci. USA* 85:2444-2448 (1988)). The BLASTX program is publicly available from NCBI and other sources ([BLAST Manual](#), Altschul et al., Natl. Cent. Biotechnol. Inf., Natl. Library Med. (NCBI NLM) NIH, Bethesda, Md. 20894; Altschul et al., *J. Mol. Biol.* 215:403-410 (1990); Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", *Nucleic Acids Res.* 25:3389-3402 (1997)). Another preferred method to determine percent identity, is by the method of DNASTAR protein alignment protocol using the Jotun-Hein algorithm (Hein et al., *Methods Enzymol.* 183:626-645 (1990)). Default parameters for the Jotun-Hein method for alignments are: for multiple alignments, gap penalty=11, gap length penalty=3; for pairwise alignments ktuple=6. As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either

individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence is intended that the amino acid sequence of the 5 polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or 10 substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually 15 among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

The term "homologous" refers to a protein or polypeptide native or naturally occurring in a given host cell. The invention includes microorganisms producing homologous proteins via recombinant DNA technology.

20 The term "percent homology" refers to the extent of amino acid sequence identity between polypeptides. When a first amino acid sequence is identical to a second amino acid sequence, then the first and second amino acid sequences exhibit 100% homology. The homology between any two polypeptides is a direct function of the total number of matching amino acids at a given position in either sequence, e.g., 25 if half of the total number of amino acids in either of the two sequences are the same then the two sequences are said to exhibit 50% homology.

30 "Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid molecule that encodes all or a substantial portion of the amino acid sequence as set forth in SEQ ID NO:57. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon 35 usage approaches the frequency of preferred codon usage of the host cell.

Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not

substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alteration in the gene sequence which reflect the degeneracy of the genetic code, or which result in the production of a chemically equivalent amino acid at a given site, are contemplated. Thus, a codon for the 5 amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as 10 aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants 15 of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity in the encoded products. Moreover, the skilled artisan recognizes that sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 °C), with the sequences exemplified herein.

20 The term "expression" refers to the transcription and translation to gene product from a gene coding for the sequence of the gene product.

The terms "plasmid", "vector", and "cassette" refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA 25 molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA 30 sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the 35 foreign gene that allow for enhanced expression of that gene in a foreign host.

Construction of Recombinant Organisms

Recombinant organisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a carbon substrate to 1,3-propanediol may be constructed using techniques well known in the art. Genes encoding

5 glycerol-3-phosphate dehydrogenase (GPD1), glycerol-3-phosphatase (GPP2), glycerol dehydratase (*dhaB1*, *dhaB2*, and *dhaB3*), dehydratase reactivation factor (*orfZ* and *orfX*) and 1,3-propanediol oxidoreductase (*dhaT*) were isolated from a native host such as *Klebsiella* or *Saccharomyces* and used to transform host strains such as *E. coli* DH5 $\alpha$ , ECL707, AA200, or KLP23.

10 Isolation of Genes

Methods of obtaining desired genes from a bacterial genome are common and well known in the art of molecular biology. For example, if the sequence of the gene is known, suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the 15 desired gene sequence. Once the sequence is isolated, the DNA may be amplified using standard primer directed amplification methods such as polymerase chain reaction (PCR) (U.S. 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors.

Alternatively, cosmid libraries may be created where large segments of 20 genomic DNA (35-45kb) may be packaged into vectors and used to transform appropriate hosts. Cosmid vectors are unique in being able to accommodate large quantities of DNA. Generally cosmid vectors have at least one copy of the *cos* DNA sequence which is needed for packaging and subsequent circularization of the foreign DNA. In addition to the *cos* sequence these vectors will also contain 25 an origin of replication such as ColE1 and drug resistance markers such as a gene resistant to ampicillin or neomycin. Methods of using cosmid vectors for the transformation of suitable bacterial hosts are well described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, herein incorporated by reference.

30 Typically to clone cosmids, foreign DNA is isolated and ligated, using the appropriate restriction endonucleases, adjacent to the *cos* region of the cosmid vector. Cosmid vectors containing the linearized foreign DNA are then reacted with a DNA packaging vehicle such as bacteriophage. During the packaging process the *cos* sites are cleaved and the foreign DNA is packaged into the head 35 portion of the bacterial viral particle. These particles are then used to transfect suitable host cells such as *E. coli*. Once injected into the cell, the foreign DNA circularizes under the influence of the *cos* sticky ends. In this manner large

segments of foreign DNA can be introduced and expressed in recombinant host cells.

Isolation And Cloning of Genes Encoding Glycerol Dehydratase (*dhaB1*, *dhaB2*, and *dhaB3*), Dehydratase Reactivating Factors (*orfZ* and *orfX*), and

5 1,3-propanediol dehydrogenase (*dhaT*)

Cosmid vectors and cosmid transformation methods were used within the context of the present invention to clone large segments of genomic DNA from bacterial genera known to possess genes capable of processing glycerol to 1,3-propanediol. Specifically, genomic DNA from *K. pneumoniae* was isolated 10 by methods well known in the art and digested with the restriction enzyme Sau3A for insertion into a cosmid vector Supercos 1 and packaged using GigapackII packaging extracts. Following construction of the vector *E. coli* XL1-Blue MR cells were transformed with the cosmid DNA. Transformants were screened for the ability to convert glycerol to 1,3-propanediol by growing the cells in the 15 presence of glycerol and analyzing the media for 1,3-propanediol formation.

Two of the 1,3-propanediol positive transformants were analyzed and the cosmids were named pKP1 and pKP2. DNA sequencing revealed extensive homology to the glycerol dehydratase gene from *C. freundii*, demonstrating that these transformants contained DNA encoding the glycerol dehydratase gene. 20 Other 1,3-propanediol positive transformants were analyzed and the cosmids were named pKP4 and pKP5. DNA sequencing revealed that these cosmids carried DNA encoding a diol dehydratase gene.

Although the instant invention utilizes the isolated genes from within a *Klebsiella* cosmid, alternate sources of dehydratase genes and dehydratase 25 reactivation factor genes include, but are not limited to, *Citrobacter*, *Clostridia* and *Salmonella* (see Table 1).

Genes Encoding G3PDH and G3P Phosphatase

The present invention provides genes suitable for the expression of G3PDH and G3P phosphatase activities in a host cell.

30 Genes encoding G3PDH are known. For example, GPD1 has been isolated from *Saccharomyces* and has the base sequence given by SEQ ID NO:53, encoding the amino acid sequence given in SEQ ID NO:54 (Wang et al., *supra*). Similarly, G3PDH activity has also been isolated from *Saccharomyces* encoded by GPD2 (Eriksson et al., *Mol. Microbiol.* 17, 95 (1995)).

35 For the purposes of the present invention it is contemplated that any gene encoding a polypeptide responsible for NADH-dependent G3PDH activity is suitable wherein that activity is capable of catalyzing the conversion of

dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). Further, it is contemplated that any gene encoding the amino acid sequence of NADH-dependent G3PDH's corresponding to the genes DAR1, GPD1, GPD2, GPD3, and *gpsA* will be functional in the present invention wherein that amino acid sequence 5 may encompass amino acid substitutions, deletions or additions that do not alter the function of the enzyme. The skilled person will appreciate that genes encoding G3PDH isolated from other sources will also be suitable for use in the present invention. Genes encoding G3P phosphatase are known. For example, GPP2 has been isolated from *Saccharomyces cerevisiae* and has the base sequence 10 given by SEQ ID NO:55, which encodes the amino acid sequence given in SEQ ID NO:56 (Norbeck et al., *J. Biol. Chem.* 271, 13875 (1996)).

For the purposes of the present invention, any gene encoding a G3P phosphatase activity is suitable for use in the method wherein that activity is capable of catalyzing the conversion of glycerol-3-phosphate plus H<sub>2</sub>O to glycerol 15 plus inorganic phosphate. Further, any gene encoding the amino acid sequence of G3P phosphatase corresponding to the genes GPP2 and GPP1 will be functional in the present invention including any amino acid sequence that encompasses amino acid substitutions, deletions or additions that do not alter the function of the G3P phosphatase enzyme. The skilled person will appreciate that genes encoding 20 G3P phosphatase isolated from other sources will also be suitable for use in the present invention.

#### Host Cells

Suitable host cells for the recombinant production of 1,3-propanediol may be either prokaryotic or eukaryotic and will be limited only by the host cell ability to 25 express the active enzymes for the 1,3-propanediol pathway. Suitable host cells will be bacteria such as *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, 30 *Bacillus*, *Streptomyces*, and *Pseudomonas*. Preferred in the present invention are *E. coli*, *E. blattae*, *Klebsiella*, *Citrobacter*, and *Aerobacter*.

Microorganisms can be converted to a high titer 1,3-propanediol producer by using the following general protocol.

1. Determine the presence in a potential host organism of an endogenous *dhaT*-like activity that allows for the steady state concentration of a toxic or inhibitory level of 3-HPA in the presence of 1-2 M 1,3-propanediol.

2. If such an activity exists in the potential host organism, perform suitable mutagenesis to delete or inactivate this activity. Confirmation of a non-functional or deleted *dhaT*-like activity can be detected by the lack of 3-HPA accumulation in the presence of 1-2 M 1,3-propanediol.
- 5 3. Express appropriate genes for a) glycerol production, if glycerol is not the carbon source, b) glycerol dehydratase and the associated maintenance system, and c) *yqhD*.

Considerations which would need to be taken with respect to certain microorganisms concern the expression or repression of endogenous *dhaT*-like enzymes under the conditions for 1,3-propanediol production. These might also include the presence of glycerol, glucose or anaerobiosis.

#### Vectors and Expression Cassettes

The present invention provides a variety of vectors and transformation and expression cassettes suitable for the cloning, transformation and expression of G3PDH, G3P phosphatase, dehydratase, and dehydratase reactivation factor into a suitable host cell. Suitable vectors will be those which are compatible with the microorganism employed. Suitable vectors can be derived, for example, from a bacteria, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast or a plant. Protocols for obtaining and using such vectors are known to those in the art (Sambrook et al., *Molecular Cloning: A Laboratory Manual* – volumes 1, 2, 3 (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1989)).

Typically, the vector or cassette contains sequences directing transcription and translation of the appropriate gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene, which harbors transcriptional initiation controls, and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell. Such control regions need not be derived from the genes native to the specific species chosen as a production host.

Initiation control regions, or promoters, which are useful to drive expression of the G3PDH and G3P phosphatase genes (DAR1 and GPP2, respectively) in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, and TPI

(useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, trp,  $\lambda P_L$ ,  $\lambda P_R$ , T7, tac, and trc (useful for expression in *E. coli*).

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; 5 however, it is most preferred if included.

For effective expression of the instant enzymes, DNA encoding the enzymes are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

10 Particularly useful in the present invention are the vectors pDT29 and pKP32 which are designed to be used in conjunction with pAH48. The essential elements of pDT29 and pKP32 are derived from the *dha* regulon isolated from *Klebsiella pneumoniae*. pDT29 contains the open reading frames *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, and *dhaB3*, nucleotide the sequences of which 15 are contained within SEQ ID NO:1. pKP32 contains the same set of open reading frames as found on pDT29, from the same source, with the difference that pKP32 lacks the *dhaT*. pAH48 is the vehicle used for the introduction of DAR1 and GPP2 genes into the host cell and more specifically comprises the DAR1 and GPP2 genes isolated from *Saccharomyces cerevisiae*.

20 **Transformation of Suitable Hosts and Expression of Genes for the Production of 1,3-propanediol**

Once suitable cassettes are constructed they are used to transform appropriate host cells. Introduction of the cassette containing the genes encoding G3PDH, G3P phosphatase, dehydratase, and dehydratase reactivation factor into 25 the host cell may be accomplished by known procedures such as by transformation (e.g., using calcium-permeabilized cells, electroporation), or by transfection using a recombinant phage virus (Sambrook et al., *supra*).

In the present invention cassettes were used to transform the *E. coli* as fully described in the GENERAL METHODS and EXAMPLES.

30 **Mutants**

In addition to the cells exemplified, it is contemplated that the present method will be able to make use of cells having single or multiple mutations specifically designed to enhance the production of 1,3-propanediol. Cells that normally divert a carbon feed stock into non-productive pathways, or that exhibit 35 significant catabolite repression could be mutated to avoid these phenotypic deficiencies. For example, many wild type cells are subject to catabolite repression from glucose and by-products in the media and it is contemplated that

mutant strains of these wild type organisms, capable of 1,3-propanediol production that are resistant to glucose repression, would be particularly useful in the present invention.

Methods of creating mutants are common and well known in the art. For example, wild type cells may be exposed to a variety of agents such as radiation or chemical mutagens and then screened for the desired phenotype. When creating mutations through radiation either ultraviolet (UV) or ionizing radiation may be used. Suitable short wave UV wavelengths for genetic mutations will fall within the range of 200 nm to 300 nm where 254 nm is preferred. UV radiation in this wavelength principally causes changes within nucleic acid sequence from guanidine and cytosine to adenine and thymidine. Since all cells have DNA repair mechanisms that would repair most UV induced mutations, agents such as caffeine and other inhibitors may be added to interrupt the repair process and maximize the number of effective mutations. Long wave UV mutations using light in the 300 nm to 400 nm range are also possible but are generally not as effective as the short wave UV light unless used in conjunction with various activators such as psoralen dyes that interact with the DNA.

Mutagenesis with chemical agents is also effective for generating mutants and commonly used substances include chemicals that affect nonreplicating DNA such as  $\text{HNO}_2$  and  $\text{NH}_2\text{OH}$ , as well as agents that affect replicating DNA such as acridine dyes, notable for causing frameshift mutations. Specific methods for creating mutants using radiation or chemical agents are well documented in the art. See for example Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., *Appl. Biochem. Biotechnol.* 36, 227 (1992), herein incorporated by reference.

After mutagenesis has occurred, mutants having the desired phenotype may be selected by a variety of methods. Random screening is most common where the mutagenized cells are selected for the ability to produce the desired product or intermediate. Alternatively, selective isolation of mutants can be performed by growing a mutagenized population on selective media where only resistant colonies can develop. Methods of mutant selection are highly developed and well known in the art of industrial microbiology. See for example Brock, *Supra*; DeMancilha et al., *Food Chem.* 14, 313 (1984).

The elimination of an undesired enzyme activity may be also accomplished by disruption of the gene encoding the enzyme. Such methods are known to those skilled in the art and are exemplified in Example 4 and Example 8.

Alterations in the 1,3-propanediol Production Pathway

Representative Enzyme Pathway. The production of 1,3-propanediol from glucose can be accomplished by the following series of steps. This series is representative of a number of pathways known to those skilled in the art and is illustrated in Figure 5. Glucose is converted in a series of steps by enzymes of the glycolytic pathway to dihydroxyacetone phosphate (DHAP) and 3-phosphoglyceraldehyde (3-PG). Glycerol is then formed by either hydrolysis of DHAP to dihydroxyacetone (DHA) followed by reduction, or reduction of DHAP to glycerol 3-phosphate (G3P) followed by hydrolysis. The hydrolysis step can be catalyzed by any number of cellular phosphatases, which are known to be non-specific with respect to their substrates, or the activity can be introduced into the host by recombination. The reduction step can be catalyzed by a NAD<sup>+</sup> (or NADP<sup>+</sup>) linked host enzyme or the activity can be introduced into the host by recombination. It is notable that the *dha* regulon contains a glycerol dehydrogenase (E.C. 1.1.1.6) that catalyzes the reversible reaction of Equation 3.



Glycerol is converted to 1,3-propanediol via the intermediate 3-hydroxypropionaldehyde (3-HPA) as has been described in detail above. The intermediate 3-HPA is produced from glycerol, Equation 1, by a dehydratase enzyme that can be encoded by the host or can be introduced into the host by recombination. This dehydratase can be glycerol dehydratase (E.C. 4.2.1.30), diol dehydratase (E.C. 4.2.1.28) or any other enzyme able to catalyze this transformation. Glycerol dehydratase, but not diol dehydratase, is encoded by the *dha* regulon. 1,3-Propanediol is produced from 3-HPA, Equation 2, by a NAD<sup>+</sup>- (or NADP<sup>+</sup>) linked host enzyme or the activity can be introduced into the host by recombination. This final reaction in the production of 1,3-propanediol can be catalyzed by 1,3-propanediol dehydrogenase (E.C. 1.1.1.202) or other alcohol dehydrogenases.

Mutations and transformations that affect carbon channeling. A variety of mutant microorganisms comprising variations in the 1,3-propanediol production pathway will be useful in the present invention. For example the introduction of a triosephosphate isomerase mutation (*tpi*-) into the microorganism of the present invention is an example of the use of a mutation to improve the performance by carbon channeling. Triosephosphate isomerase is the enzyme responsible for the

conversion of DAHP to 3-phosphoglyceraldehyde, and as such allows the diversion of carbon flow from the main pathway form glucose to glycerol and 1,3-propanediol (Figure 5). Thus, the deletion mutation (*tpi*-) enhances the overall metabolic efficiency of the desired pathway over that described in the art.

5 Similarly, mutations which block alternate pathways for intermediates of the 1,3-propanediol production pathway would also be useful to the present invention. For example, the elimination of glycerol kinase prevents glycerol, formed from G3P by the action of G3P phosphatase, from being re-converted to G3P at the expense of ATP (Figure 5). Also, the elimination of glycerol dehydrogenase (for 10 example, *gldA*) prevents glycerol, formed from DHAP by the action of NADH-dependent glycerol-3-phosphate dehydrogenase, from being converted to dihydroxyacetone (Figure 5). Mutations can be directed toward a structural gene so as to impair or improve the activity of an enzymatic activity or can be directed toward a regulatory gene, including promoter regions and ribosome binding sites, 15 so as to modulate the expression level of an enzymatic activity.

It is thus contemplated that transformations and mutations can be combined so as to control particular enzyme activities for the enhancement of 1,3-propanediol production. Thus, it is within the scope of the present invention to anticipate modifications of a whole cell catalyst which lead to an increased 20 production of 1,3-propanediol.

The present invention utilizes a preferred pathway for the production of 1,3-propanediol from a sugar substrate where the carbon flow moves from glucose to DHAP, G3P, Glycerol, 3-HPA and finally to 1,3-propanediol. The present production strains have been engineered to maximize the metabolic efficiency of 25 the pathway by incorporating various deletion mutations that prevent the diversion of carbon to non-productive compounds. Glycerol may be diverted from conversion to 3HPA by transformation to either DHA or G3P via glycerol dehydrogenase or glycerol kinase as discussed above (Figure 5). Accordingly, the present production strains contain deletion mutations in the *gldA* and *glpK* genes. 30 Similarly DHAP may be diverted to 3-PG by triosephosphate isomerase, thus the present production microorganism also contains a deletion mutation in this gene. The present method additionally incorporates a dehydratase enzyme for the conversion of glycerol to 3HPA, which functions in concert with the reactivation factor, encoded by *orfX* and *orfZ* of the *dha* regulon (Figure 5). Although 35 conversion of the 3HPA to 1,3-propanediol is typically accomplished via a 1,3-propanediol oxidoreductase, the present method utilizes a non-specific catalytic activity that produces greater titers and yields of the final product,

1,3-propanediol (Figure 5). In such a process, titers of 1,3-propanediol of at least 10 g/L are achieved, where titers of 200 g/L are expected.

Alternatively, an improved process for 1,3-propanediol production may utilize glycerol or dihydroxyacetone as a substrate where the pathway comprises  
5 only the last three substrates, glycerol → 3HPA → 1,3-propanediol. In such a process, the oxidoreductase is again eliminated in favor of the non-specific catalytic activity, (expected to be an alcohol dehydrogenase), however the need for deletion mutations are nullified by the energy considerations of adding glycerol to the culture. In such a process titers of 1,3-propanediol of at least  
10 71 g/L are achieved where titers of 200 g/L are expected.

Similarly it is within the scope of the invention to provide mutants of wildtype microorganisms that have been modified by the deletion or mutation of the *dhaT* activity to create improved 1,3-propandiol producers. For example, microorganisms, which naturally contain all the elements of the *dha* regulon, may  
15 be manipulated so as to inactivate the *dhaT* gene encoding the 1,3-propandiol oxidoreductase activity. These microorganisms will be expected to produce higher yields and titers of 1,3-propanediol, mediated by the presence of an endogenous catalytic activity, expected to be an alcohol dehydrogenase.  
Examples of such microorganisms include but are not limited to *Klebsiella sp.*,  
20 *Citrobacter sp.*, and *Clostridium sp.*

#### Media and Carbon Substrates

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose,  
25 polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated.  
30 Glycerol production from single carbon sources (e.g., methanol, formaldehyde or formate) has been reported in methylotrophic yeasts (K. Yamada et al., *Agric. Biol. Chem.* 53(2), 541-543 (1989)) and in bacteria (Hunter et. al., *Biochemistry* 24, 4148-4155 (1985)). These microorganisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce  
35 glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-momophosphate (Gottschalk, Bacterial Metabolism, Second Edition, Springer-Verlag: New York (1986)). The

ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a 6-carbon sugar that becomes fructose and eventually the three-carbon product glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic pathway  
5 via methylenetetrahydrofolate.

In addition to one and two carbon substrates, methylotrophic microorganisms are also known to utilize a number of other carbon-containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the  
10 carbon from methylamine to form trehalose or glycerol (Bellion et al., *Microb. Growth Cl Compd.*, [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., *Arch. Microbiol.* 153(5), 485-489 (1990)). Hence, it is contemplated that the source of  
15 carbon utilized in the present invention may encompass a wide variety of carbon-containing substrates and will only be limited by the choice of microorganism or process.

Although it is contemplated that all of the above mentioned carbon substrates and mixtures (co-feed) thereof are suitable in the present invention,  
20 preferred carbon substrates are glucose, fructose, sucrose, or methanol where the process intends to produce an endogenous glycerol, and glycerol or dihydroxyacetone where the process anticipates a glycerol or dihydroxyacetone feed.

In addition to an appropriate carbon source, fermentation media must  
25 contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for 1,3-propanediol production. Particular attention is given to Co(II) salts and/or vitamin B<sub>12</sub> or precursors thereof.

Adenosyl-cobalamin (coenzyme B<sub>12</sub>) is an essential cofactor for  
30 dehydratase activity. Synthesis of coenzyme B<sub>12</sub> is found in prokaryotes, some of which are able to synthesize the compound *de novo*, for example, *Escherichia blattae*, *Klebsiella* species, *Citrobacter* species, and *Clostridium* species, while others can perform partial reactions. *E. coli*, for example, cannot fabricate the corrin ring structure, but is able to catalyze the conversion of cobinamide to  
35 corrinoid and can introduce the 5'-deoxyadenosyl group. Thus, it is known in the art that a coenzyme B<sub>12</sub> precursor, such as vitamin B<sub>12</sub>, need be provided in *E. coli* fermentations.

Vitamin B<sub>12</sub> additions to *E. coli* fermentations may be added continuously, at a constant rate or staged as to coincide with the generation of cell mass, or may be added in single or multiple bolus additions. Preferred ratios of vitamin B<sub>12</sub> (mg) fed to cell mass (OD550) are from 0.06 to 0.60. Most preferred ratios of 5 vitamin B<sub>12</sub> (mg) fed to cell mass (OD550) are from 0.12 to 0.48.

Although vitamin B<sub>12</sub> is added to the transformed *E. coli* of the present invention it is contemplated that other microorganisms, capable of *de novo* B<sub>12</sub> biosynthesis will also be suitable production cells and the addition of B<sub>12</sub> to these microorganisms will be unnecessary.

10 **Culture Conditions:**

Typically cells are grown at 35 °C in appropriate media. Preferred growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used and the 15 appropriate medium for growth of the particular microorganism will be known by someone skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2':3'-monophosphate, may also be incorporated into the reaction media. Similarly, the use of agents known to modulate enzymatic activities (e.g., methyl 20 viologen) that lead to enhancement of 1,3-propanediol production may be used in conjunction with or as an alternative to genetic manipulations.

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred as the initial condition.

Reactions may be performed under aerobic or anaerobic conditions where 25 anaerobic or microaerobic conditions are preferred.

Fed-batch fermentations may be performed with carbon feed, for example, glucose, limited or excess.

**Batch and Continuous Fermentations:**

The present process employs a batch method of fermentation. Classical 30 batch fermentation is a closed system where the composition of the media is set at the beginning of the fermentation and is not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the media is inoculated with the desired microorganism or microorganisms and fermentation is permitted to occur adding nothing to the system. Typically, however, "batch" 35 fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change

constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are  
5 responsible for the bulk of production of end product or intermediate.

A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when  
10 catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO<sub>2</sub>. Batch and Fed-Batch  
15 fermentations are common and well known in the art and examples may be found in Brock, *supra*.

Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined  
20 fermentation media is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for the modulation of one factor or any  
25 number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant.  
30 Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to media being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a  
35 variety of methods are detailed by Brock, *supra*.

It is contemplated that the present invention may be practiced using batch, fed-batch or continuous processes and that any known mode of fermentation

would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for 1,3-propanediol production.

Identification and purification of 1,3-propanediol:

5       Methods for the purification of 1,3-propanediol from fermentation media are known in the art. For example, propanediols can be obtained from cell media by subjecting the reaction mixture to extraction with an organic solvent, distillation, and column chromatography (U.S. 5,356,812). A particularly good organic solvent for this process is cyclohexane (U.S. 5,008,473).

10      1,3-Propanediol may be identified directly by submitting the media to high pressure liquid chromatography (HPLC) analysis. Preferred in the present invention is a method where fermentation media is analyzed on an analytical ion exchange column using a mobile phase of 0.01N sulfuric acid in an isocratic fashion.

15      EXAMPLES

GENERAL METHODS

Procedures for phosphorylations, ligations and transformations are well known in the art. Techniques suitable for use in the following examples may be found in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989).

20      Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, D.C. (1994) or Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA. All reagents and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

25      The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "mL" means milliliters, "L" means liters, 50 amp is 50 µg/mL ampicillin, and LB-50 amp is Luria-Bertani broth containing 50 µg/mL ampicillin.

30      Within the tables the following abbreviations are used. "Con." is conversion, "Sel." is selectivity based on carbon, and "nd" is not detected.

Strains and vectors used and constructed in the following examples are listed in the chart below:

STRAIN/PLASMID	DELETION	ORF/GENE
KLP23	<i>gldA</i> <i>glpK</i>	
RJ8m	<i>gldA</i> <i>glpK</i> <i>Tpi</i>	
pAH48		GPP2 DAR1
pDT29		<i>dhaR</i> <i>orfY</i> <i>dhaT</i> <i>orfX</i> <i>orfW</i> <i>dhaB1</i> <i>dhaB2</i> <i>dhaB3</i> <i>orfZ</i>
pKP32		<i>dhaR</i> <i>orfY</i> <i>orfX</i> <i>orfW</i> <i>dhaB1</i> <i>dhaB2</i> <i>dhaB3</i> <i>orfZ</i>

5

## ENZYME ASSAYS

### Assays for dehydratase enzymes:

Dehydratase activity in cell-free extracts was determined using either glycerol or 1,2-propanediol as substrate. Typically, cell-free extracts were prepared by cell disruption using a french press followed by centrifugation of the cellular debris. The assay, based on the reaction of aldehydes with methylbenzo-2-thiazolone hydrazone, has been described by Forage and Foster (*Biochim. Biophys. Acta* 569, 249 (1979)).

Honda et al. (*J. Bacteriol.* 143, 1458 (1980)) disclose an assay that measures the reactivation of dehydratases. Dehydratase activity was determined in toluenized whole cells, with and without ATP, using either glycerol or 1,2-propanediol as substrate. Reactivation was determined by the ratio of product formation with versus without the ATP addition. Product formation (3-HPA or

propionaldehyde when glycerol or 1,2-propanediol is used as substrate, respectively) was measured directly, using HPLC, or indirectly, using the methylbenzo-2-thiazolone hydrazone reagent. Alternatively, product formation was determined by coupling the conversion of the aldehyde to its respective  
5 alcohol using a NADH linked alcohol dehydrogenase and monitoring the disappearance of NADH.

Assays for 1,3-propanediol oxidoreductase:

The activity of 1,3-propanediol oxidoreductase, sometimes referred to as 1,3-propanediol dehydrogenase, was determined for cell-free extracts in solution  
10 or in slab gels using 1,3-propanediol and NAD<sup>+</sup> as substrates has been described (Johnson and Lin, *J. Bacteriol.* 169, 2050 (1987)). Alternatively, the conversion of 3-HPA and NADH to 1,3-propanediol and NAD<sup>+</sup> was determined by the disappearance of NADH. The slab gel assay has the potential advantage of separating the activity of 1,3-propanediol oxidoreductase (*dhaT*) from that of non-specific alcohol dehydrogenases by virtue of size separation. The native  
15 molecular weights of 1,3-propanediol oxidoreductases (*dhaT*) from *Citrobacter freundii*, *Klebsiella pneumoniae*, and *Clostridium pasteurianum* are unusually large, on the order of 330,000 to 440,000 daltons. *Lactobacillus brevis* and *Lactobacillus buchneri* contain dehydratase associated 1,3-propanediol  
20 oxidoreductases with properties similar to those of known 1,3-propanediol oxidoreductases (*dhaT*).

Assays for glycerol 3-phosphate dehydrogenase activity:

A procedure was used as modified below from a method published by Bell et al. (*J. Biol. Chem.* 250, 7153 (1975)). This method involved incubating a cell-free extract sample in a cuvette that contained 0.2 mM NADH, 2.0 mM dihydroxyacetone phosphate (DHAP), and enzyme in 0.1 M Tris/HCl, pH 7.5 buffer with 5 mM DTT, in a total volume of 1.0 mL at 30 °C. A background rate of the reaction of enzyme and NADH was first determined at 340 nm for at least 3 min. The second substrate, DHAP, was subsequently added and the absorbance change over time was further monitored for at least 3 min. G3PDH activity was defined by subtracting the background rate from the gross rate.  
30

Assay for glycerol-3-phosphatase activity:

The assay for enzyme activity was performed by incubating the extract with an organic phosphate substrate in a bis-Tris or MES and magnesium buffer, pH 6.5. The substrate used was either l- $\alpha$ -glycerol phosphate, or d,l- $\alpha$ -glycerol phosphate. The final concentrations of the reagents in the assay are: buffer (20 mM, bis-Tris or 50 mM MES); MgCl<sub>2</sub> (10 mM); and substrate (20 mM). If  
35

the total protein in the sample was low and no visible precipitation occurs with an acid quench, the sample was conveniently assayed in the cuvette. This method involved incubating an enzyme sample in a cuvette that contained 20 mM substrate (50 µL, 200 mM), 50 mM MES, 10 mM MgCl<sub>2</sub>, pH 6.5 buffer. The 5 final phosphatase assay volume was 0.5 mL. The enzyme-containing sample was added to the reaction mixture; the contents of the cuvette were mixed and then the cuvette was placed in a circulating water bath at T = 37 °C for 5 to 120 min, the length of time depending on whether the phosphatase activity in the enzyme sample ranged from 2 to 0.02 U/mL. The enzymatic reaction was quenched by 10 the addition of the acid molybdate reagent (0.4 mL). After the Fiske SubbaRow reagent (0.1 mL) and distilled water (1.5 mL) were added, the solution was mixed and allowed to develop. After 10 min, to allow full color development, the absorbance of the samples was read at 660 nm using a Cary 219 UV/vis spectrophotometer. The amount of inorganic phosphate released was compared to 15 a standard curve that was prepared by using a stock inorganic phosphate solution (0.65 mM) and preparing 6 standards with final inorganic phosphate concentrations ranging from 0.026 to 0.130 µmol/mL.

Assay for glycerol kinase activity:

An appropriate amount of enzyme, typically a cell-free crude extract, was 20 added to a reaction mixture containing 40 mM ATP, 20 mM MgSO<sub>4</sub>, 21 mM uniformly <sup>13</sup>C labelled glycerol (99%, Cambridge Isotope Laboratories), and 0.1 M Tris-HCl, pH 9 for 75 min at 25 °C. The conversion of glycerol to glycerol 3-phosphate was detected by <sup>13</sup>C-NMR (125 MHz): glycerol (63.11 ppm, δ, J = 41 Hz and 72.66 ppm, t, J = 41 Hz); glycerol 3-phosphate (62.93 ppm, δ, J = 41 Hz; 65.31 ppm, br d, J = 43 Hz; and 72.66 ppm, dt, J = 6, 41 Hz).

NADH-linked glycerol dehydrogenase assay:

NADH -linked glycerol dehydrogenase activity (*gldA*) in cell-free extracts from *E. coli* strains was determined after protein separation by non-denaturing polyacrylamide gel electrophoresis. The conversion of glycerol plus NAD<sup>+</sup> to 30 dihydroxyacetone plus NADH was coupled with the conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to a deeply colored formazan, using phenazine methosulfate (PMS) as mediator (Tang et al., *J. Bacteriol.* 140, 182 (1997)).

Electrophoresis was performed in duplicate by standard procedures using 35 native gels (8-16% TG, 1.5 mm, 15 lane gels from Novex, San Diego, CA). Residual glycerol was removed from the gels by washing 3x with 50 mM Tris or potassium carbonate buffer, pH 9 for 10 min. The duplicate gels were developed,

with and without glycerol (approximately 0.16 M final concentration), in 15 mL of assay solution containing 50 mM Tris or potassium carbonate, pH 9, 60 mg ammonium sulfate, 75 mg NAD<sup>+</sup>, 1.5 mg MTT, and 0.5 mg PMS.

The presence or absence of NADH-linked glycerol dehydrogenase activity  
5 in *E. coli* strains (*gldA*) was also determined, following polyacrylamide gel electrophoresis, by reaction with polyclonal antibodies raised to purified *K. pneumoniae* glycerol dehydrogenase (*dhaD*).

Isolation and identification of 1,3-propanediol:

The conversion of glycerol to 1,3-propanediol was monitored by HPLC.  
10 Analyses were performed using standard techniques and materials available to one of skill in the art of chromatography. One suitable method utilized a Waters Maxima 820 HPLC system using UV (210 nm) and RI detection. Samples were injected onto a Shodex SH-1011 column (8 mm x 300 mm, purchased from Waters, Milford, MA) equipped with a Shodex SH-1011P precolumn (6 mm x  
15 50 mm), temperature controlled at 50 °C, using 0.01 N H<sub>2</sub>SO<sub>4</sub> as mobile phase at a flow rate of 0.5 mL/min. When quantitative analysis was desired, samples were prepared with a known amount of trimethylacetic acid as external standard. Typically, the retention times of glucose (RI detection), glycerol, 1,3-propanediol (RI detection), and trimethylacetic acid (UV and RI detection) were 15.27 min,  
20 20.67 min, 26.08 min, and 35.03 min, respectively.

Production of 1,3-propanediol was confirmed by GC/MS. Analyses were performed using standard techniques and materials available to one of skill in the art of GC/MS. One suitable method utilized a Hewlett Packard 5890 Series II gas chromatograph coupled to a Hewlett Packard 5971 Series mass selective detector  
25 (EI) and a HP-INNOWax column (30 m length, 0.25 mm i.d., 0.25 micron film thickness). The retention time and mass spectrum of 1,3-propanediol generated were compared to that of authentic 1,3-propanediol (*m/e*: 57, 58).

An alternative method for GC/MS involved derivatization of the sample. To 1.0 mL of sample (e.g., culture supernatant) was added 30 µL of concentrated  
30 (70% v/v) perchloric acid. After mixing, the sample was frozen and lyophilized. A 1:1 mixture of bis(trimethylsilyl)trifluoroacetamide:pyridine (300 µL) was added to the lyophilized material, mixed vigorously and placed at 65 °C for one h. The sample was clarified of insoluble material by centrifugation. The resulting liquid partitioned into two phases, the upper of which was used for analysis. The  
35 sample was chromatographed on a DB-5 column (48 m, 0.25 mm I.D., 0.25 µm film thickness; from J&W Scientific) and the retention time and mass spectrum of the 1,3-propanediol derivative obtained from culture supernatants were compared

to that obtained from authentic standards. The mass spectra of TMS-derivatized 1,3-propanediol contains the characteristic ions of 205, 177, 130 and 115 AMU.

Cell Lysis:

Cell lysis was estimated by measuring the extracellular soluble protein concentration in the fermentation broth. Fermenter samples were centrifuged in a desktop centrifuge (typically, 3-5 min at 12,000 rpm in an Eppendorf, Model 5415C micro centrifuge) in order to separate cells. The resulting supernatant was analyzed for protein concentration by the Bradford method using a commercially available reagent (Bio-Rad Protein Assay, Bio-Rad, Hercules, CA).

10 Viability:

Cell viability was determined by plating, at appropriate dilutions, cells obtained from the fermenter on non-selective LB agar plates. Cell viability between fermenter experiments is compared by using the ratio of viable cells per mL of fermenter broth divided by OD<sub>550</sub> (AU).

15 EXAMPLE 1

CLONING AND TRANSFORMATION OF *E. COLI* HOST CELLS WITH COSMID DNA FOR THE EXPRESSION OF 1,3-PROPANEDIOL

Media:

Synthetic S12 medium was used in the screening of bacterial transformants 20 for the ability to make 1,3-propanediol. S12 medium contains: 10 mM ammonium sulfate, 50 mM potassium phosphate buffer, pH 7.0, 2 mM MgCl<sub>2</sub>, 0.7 mM CaCl<sub>2</sub>, 50 µM MnCl<sub>2</sub>, 1 µM FeCl<sub>3</sub>, 1 µM ZnCl, 1.7 µM CuSO<sub>4</sub>, 2.5 µM CoCl<sub>2</sub>, 2.4 µM Na<sub>2</sub>MoO<sub>4</sub>, and 2 µM thiamine hydrochloride.

Medium A used for growth and fermentation consisted of: 10 mM ammonium sulfate; 50 mM MOPS/KOH buffer, pH 7.5; 5 mM potassium phosphate buffer, pH 7.5; 2 mM MgCl<sub>2</sub>; 0.7 mM CaCl<sub>2</sub>; 50 µM MnCl<sub>2</sub>; 1 µM FeCl<sub>3</sub>; 1 µM ZnCl; 1.72 µM CuSO<sub>4</sub>; 2.53 µM CoCl<sub>2</sub>; 2.42 µM Na<sub>2</sub>MoO<sub>4</sub>; 2 µM thiamine hydrochloride; 0.01% yeast extract; 0.01% casamino acids; 0.8 µg/mL vitamin B<sub>12</sub>; and 50 µg/mL amp. Medium A was supplemented with either 0.2% 30 glycerol or 0.2% glycerol plus 0.2% D-glucose as required.

Cells:

*Klebsiella pneumoniae* ECL2106 (Ruch et al., *J. Bacteriol.* 124, 348 (1975)), also known in the literature as *K. aerogenes* or *Aerobacter aerogenes*, was obtained from E. C. C. Lin (Harvard Medical School, Cambridge, MA) and 35 was maintained as a laboratory culture.

*Klebsiella pneumoniae* ATCC 25955 was purchased from American Type Culture Collection (Manassas, VA).

*E. coli* DH5 $\alpha$  was purchased from Gibco/BRL and was transformed with the cosmid DNA isolated from *Klebsiella pneumoniae* ATCC 25955 containing a gene coding for either a glycerol or diol dehydratase enzyme. Cosmids containing the glycerol dehydratase were identified as pKP1 and pKP2 and cosmid 5 containing the diol dehydratase enzyme were identified as pKP4. Transformed DH5 $\alpha$  cells were identified as DH5 $\alpha$ -pKP1, DH5 $\alpha$ -pKP2, and DH5 $\alpha$ -pKP4.

*E. coli* ECL707 (Sprenger et al., *J. Gen. Microbiol.* 135, 1255 (1989)) was obtained from E. C. C. Lin (Harvard Medical School, Cambridge, MA) and was similarly transformed with cosmid DNA from *Klebsiella pneumoniae*. These 10 transformants were identified as ECL707-pKP1 and ECL707-pKP2, containing the glycerol dehydratase gene and ECL707-pKP4 containing the diol dehydratase gene.

*E. coli* AA200 containing a mutation in the *tpi* gene (Anderson et al., *J. Gen. Microbiol.* 62, 329 (1970)) was purchased from the *E. coli* Genetic Stock 15 Center, Yale University (New Haven, CT) and was transformed with *Klebsiella* cosmid DNA to give the recombinant microorganisms AA200-pKP1 and AA200-pKP2, containing the glycerol dehydratase gene, and AA200-pKP4, containing the diol dehydratase gene.

DH5 $\alpha$ :

20 Six transformation plates containing approximately 1,000 colonies of *E. coli* XL1-Blue MR transfected with *K. pneumoniae* DNA were washed with 5 mL LB medium and centrifuged. The bacteria were pelleted and resuspended in 5 mL LB medium + glycerol. An aliquot (50  $\mu$ L) was inoculated into a 15 mL tube containing S12 synthetic medium with 0.2% glycerol + 400 ng per mL of 25 vitamin B<sub>12</sub> + 0.001% yeast extract + 50 amp. The tube was filled with the medium to the top and wrapped with parafilm and incubated at 30 °C. A slight turbidity was observed after 48 h. Aliquots, analyzed for product distribution as described above at 78 h and 132 h, were positive for 1,3-propanediol, the later time points containing increased amounts of 1,3-propanediol.

30 The bacteria, testing positive for 1,3-propanediol production, were serially diluted and plated onto LB-50 amp plates in order to isolate single colonies. Forty-eight single colonies were isolated and checked again for the production of 1,3-propanediol. Cosmid DNA was isolated from 6 independent clones and transformed into *E. coli* strain DH5 $\alpha$ . The transformants were again checked for 35 the production of 1,3-propanediol. Two transformants were characterized further and designated as DH5 $\alpha$ -pKP1 and DH5 $\alpha$ -pKP2.

A 12.1 kb EcoRI-SalI fragment from pKP1, subcloned into pIBI31 (IBI Biosystem, New Haven, CT), was sequenced and termed pHK28-26 (SEQ ID NO:1). Sequencing revealed the loci of the relevant open reading frames of the *dha* operon encoding glycerol dehydratase and genes necessary for regulation.

5 Referring to SEQ ID NO:1, a fragment of the open reading frame for *dhaK1* encoding dihydroxyacetone kinase is found at bases 1-399 (complement); the open reading frame *dhaD* encoding glycerol dehydrogenase is found at bases 1010-2107; the open reading frame *dhaR* encoding the repressor is found at bases 2209-4134; the open reading frame *orfW*, encoding a protein of unknown function

10 is found at bases 4112-4642 (complement); the open reading frame *orfX* encoding a dehydratase reactivation protein is found at bases 4643-4996 (complement); the open reading frame *dhaT* encoding 1,3-propanediol oxidoreductase is found at bases 5017-6180 (complement); the open reading frame *orfY*, encoding a protein of unknown function is found at bases 6202-6630 (complement); the open reading

15 frame *dhaB1* encoding the alpha subunit glycerol dehydratase is found at bases 7044-8711; the open reading frame *dhaB2* encoding the beta subunit glycerol dehydratase is found at bases 8724-9308; the open reading frame *dhaB3* encoding the gamma subunit glycerol dehydratase is found at bases 9311-9736; the open reading frame *dhaBX*, encoding a dehydratase reactivation protein is found at

20 bases 9749-11572; and a fragment of the open reading frame for *glpF* encoding a glycerol uptake facilitator protein is found at bases 11626-12145.

Single colonies of *E. coli* XL1-Blue MR transfected with packaged cosmid DNA from *K. pneumoniae* were inoculated into microtiter wells containing 200 µL of S15 medium (ammonium sulfate, 10 mM; potassium phosphate buffer, pH 7.0, 1 mM; MOPS/KOH buffer, pH 7.0, 50 mM; MgCl<sub>2</sub>, 2 mM; CaCl<sub>2</sub>, 0.7 mM; MnCl<sub>2</sub>, 50 µM; FeCl<sub>3</sub>, 1 µM; ZnCl<sub>2</sub>, 1 µM; CuSO<sub>4</sub>, 1.72 µM; CoCl<sub>2</sub>, 2.53 µM; Na<sub>2</sub>MoO<sub>4</sub>, 2.42 µM; and thiamine hydrochloride, 2 µM) + 0.2% glycerol + 400 ng/mL of vitamin B<sub>12</sub> + 0.001% yeast extract + 50 µg/mL ampicillin. In addition to the microtiter wells, a master plate containing 25 LB-50 amp was also inoculated. After 96 h, 100 µL was withdrawn and centrifuged in a Rainin microfuge tube containing a 0.2 micron nylon membrane filter. Bacteria were retained and the filtrate was processed for HPLC analysis. Positive clones demonstrating 1,3-propanediol production were identified after screening approximately 240 colonies. Three positive clones were identified, two 30 of which had grown on LB-50 amp and one of which had not. A single colony, isolated from one of the two positive clones grown on LB-50 amp and verified for the production of 1,3-propanediol, was designated as pKP4. Cosmid DNA was

isolated from *E. coli* strains containing pKP4 and *E. coli* strain DH5 $\alpha$  was transformed. An independent transformant, designated as DH5 $\alpha$ -pKP4, was verified for the production of 1,3-propanediol.

ECL707:

5       *E. coli* strain ECL707 was transformed with cosmid *K. pneumoniae* DNA corresponding to one of pKP1, pKP2, pKP4 or the Supercos vector alone and named ECL707-pKP1, ECL707-pKP2, ECL707-pKP4, and ECL707-sc, respectively. ECL707 is defective in *glpK*, *glcD*, and *ptsD* which encode the ATP-dependent glycerol kinase, NAD $^+$ -linked glycerol dehydrogenase, and  
10      enzyme II for dihydroxyacetone of the phosphoenolpyruvate-dependent phosphotransferase system, respectively.

Twenty single colonies of each cosmid transformation and five of the Supercos vector alone (negative control) transformation, isolated from LB-50 amp plates, were transferred to a master LB-50 amp plate. These isolates were also  
15      tested for their ability to convert glycerol to 1,3-propanediol in order to determine if they contained dehydratase activity. The transformants were transferred with a sterile toothpick to microtiter plates containing 200  $\mu$ L of Medium A supplemented with either 0.2% glycerol or 0.2% glycerol plus 0.2% D-glucose.  
After incubation for 48 h at 30 °C, the contents of the microtiter plate wells were  
20      filtered through a 0.45 micron nylon filter and chromatographed by HPLC. The results of these tests are given in Table 2.

**TABLE 2**  
**Conversion of glycerol to 1,3-propanediol by transformed ECL707**

<u>transformant</u>	<u>glycerol*</u>	<u>glycerol plus glucose*</u>
ECL707-pKP1	19/20	19/20
ECL707-pKP2	18/20	20/20
ECL707-pKP4	0/20	20/20
ECL707-sc	0/5	0/5

\*(Number of positive isolates/number of isolates tested)

AA200:

25       *E. coli* strain AA200 was transformed with cosmid *K. pneumoniae* DNA corresponding to one of pKP1, pKP2, pKP4 and the Supercos vector alone and named AA200-pKP1, AA200-pKP2, AA200-pKP4, and AA200-sc, respectively. Strain AA200 is defective in triosephosphate isomerase (*tpi* $^-$ ).

30       Twenty single colonies of each cosmid transformation and five of the empty vector transformation were isolated and tested for their ability to convert

glycerol to 1,3-propanediol as described for *E. coli* strain ECL707. The results of these tests are given in Table 3.

TABLE 3

## Conversion of glycerol to 1,3-propanediol by transformed AA200

<u>transformant</u>	<u>glycerol*</u>	<u>glycerol plus glucose*</u>
AA200-pKP1	17/20	17/20
AA200-pKP2	17/20	17/20
AA200-pKP4	2/20	16/20
AA200-sc	0/5	0/5

\*(Number of positive isolates/number of isolates tested)

5

EXAMPLE 2

ENGINEERING OF GLYCEROL KINASE MUTANTS OF *E. COLI* FMS  
FOR PRODUCTION OF GLYCEROL FROM GLUCOSE

Construction of integration plasmid for glycerol kinase gene replacement in *E. coli* FMS:

10        *E. coli* FMS (ATCC 53911) genomic DNA was prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). A 1.0 kb DNA fragment containing partial *glpF* and glycerol kinase (*glpK*) genes was amplified by PCR (Mullis and Falloona, *Methods Enzymol.* 155, 335 (1987)) from FMS genomic DNA using primers SEQ ID NO:2 and SEQ ID NO:3. A 1.1 kb DNA  
15        fragment containing partial *glpK* and *glpX* genes was amplified by PCR from FMS genomic DNA using primers SEQ ID NO:4 and SEQ ID NO:5. A *Mun*I site was incorporated into primer SEQ ID NO:4. The 5' end of primer SEQ ID NO:4 was the reverse complement of primer SEQ ID NO:3 to enable subsequent overlap extension PCR. The gene splicing by overlap extension technique (Horton et al.,  
20        *BioTechniques* 8, 528 (1990)) was used to generate a 2.1 kb fragment by PCR using the above two PCR fragments as templates and primers SEQ ID NO:2 and SEQ ID NO:5. This fragment represented a deletion of 0.8 kb from the central region of the 1.5 kb *glpK* gene. Overall, this fragment had 1.0 kb and 1.1 kb flanking regions on either side of the *Mun*I cloning site (within the partial *glpK*) to  
25        allow for chromosomal gene replacement by homologous recombination.

30        The above 2.1 kb PCR fragment was blunt-ended (using mung bean nuclease) and cloned into the pCR-Blunt vector using the Zero Blunt PCR Cloning Kit (Invitrogen, San Diego, CA) to yield the 5.6 kb plasmid pRN100 containing kanamycin and Zeocin resistance genes. The 1.2 kb *Hinc*II fragment from pLoxCat1 (unpublished results), containing a chloramphenicol-resistance

gene flanked by bacteriophage P1 *loxP* sites (Snaith et al., *Gene* 166, 173 (1995)), was used to interrupt the *glpK* fragment in plasmid pRN100 by ligating it to *Mun*I-digested (and blunt-ended) plasmid pRN100 to yield the 6.9 kb plasmid pRN101-1. A 376 bp fragment containing the R6K origin was amplified by PCR 5 from the vector pGP704 (Miller and Mekalanos, *J. Bacteriol.* 170, 2575-2583 (1988)) using primers SEQ ID NO:6 and SEQ ID NO:7, blunt-ended, and ligated to the 5.3 kb *Asp*718-*Aat*II fragment (which was blunt-ended) from pRN101-1 to yield the 5.7 kb plasmid pRN102-1 containing kanamycin and chloramphenicol 10 resistance genes. Substitution of the ColE1 origin region in pRN101-1 with the R6K origin to generate pRN102-1 also involved deletion of most of the Zeocin resistance gene. The host for pRN102-1 replication was *E. coli* SY327 (Miller and Mekalanos, *J. Bacteriol.* 170, 2575-2583 (1988)) which contains the *pir* gene necessary for the function of the R6K origin.

Engineering of glycerol kinase mutant RJF10m with chloramphenicol resistance 15 gene interrupt:

*E. coli* FM5 was electrotransformed with the non-replicative integration plasmid pRN102-1 and transformants that were chloramphenicol-resistant (12.5 µg/mL) and kanamycin-sensitive (30 µg/mL) were further screened for glycerol non-utilization on M9 minimal medium containing 1 mM glycerol. An 20 *Eco*RI digest of genomic DNA from one such mutant, RJF10m, when probed with the intact *glpK* gene via Southern analysis (Southern, *J. Mol. Biol.* 98, 503-517 (1975)) indicated that it was a double-crossover integrant (*glpK* gene replacement) since the two expected 7.9 kb and 2.0 kb bands were observed, owing to the presence of an additional *Eco*RI site within the chloramphenicol resistance gene. 25 The wild-type control yielded the single expected 9.4 kb band. A <sup>13</sup>C NMR analysis of mutant RJF10m confirmed that it was incapable of converting <sup>13</sup>C-labeled glycerol and ATP to glycerol-3-phosphate. This *glpK* mutant was further analyzed by genomic PCR using primer combinations SEQ ID NO:8 and SEQ 30 ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, and SEQ ID NO:8 and SEQ ID NO:11 which yielded the expected 2.3 kb, 2.4 kb, and 4.0 kb PCR fragments respectively. The wild-type control yielded the expected 3.5 kb band with primers SEQ ID NO:8 and SEQ ID NO:11. The *glpK* mutant RJF10m was electrotransformed with plasmid pAH48 to allow glycerol production from glucose. The *glpK* mutant *E. coli* RJF10m has been deposited with ATCC under 35 the terms of the Budapest Treaty on 24 November 1997.

Engineering of glycerol kinase mutant Rjf10 with chloramphenicol resistance gene interrupt removed:

After overnight growth on YENB medium (0.75% yeast extract, 0.8% nutrient broth) at 37 °C, *E. coli* Rjf10m in a water suspension was electrotransformed with plasmid pJW168 (unpublished results), which contained the bacteriophage P1 Cre recombinase gene under the control of the IPTG-inducible *lacUV5* promoter, a temperature-sensitive pSC101 replicon, and an ampicillin resistance gene. Upon outgrowth in SOC medium at 30 °C, transformants were selected at 30 °C (permissive temperature for pJW168 replication) on LB agar medium supplemented with carbenicillin (50 µg/mL) and IPTG (1 mM). Two serial overnight transfers of pooled colonies were carried out at 30 °C on fresh LB agar medium supplemented with carbenicillin and IPTG in order to allow excision of the chromosomal chloramphenicol resistance gene via recombination at the *loxP* sites mediated by the Cre recombinase (Hoess and Abremski, *J. Mol. Biol.* 181, 351-362 (1985)). Resultant colonies were replicated on to LB agar medium supplemented with carbenicillin and IPTG and LB agar supplemented with chloramphenicol (12.5 µg/mL) to identify colonies that were carbenicillin-resistant and chloramphenicol-sensitive indicating marker gene removal. An overnight 30 °C culture of one such colony was used to inoculate 10 mL of LB medium. Upon growth at 30 °C to OD (600 nm) of 0.6 AU, the culture was incubated at 37 °C overnight. Several dilutions were plated on prewarmed LB agar medium and the plates incubated overnight at 42 °C (the non-permissive temperature for pJW168 replication). Resultant colonies were replicated on to LB agar medium and LB agar medium supplemented with carbenicillin (75 µg/mL) to identify colonies that were carbenicillin-sensitive indicating loss of plasmid pJW168. One such *glpK* mutant, Rjf10, was further analyzed by genomic PCR using primers SEQ ID NO:8 and SEQ ID NO:11 and yielded the expected 3.0 kb band confirming marker gene excision. Glycerol non-utilization by mutant Rjf10 was confirmed by lack of growth on M9 minimal medium containing 1 mM glycerol. The *glpK* mutant Rjf10 was electrotransformed with plasmid pAH48 to allow glycerol production from glucose.

EXAMPLE 3

CONSTRUCTION OF *E. COLI* STRAIN WITH *gldA* GENE KNOCKOUT

The *gldA* gene was isolated from *E. coli* by PCR (K. B. Mullis and F. A. Falloona, *Meth. Enzymol.* 155, 335-350 (1987)) using primers SEQ ID NO:12 and SEQ ID NO:13, which incorporate terminal Sph1 and Xba1 sites, respectively,

and cloned (T. Maniatis (1982) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor, NY) between the Sph1 and Xba1 sites in pUC18, to generate pKP8. pKP8 was cut at the unique Sal1 and Nco1 sites within the *gldA* gene, the ends flushed with Klenow and religated, resulting in a 109 bp deletion in the middle of *gldA* and regeneration of a unique Sal1 site, to generate pKP9. A 1.4 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and including about 400 bps of DNA upstream of the translational start codon and about 100 bps of DNA downstream of the translational stop codon, was isolated from pET-28a(+) (Novagen, Madison, Wis) by PCR using primers SEQ ID NO:14 and SEQ ID NO:15, which incorporate terminal Sal1 sites, and subcloned into the unique Sal1 site of pKP9, to generate pKP13. A 2.1 kb DNA fragment beginning 204 bps downstream of the *gldA* translational start codon and ending 178 bps upstream of the *gldA* translational stop codon, and containing the kan insertion, was isolated from pKP13 by PCR using primers SEQ ID NO:16 and SEQ ID NO:17, which incorporate terminal Sph1 and Xba1 sites, respectively, was subcloned between the Sph1 and Xba1 sites in pMAK705 (Genencor International, Palo Alto, CA), to generate pMP33. *E. coli* FM5 was transformed with pMP33 and selected on 20 µg/mL kan at 30 °C, which is the permissive temperature for pMAK705 replication. One colony was expanded overnight at 30 °C in liquid media supplemented with 20 µg/mL kan. Approximately 32,000 cells were plated on 20 µg/mL kan and incubated for 16 h at 44 °C, which is the restrictive temperature for pMAK705 replication. Transformants growing at 44 °C have plasmid integrated into the chromosome, occurring at a frequency of approximately 0.0001. PCR and Southern blot (E.M. Southern, *J. Mol. Biol.* 98, 503-517 (1975)) analyses were used to determine the nature of the chromosomal integration events in the transformants. Western blot analysis (Towbin et al., *Proc. Natl. Acad. Sci.* 76, 4350 (1979)) was used to determine whether glycerol dehydrogenase protein, the product of *gldA*, is produced in the transformants. An activity assay was used to determine whether glycerol dehydrogenase activity remained in the transformants. Activity in glycerol dehydrogenase bands on native gels was determined by coupling the conversion of glycerol plus NAD<sup>+</sup> to dihydroxyacetone plus NADH to the conversion of a tetrazolium dye, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to a deeply colored formazan, with phenazine methosulfate as mediator. Glycerol dehydrogenase also requires the presence of 30 mM ammonium sulfate and 100 mM Tris, pH 9 (Tang et al., *J. Bacteriol.* 140, 182 (1997)). Of 8 transformants analyzed, 6 were determined to be *gldA*.

knockouts. *E. coli* MSP33.6 has been deposited with ATCC under the terms of the Budapest Treaty on 24 November 1997.

EXAMPLE 4

CONSTRUCTION OF AN *E. COLI* STRAIN  
5 WITH *glpK* AND *gldA* GENE KNOCKOUTS

A 1.6 kb DNA fragment containing the *gldA* gene and including 228 bps of DNA upstream of the translational start codon and 220 bps of DNA downstream of the translational stop codon was isolated from *E. coli* by PCR using primers SEQ ID NO:18 and SEQ ID NO:19, which incorporate terminal Sph1 and Xba1 sites, respectively, and cloned between the Sph1 and Xba1 sites of pUC18, to generate pQN2. pQN2 was cut at the unique Sal1 and Nco1 sites within the *gldA* gene, the ends flushed with Klenow and religated, resulting in a 109 bps deletion in the middle of *gldA* and regeneration of a unique Sal1 site, to generate pQN4. A 1.2 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and flanked by loxP sites was isolated from pLoxKan2 (Genencor International, Palo Alto, CA) as a Stu1/Xho1 fragment, the ends flushed with Klenow, and subcloned into pQN4 at the Sal1 site after flushing with Klenow, to generate pQN8. A 0.4 kb DNA fragment containing the R6K origin of replication was isolated from pGP704 (Miller and Mekalanos, 10 *J. Bacteriol.* 170, 2575-2583 (1988)) by PCR using primers SEQ ID NO:20 and SEQ ID NO:21, which incorporate terminal Sph1 and Xba1 sites, respectively, and ligated to the 2.8 kb Sph1/Xba1 DNA fragment containing the *gldA::kan* cassette from pQN8, to generate pKP22. A 1.0 kb DNA fragment containing the gene conferring chloramphenicol resistance (cam), and flanked by loxP sites was 15 isolated from pLoxCat2 (Genencor International, Palo Alto, CA) as an Xba1 fragment, and subcloned into pKP22 at the Xba1 site, to generate pKP23. *E. coli* strain RJF10 (see Example 2), which is *glpK-*, was transformed with pKP23 and transformants with the phenotype kanRcamS were isolated, indicating double crossover integration, which was confirmed by southern blot analysis. Glycerol 20 dehydrogenase gel activity assays (as described in Example 3) demonstrated that active glycerol dehydrogenase was not present in these transformants. The kan marker was removed from the chromosome using the Cre-producing plasmid pJW168, as described in Example 2, to produce strain KLP23. Several isolates 25 with the phenotype kanS demonstrated no glycerol dehydrogenase activity, and southern blot analysis confirmed loss of the kan marker.

EXAMPLE 5PLASMID CONSTRUCTION AND STRAIN CONSTRUCTION FOR THE  
EXPRESSION OF GLYCEROL 3-PHOSPHATE DEHYDROGENASE (DAR1)  
AND/OR GLYCEROL 3-PHOSPHATASE (GPP2)5 Construction of expression cassettes for glycerol 3-phosphatase (gpp2):

The *Saccharomyces cerevisiae* chromosome V lambda clone 6592 (GenBank, accession # U18813x11) was obtained from ATCC. The glycerol 3-phosphate phosphatase gene (GPP2) was cloned by cloning from the lambda clone as target DNA using synthetic primers (SEQ ID NO:22 with SEQ ID NO:23) incorporating an BamHI-RBS-XbaI site at the 5' end and a SmaI site at the 3' end. The product was subcloned into pCR-Script (Stratagene, Madison, WI) at the SrfI site to generate the plasmid pAH15 containing GPP2. The plasmid pAH15 contains the GPP2 gene in the inactive orientation for expression from the lac promoter in pCR-Script SK+. The BamHI-SmaI fragment from pAH15 containing the GPP2 gene was inserted into pBlueScriptII SK+ to generate plasmid pAH19. The pAH19 contains the GPP2 gene in the correct orientation for expression from the lac promoter. The XbaI-PstI fragment from pAH19 containing the GPP2 gene was inserted into pPHOX2 to create plasmid pAH21. The pAH21/DH5 $\alpha$  is the expression plasmid.

20 Construction of expression cassettes for glycerol 3-phosphate dehydrogenase (DAR1):

DAR1 was isolated by PCR cloning from genomic *S. cerevisiae* DNA using synthetic primers (SEQ ID NO:24 with SEQ ID NO:25). Successful PCR cloning places an NcoI site at the 5' end of DAR1 where the ATG within NcoI is the DAR1 initiator methionine. At the 3' end of DAR1 a BamHI site is introduced following the translation terminator. The PCR fragments were digested with NcoI + BamHI and cloned into the same sites within the expression plasmid pTrc99A (Pharmacia, Piscataway, NJ) to give pDAR1A.

In order to create a better ribosome binding site at the 5' end of DAR1, an 30 SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:26 with SEQ ID NO:27) was inserted into the NcoI site of pDAR1A to create pAH40. Plasmid pAH40 contains the new RBS and DAR1 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ). The NcoI-BamHI fragment from pDAR1A and a second set of 35 SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:28 with SEQ ID NO:29) was inserted into the SpeI-BamHI site of pBC-SK+

(Stratagene, Madison, WI) to create plasmid pAH42. The plasmid pAH42 contains a chloramphenicol resistant gene.

Construction of expression cassettes for dar1 and gpp2:

5 Expression cassettes for DAR1 and GPP2 were assembled from the individual DAR1 and GPP2 subclones described above using standard molecular biology methods. The BamHI-PstI fragment from pAH19 containing the ribosomal binding site (RBS) and GPP2 gene was inserted into pAH40 to create pAH43. The BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was inserted into pAH42 to create pAH45.

10 The ribosome binding site at the 5' end of GPP2 was modified as follows. A BamHI-RBS-SpeI linker, obtained by annealing synthetic primers GATCCAGGAAACAGA (SEQ ID NO:30) with CTAGTCTGTTCCCTG (SEQ ID NO:31) to the XbaI-PstI fragment from pAH19 containing the GPP2 gene, was inserted into the BamHI-PstI site of pAH40 to create pAH48. Plasmid pAH48 15 contains the DAR1 gene, the modified RBS, and the GPP2 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ).

Transformation of *E. coli*:

20 The plasmids described here were transformed into *E. coli* DH5 $\alpha$ , FM5 and KLP23 using standard molecular biology techniques. The transformants were verified by their DNA RFLP pattern.

EXAMPLE 6

CONSTRUCTION OF EXPRESSION PLASMIDS FOR USE IN  
TRANSFORMATION OF *ESCHERICHIA COLI* WITH GENES FROM THE  
25 *KLEBSIELLA PNEUMONIAE dha* REGULON

Construction of the expression vector pTacIQ:

The *E. coli* expression vector pTacIQ was prepared by inserting lacIQ gene (Farabaugh, *Nature* 274(5673), 765-769 (1978)) and tac promoter (Amann et al., *Gene* 25, 167-178 (1983)) into the restriction endonuclease site EcoRI of pBR322 (Sutcliffe, *Cold Spring Harb. Symp. Quant. Biol.* 43, 77-90 (1979)). A multiple cloning site and terminator sequence (SEQ ID NO:32) replaces the pBR322 sequence from EcoRI to SphI.

Subcloning the glycerol dehydratase genes (*dhaB1 ,2,3, X*):

35 The open reading frame for the *dhaB3* gene was amplified from pHK28-26 by PCR using primers (SEQ ID NO:33 and SEQ ID NO:34) incorporating an EcoRI site at the 5' end and a XbaI site at the 3' end. The product was subcloned

into pLitmus29 (New England Biolab, Inc., Beverly, MA) to generate the plasmid pDHAB3 containing *dhaB3*.

The region containing the entire coding region for *dhaB1*, *dhaB2*, *dhaB3* and *dhaBX* of the *dhaB* operon from pHK28-26 was cloned into pBluescriptIIKS+ (Stratagene, La Jolla, CA) using the restriction enzymes KpnI and EcoRI to create the plasmid pM7.

The *dhaBX* gene was removed by digesting plasmid pM7 with Apal and XbaI, purifying the 5.9 kb fragment and ligating it with the 325-bp Apal-XbaI fragment from plasmid pDHAB3 to create pM11 containing *dhaB1*, *dhaB2* and *dhaB3*.

The open reading frame for the *dhaB1* gene was amplified from pHK28-26 by PCR using primers (SEQ ID NO:35 and SEQ ID NO:36) incorporating a HindIII site and a consensus ribosome binding site at the 5' end and a XbaI site at the 3' end. The product was subcloned into pLitmus28 (New England Biolab, Inc., Beverly, MA) to generate the plasmid pDT1 containing *dhaB1*.

A NotI-XbaI fragment from pM11 containing part of the *dhaB1* gene, the *dhaB2* gene and the *dhaB3* gene was inserted into pDT1 to create the *dhaB* expression plasmid, pDT2. The HindIII-XbaI fragment containing the *dhaB(1,2,3)* genes from pDT2 was inserted into pTaciQ to create pDT3.

**20      Subcloning the 1,3-propanediol dehydrogenase gene (*dhaT*):**

The KpnI-SacI fragment of pHK28-26, containing the 1,3-propanediol dehydrogenase (*dhaT*) gene, was subcloned into pBluescriptII KS+ creating plasmid pAH1. The *dhaT* gene was amplified by PCR from pAH1 as template DNA and synthetic primers (SEQ ID NO:37 with SEQ ID NO:38) incorporating an XbaI site at the 5' end and a BarnHI site at the 3' end. The product was subcloned into pCR-Script (Stratagene) at the SrfI site to generate the plasmids pAH4 and pAH5 containing *dhaT*. The plasmid pAH4 contains the *dhaT* gene in the right orientation for expression from the lac promoter in pCR-Script and pAH5 contains *dhaT* gene in the opposite orientation. The XbaI-BamHI fragment from pAH4 containing the *dhaT* gene was inserted into pTaciQ to generate plasmid pAH8. The HindII-BamHI fragment from pAH8 containing the RBS and *dhaT* gene was inserted into pBluescriptIIKS+ to create pAH11.

**Construction of an expression cassette for *dhaT* and *dhaB(1,2,3)*:**

An expression cassette for *dhaT* and *dhaB(1,2,3)* was assembled from the individual *dhaB(1,2,3)* and *dhaT* subclones described previously using standard molecular biology methods. A SpeI-SacI fragment containing the *dhaB(1,2,3)* genes from pDT3 was inserted into pAH11 at the SpeI-SacI sites to create pAH24.

A SalI-XbaI linker (SEQ ID NO:39 and SEQ ID NO:40) was inserted into pAH5 that was digested with the restriction enzymes SalI-XbaI to create pDT16. The linker destroys the XbaI site. The 1 kb SalI-MluI fragment from pDT16 was then inserted into pAH24 replacing the existing SalI-MluI fragment to create pDT18.

5 pDT21 was constructed by inserting the SalI-NotI fragment from pDT18 and the NotI-XbaI fragment from pM7 into pCL1920 (SEQ ID NO:41). The glucose isomerase promoter sequence from *Streptomyces* (SEQ ID NO:42) was cloned by PCR and inserted into EcoRI-HinDIII sites of pLitmus28 to construct pDT5. pCL1925 was constructed by inserting EcoRI-PvuII fragment of pDT5 into the 10 EcoRI-PvuI site of pCL1920. pDT24 was constructed by cloning the HinDIII-MluII fragment of pDT21 and the MluI-XbaI fragment of pDT21 into the HinDIII-XbaI sites of pCL1925.

Construction of an expression cassette for *dhaT* and *dhaB(1,2,3,X)*:

pDT21 was constructed by inserting the SalI-NotI fragment from pDT18 15 and the NotI-XbaI fragment from pM7 into pCL1920 (SEQ ID NO:41). The glucose isomerase promoter sequence from *Streptomyces* (SEQ ID NO:42) was cloned by PCR and inserted into EcoRI-HinDIII sites of pLitmus28 to construct pDT5. pCL1925 was constructed by inserting EcoRI-PvuII fragment of pDT5 into the EcoRI-PvuI site of pCL1920. pDT24 was constructed by cloning the 20 HinDIII-MluII fragment of pDT21 and the MluI-XbaI fragment of pDT21 into the HinDIII-XbaI sites of pCL1925.

Construction of an expression cassette for *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW* and *dhaB(1,2,3,X)*:

pDT29 was constructed by inserting the SacI-EcoRI fragment of 25 pHK28-26 into SacI-EcoRI sites of pCL1925.

Construction of an expression cassette for *dhaR*, *orfY*, *orfX*, *orfW* and *dhaB(1,2,3,X)*:

A derivative of plasmid pDT29 was constructed in which all except the first 5 and the last 5 codons (plus stop codon) of the gene *dhaT* were deleted by a 30 technique known as PCR-mediated overlap extension. Using pDT29 as template, 2 primary PCR products were generated using the following primers:

SEQ ID NO:43 = 5'GAC GCA ACA GTA TTC CGT CGC3';  
SEQ ID NO:44 = 5'ATG AGC TAT CGT ATG TTC CGC CAG GCA TTC TGA GTG TTA ACG3';  
35 SEQ ID NO:45 = 5'GCC TGG CGG AAC ATA CGA TAG CTC ATA ATA TAC3';  
SEQ ID NO:46 = 5'CGG GGC GCT GGG CCA GTA CTG3'.

SEQ ID NO:45 was paired with SEQ ID NO:46 to generate a product of 931 bps and encompassing nucleic acid including 5' dhaB1 (to unique Scal site), all of orfY, and the first five codons of *dhaT*. SEQ ID NO:43 was paired with SEQ ID NO:44 to generate a product of 1348 bps and encompassing nucleic acid including the last five codons (plus stop codon) of *dhaT*, all of *orfX*, all of *orfW*, and 5' *dhaR* (to unique SapI site). The 15 bases at the 5' end of SEQ ID NO:44 constitute a tail that is the inverse complement of a 15 base portion of SEQ ID NO:45. Similarly, the 11 bases at the 5' end of SEQ ID NO:45 constitute a tail that is the inverse complement of an 11 base portion of SEQ ID NO:44. Thus, the 2 primary PCR products were joined together after annealing (via 26 bp tail overlap) and extending by PCR, to generate a third nucleic acid product of 2253 bps. This third PCR product was digested with SapI and Scal and ligated into pDT29 which was also digested with SapI and Scal, to generate the plasmid pKP32, which is identical to pDT29, except for the large, in-frame deletion within *dhaT*.

#### EXAMPLE 7

##### CONVERSION OF GLUCOSE TO 1,3-PROPANEDIOL USING

*E. COLI* STRAIN KLP23/pAH48/pDT29 AND

THE IMPROVED PROCESS USING KLP23/pAH48/pKP32

20 Pre-Culture:

KLP23/pAH48/pDT29 and KLP23/pAH48/pKP32 were pre-cultured for seeding a fermenter in 2YT medium (10 g/L yeast extract, 16 g/L tryptone, and 10 g/L NaCl) containing 200 mg/L carbenicillin (or ampicillin) and 50 mg/L spectinomycin. KLP23/pAH48/pKP32 is identical to KLP23/pAH48/pDT29 except that *dhaT* is deleted.

Cultures were started from frozen stocks (10% DMSO as cryoprotectant) in 500 mL of medium in a 2-L Erlenmeyer flask, grown at 35 °C in a shaker at 250 rpm until an OD<sub>550</sub> of approximately 1.0 AU was reached and used to seed the fermenter.

30 Fermenter medium:

The following components were sterilized together in the fermenter vessel: 45 g KH<sub>2</sub>PO<sub>4</sub>, 12 g citric acid, 12 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 30 g yeast extract, 2.0 g ferric ammonium citrate, 5 mL Mazu DF204 as antifoam, 1.2 g CaCl<sub>2</sub>·2H<sub>2</sub>O, and 7.3 mL sulfuric acid. The pH was raised to 6.8 with 20-28% NH<sub>4</sub>OH and the following components were added: 1.2 g carbenicillin or ampicillin, 0.30 g spectinomycin, 60 mL of a solution of trace elements and glucose (from a 60-67 weight % feed). After inoculation, the volume was 6.0 L and the glucose

concentration was 10 g/L. The solution of trace elements contained (g/L): citric acid. H<sub>2</sub>O (4.0), MnSO<sub>4</sub>·H<sub>2</sub>O (3.0), NaCl (1.0), FeSO<sub>4</sub>·7H<sub>2</sub>O (0.10), CoCl<sub>2</sub>·6H<sub>2</sub>O (0.10), ZnSO<sub>4</sub>·7H<sub>2</sub>O (0.10), CuSO<sub>4</sub>·5H<sub>2</sub>O (0.010), H<sub>3</sub>BO<sub>3</sub> (0.010), and Na<sub>2</sub>MoO<sub>4</sub>·2H<sub>2</sub>O (0.010).

5    Fermentation growth:

A 15 L stirred tank fermenter was prepared with the medium described above. The temperature was controlled at 35 °C and aqueous ammonia (20-28 weight %) was used to control pH at 6.8. Initial values for air flow rate (set to minimum values of between 6 and 12 standard liters per min) and agitator speed (set to minimum values of between 350 and 690 rpm) were set so that dissolved oxygen (DO) control was initiated when OUR values reached approximately 140 mmol/L/h. Back pressure was controlled at 0.5 bar. DO control was set at 10%. Except for minor excursions, glucose was maintained at between 0 g/L and 10 g/L with a 60% or 67% (wt) feed. Vitamin B<sub>12</sub> or 10 coenzyme B<sub>12</sub> was added as noted below.

15    coenzyme B<sub>12</sub> was added as noted below.

Fermentation with KLP23/pAH48/pDT29:

A representative fermentation summary of the conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain KLP23/pAH48/pDT29 is given in Table 4. Vitamin B<sub>12</sub> (0.075 g/L, 500 mL) was fed, starting 3 h after inoculation, 20 at a rate of 16 mL/h. The yield of 1,3-propanediol was 24 wt % (g 1,3-propanediol/g glucose consumed) and a titer of 68 g/L 1,3-propanediol was obtained.

**TABLE 4**  
Representative fermentation summary of the conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain KLP23/pAH48/pDT29

Time (h)	OD <sub>550</sub> (AU)	DO (%)	Glucose (g/L)	Glycerol (g/L)	1,3-PD (g/L)
0	0	150	12.9	0.0	0
6	17	80	8.3	3.1	1
12	42	53	2.8	12.5	9
18	98	9	5.7	12.6	32
24	136	11	32.8	12.0	51
30	148	10	12.3	13.3	62
32	152	11	12.5	14.3	65
38	159	11	1.5	17.2	68

Similar results were obtained with an identical vitamin B<sub>12</sub> feed at twice the concentration or bolus additions of vitamin B<sub>12</sub> across the time course of the fermentation. The highest titer obtained was 77 g/L.

Improved fermentation with KLP23/pAH48/pKP32:

5 A representative fermentation summary of the conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain KLP23/pAH48/pKP32 is given in Table 5. Vitamin B<sub>12</sub> (0.150 g/L, 500 mL) was fed, starting 3 h after inoculation, at a rate of 16 mL/h. After 36 h, approximately 2 L of fermentation broth was purged in order to allow for the continued addition of glucose feed. The yield of  
10 1,3-propanediol was 26 wt % (g 1,3-propanediol/g glucose consumed) and a titer of 112 g/L 1,3-propanediol was obtained.

TABLE 5

Representative fermentation summary of the improved conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain KLP23/pAH48/pKP32

Time (h)	OD550 (AU)	DO (%)	Glucose (g/L)	Glycerol (g/L)	1,3-PD (g/L)
0	0	148	12.8	0.0	0
6	22	84	6.9	3.3	0
12	34	90	9.7	10.4	7
18	66	43	9.3	5.9	24
24	161	9	0.2	2.5	46
30	200	10	0.2	6.0	67
36	212	10	1.2	9.7	88
42	202	2	0.1	15.5	98
48	197	12	1.2	23.8	112

Similar results were obtained with an identical vitamin B<sub>12</sub> feed at half the  
15 concentration or bolus additions of vitamin B<sub>12</sub> across the time course of the fermentation. The highest titer obtained was 114 g/L.

EXAMPLE 8

ENGINEERING OF TRIOSEPHOSPHATE ISOMERASE MUTANT OF  
*E. COLI* KLP23 FOR ENHANCED YIELD OF  
20 1,3-PROPANEDIOL FROM GLUCOSE

Construction of plasmid for triosephosphate isomerase gene replacement in *E. coli* KLP23:

*E. coli* KLP23 genomic DNA was prepared using the Puregene DNA Isolation Kit (Genta Systems, Minneapolis, MN). A 1.0 kb DNA fragment  
25 containing *cdh* and the 3' end of triosephosphate isomerase (*tpiA*) genes was

amplified by PCR (Mullis and Faloona, *Methods Enzymol.* 155, 335-350 (1987)) from KLP23 genomic DNA using primers SEQ ID NO:47 and SEQ ID NO:48. A 1.0 kb DNA fragment containing the 5' end of *tpiA*, *yiiQ*, and the 5' end of *yiiR* genes was amplified by PCR from KLP23 genomic DNA using primers SEQ ID NO:49 and SEQ ID NO:50. A *Sca*I site was incorporated into primer SEQ ID NO:49. The 5' end of primer SEQ ID NO:49 was the reverse complement of primer SEQ ID NO:48 to enable subsequent overlap extension PCR. The gene splicing by overlap extension technique (Horton et al., *BioTechniques* 8, 528-535 (1990)) was used to generate a 2.0 kb fragment by PCR using the above two PCR fragments as templates and primers SEQ ID NO:47 and SEQ ID NO:50. This fragment represented a deletion of 73% of the 768 bp *tpiA* structural gene. Overall, this fragment had 1.0 kb flanking regions on either side of the *Sca*I cloning site (within the partial *tpiA*) to allow for chromosomal gene replacement by homologous recombination.

The above blunt-ended 2.0 kb PCR fragment was cloned into the pCR-Blunt vector using the Zero Blunt PCR Cloning Kit (Invitrogen, San Diego, CA) to yield the 5.5 kb plasmid pRN106-2 containing kanamycin and Zeocin resistance genes. The 1.2 kb *Hinc*II fragment from pLoxCat1 (unpublished results), containing a chloramphenicol-resistance gene flanked by bacteriophage P1 *loxP* sites (Snaith et al., *Gene* 166, 173-174 (1995)), was used to interrupt the *tpiA* fragment in plasmid pRN106-2 by ligating it to *Sca*I-digested plasmid pRN106-2 to yield the 6.8 kb plasmid pRN107-1.

Engineering of triosephosphate isomerase mutant RJ8m by linear DNA transformation:

Using pRN107-1 as template and primers SEQ ID NO:47 and SEQ ID NO:50, the 3.2 kb fragment containing *tpiA* flanking regions and the *loxP-CmR-loxP* cassette was PCR amplified and gel-extracted. *E. coli* KLP23 was electrotransformed with up to 1 µg of this 3.2 kb linear DNA fragment and transformants that were chloramphenicol-resistant (12.5 µg/mL) and kanamycin-sensitive (30 µg/mL) were further screened on M9 minimal media for poor glucose utilization on 1 mM glucose, for normal gluconate utilization on 1 mM gluconate, and to ensure the glycerol non-utilization phenotype of host KLP23 on 1 mM glycerol. An *Eco*RI digest of genomic DNA from one such mutant, RJ8m, when probed with the intact *tpiA* gene via Southern analysis (*Southern, J. Mol. Biol.* 98, 503-517 (1975)) indicated that it was a double-crossover integrant (*tpiA* gene replacement) since the two expected 6.6 kb and 3.0 kb bands were observed, owing to the presence of an additional *Eco*RI site within the chloramphenicol

resistance gene. As expected, the host KLP23 and wild-type FMS controls yielded single 8.9 kb and 9.4 kb bands respectively. This *tpiA* mutant was further analyzed by genomic PCR using primers SEQ ID NO:51 and SEQ ID NO:52, which yielded the expected 4.6 kb PCR fragment while for the same primer pair 5 the host KLP23 and wild-type FMS strains both yielded the expected 3.9 kb PCR fragment. When cell-free extracts from *tpiA* mutant RJ8m and host KLP23 were tested for *tpiA* activity using glyceraldehyde 3-phosphate as substrate, no activity was observed with RJ8m. The *tpiA* mutant RJ8m was electrotransformed with 10 plasmid pAH48 to allow glycerol production from glucose and also with both plasmids pAH48 and pDT29 or pKP32 to allow 1,3-propanediol production from glucose. The chloramphenicol resistance marker was eliminated from RJ8m to give RJ8.

#### EXAMPLE 9

#### CONVERSION OF GLUCOSE TO 1,3-PROPANEDIOL USING *E. COLI* STRAIN RJ8/pAH48/pDT29 AND THE IMPROVED PROCESS USING RJ8/pAH48/pKP32

##### Pre-Culture:

RJ8/pAH48/pDT29 and RJ8/pAH48/pKP32 were pre-cultured for seeding a fermenter as described in Example 7. RJ8/pAH48/pKP32 is identical to 20 RJ8/pAH48/pDT29 except that *dhaT* is deleted.

##### Fermenter medium:

Fermenter medium was as described in Example 7.

##### Fermentation growth:

Fermenter growth was as described in Example 7 except that initial values 25 for air flow rate (set to minimum values of between 5 and 6 standard liters per min) and agitator speed (set to minimum values of between 300 and 690 rpm) were set so that dissolved oxygen (DO) control was initiated when OUR values reached between 60 and 100 mmol/L/h. Vitamin B<sub>12</sub> or coenzyme B<sub>12</sub> was added as noted below.

##### 30 Fermentation with RJ8/pAH48/pDT29:

A representative fermentation summary of the conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain RJ8/pAH48/pDT29 is given in Table 6. Vitamin B<sub>12</sub> was provided as bolus additions of 2, 16 and 16 mg at 2, 8, and 26 h, respectively. The yield of 1,3-propanediol was 35 wt % (g 35 1,3-propanediol/g glucose consumed) and a titer of 50.1 g/L 1,3-propanediol was obtained.

**TABLE 6**  
 Representative fermentation summary of the conversion of glucose to  
 1,3-propanediol (1,3-PD) using *E. coli* strain RJ8/pAH48/pDT29

Time (h)	OD550 (AU)	DO (%)	Glucose (g/L)	Glycerol (g/L)	1,3-PD (g/L)
0	0	140	10.6	0.1	0.0
6	5	107	11.1	0.5	0.4
10	16	90	8.5	1.7	1.3
14	25	86	1.8	2.4	5.9
19	38	53	3.5	5.9	15.4
25	53	38	0.1	9.2	26.7
31	54	10	4.5	7.4	39.0
37	37	23	17.2	6.0	45.0
43	21	13	9.9	7.7	50.1

Improved fermentation with RJ8/pAH48/pKP32:

A representative fermentation summary of the conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain RJ8/pAH48/pKP32 is given in 5 Table 7. Vitamin B<sub>12</sub> was provided as bolus additions of 48 and 16 mg at approximately 26 and 44 hr, respectively. The yield of 1,3-propanediol was 34 wt % (g 1,3-propanediol/g glucose consumed) and a titer of 129 g/L 1,3-propanediol was obtained.

**TABLE 7**  
 Representative fermentation summary of the improved conversion of glucose to 1,3-propanediol (1,3-PD) using *E. coli* strain RJ8/pAH48/pKP32.

Time (h)	OD550 (AU)	DO (%)	Glucose (g/L)	Glycerol (g/L)	1,3-PD (g/L)
0	0	150	12.6	0.1	0
6	12	113	6.0	2.6	0
12	24	99	0.0	10.6	0
18	51	76	2.4	28.9	0
24	78	82	2.4	44.2	5
30	114	70	3.8	26.9	33
36	111	72	0.0	20.0	57
42	139	65	0.1	21.9	69
48	157	36	0.1	22.4	79
55	158	25	0.2	21.4	94
64	169	14	0.1	15.8	113
72	169	12	0.1	13.4	119
74	162	14	0.1	14.8	129

EXAMPLE 10IDENTIFICATION OF THE *E. COLI* NON-SPECIFIC CATALYTIC ACTIVITY (*yqhD*) IN THE IMPROVED 1,3-PROPANEDIOL PROCESSDemonstration of non-specific catalytic activity in 1,3-propanediol-producing fermentations with the improved catalyst:

A whole cell assay for 1,3-propanediol dehydrogenase activity was used to demonstrate that the non-specific catalytic activity in *E. coli* is present under fermentative conditions after the addition of vitamin B<sub>12</sub> and the production of 3-hydroxypropionaldehyde (3-HPA), but not before. A recombinant *E. coli* strain containing the glycerol-production and 1,3-propanediol-production plasmids, pAH48 and pKP32, respectively, was grown in 10 L fermenters, essentially as described in Example 7, but in the absence of vitamin B<sub>12</sub>. A vitamin B<sub>12</sub> bolus (48 mg) was added when the tanks reached approximately 100 OD<sub>550</sub>. Aliquots of cells were taken from the tanks immediately before and 2 h post-vitamin B<sub>12</sub> addition. The cells were recovered by centrifugation and resuspended to their original volume in PBS buffer containing 150 µg/mL chloramphenicol to inhibit new protein synthesis. An appropriate volume of the chloramphenicol treated cells was added to 250 mL baffled flasks containing a reaction mixture (PBS buffer containing 10 g/L glucose, 10 g/L glycerol, 1 mg/L coenzyme B<sub>12</sub>, and 150 µg/mL chloramphenicol) so that the final volume was 50 mL at an OD<sub>550</sub> of approximately 10. The flasks, protected from light, were shaken at 250 rpm at 35 °C. Aliquots for HPLC analysis were taken over time. Time-dependent production of 3-HPA was observed in flasks containing cells recovered from the fermenter either pre- or post-vitamin B<sub>12</sub> addition. In direct contrast, significant levels of 1,3-propanediol were observed only in those flasks containing cells recovered from the fermenter post-vitamin B<sub>12</sub> addition.

Detection of non-specific catalytic activity in cell-free extracts:

A native gel activity stain assay was used to demonstrate non-specific catalytic activity in cell-free extracts. Cells were recovered, pre- and post-vitamin B<sub>12</sub> addition, from representative 10-L fermentations employing recombinant *E. coli* strains containing the glycerol-production and 1,3-propanediol-production plasmids, pAH48 and pKP32, respectively; and cell-free extracts were prepared by cell disruption using a French press. The cell-free extracts, a preparation of pure *Klebsiella pneumoniae* 1,3-propanediol dehydrogenase (*dhaT*), and molecular weight standards were applied to and run out on native gradient polyacrylamide gels. The gels were then exposed to either the substrates 1,3-propanediol and NAD<sup>+</sup> or ethanol and NAD<sup>+</sup>. As expected in the gels where 1,3-propanediol was

the substrate, an activity stain for DhaT was observed which migrated on the native gel at approximately 340 Kdal. This activity was observed only in lanes where pure *Klebsiella pneumoniae* 1,3-propanediol dehydrogenase was applied. In contrast, where 1,3-propanediol was the substrate and post-vitamin B<sub>12</sub> cell-free extracts were applied, a non-specific catalytic activity was observed at approximately 90 Kdal. When ethanol was used as a substrate, neither the DhaT band nor the non-specific catalytic activity band were visible, but a separate band was found pre- and post-vitamin B<sub>12</sub> addition at approximately 120 Kdal. This new band most likely represents an alcohol dehydrogenase with specificity towards ethanol as substrate as is typically found in all organisms.

This native gel assay, where proteins are separated by molecular weight prior to the enzymatic assay step, offered greater sensitivity and accuracy in measuring the reduction of 1,3-propanediol in those constructs with low activity and where the activity is likely to be distinct from the alcohol dehydrogenases with specificity towards ethanol as substrate that have been well characterized for *E. coli* and found in all organisms. The dehydrogenase assay works on the principle that dehydrogenase catalyzes the transfer of electrons from 1,3-propanediol (or other alcohols) to NAD<sup>+</sup>. PMS (phenazine methosulfate) then couples electron transfer between NADH and a tetrazolium bromide dye (MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) which forms a precipitate in the gel. After a few hours to overnight soaking in the substrates, the gels are washed to remove reagents and soluble dye. At bands on the gel where there is an active dehydrogenase, an insoluble blue dye forms. Various aspects of the assay have been described by Johnson and Lin (*J. Bacteriol.* 169:2050 (1987)).

**25     Purification and identification of the non-specific catalytic activity in *E. coli*:**

A large scale, partial purification of non-specific catalytic activity was performed on cells harvested from the end of a typical 1,3-propanediol production run as described in the improved process using KLP23/pAH48/pKP32 of Example 7. The cell pellet (16 g) was washed and resuspended three times in 20 mL of 50 mM Hepes buffer, pH 7.5. The cells in the suspension were lysed by sonication. The cell-free extract was obtained by centrifugation (15 min, 20,000 x g, 10 °C) and the supernatant was further clarified by addition of 250 mg of protamine sulfate with stirring on ice. The supernatant obtained by centrifugation (20 min, 20,000 x g, 10 °C) was fractionated by passage through a Superdex® 200 preparative grade column (6 x 60 cm) equilibrated with Hepes buffer. Fractions of 10 mL each were collected and an aliquot of each was concentrated twenty-five-fold using 10,000 MW cutoff Centricon® membranes prior to assay by the native

gel activity stain. The non-specific catalytic activity was identified in fractions 107-112, and the peak activity in fractions 108-109. A larger aliquot (7 mL each) of fractions 108 and 109 were concentrated fifty-fold and loaded on all lanes of a 12-lane native gel. The gel was cut in half and one half was stained for 5 dehydrogenase activity where a dark blue band appeared that represented the non-specific catalytic activity. The unstained gel was aligned top to bottom with the stained gel and a band was cut on the unstained gel that corresponded to the band of non-specific catalytic activity. The gel strip was pulverized and soluble protein was extracted by immersing the pulverized particles in 0.5 mL of 2D-loading 10 buffer, heating to 95 °C for 5 min, and centrifugation to remove the gel particles. The supernatant was loaded onto an isoelectricfocusing (IEF) strip for 2-dimension polyacrylamide gel electrophoresis (2D-PAGE) using conditions described for 2D-PAGE of *E. coli* extracts in the Swiss 2D database (<http://www.expasy.ch/ch2d/>; Tonella et al. *Electrophoresis* 19:1960-1971 15 (1998)). The gel was transferred to a PVDF membrane by electroblotting. The membrane was stained for proteins using the Colloidal blue gel stain. The stained blot used to obtain the identity of the non-specific catalytic activity is shown in Figure 6. Spots were identified using standard techniques for amino terminus peptide sequencing. Only a single spot (Spot A) encoded for an oxidoreductase 20 activity. Nineteen cycles of Spot A (Figure 6) yielded a 100% identity match by the FASTA search tool with the amino-terminus of *yqhD*, an *E. coli* open reading frame with putative oxidoreductase activity. Complete amino acid sequence for the protein encoded by *yqhD* is given in SEQ ID NO:57; the corresponding DNA sequence is given in SED ID NO:58. The *yqhD* gene has 40% identity to the gene 25 *adhB* in *Clostridium*, a probable NADH-dependent butanol dehydrogenase 2.

Gene Disruption of *yqhD* in *E. coli* KLP23:

Biochemical assays and amino-terminal amino acid sequencing suggested that non-specific catalytic activity may be encoded by the *E. coli* *yqhD* gene. This gene of unknown function encodes a hypothetical oxidoreductase and contains 30 two alcohol dehydrogenase signatures also found in the *Citrobacter freundii* and *Klebsiella pneumoniae* 1,3-propanediol dehydrogenase encoded by the *dhaT* gene.

To disrupt this gene, *yqhD* and 830 bp of 5'-flanking DNA sequence and 906 bp of 3'-flanking DNA sequence were amplified from *E. coli* KLP23 (Example 4) genomic DNA in a PCR using *Taq* polymerase and the following 35 primers:

(SEQ ID NO:59) 5'-GCGGTACCGTTGCTCGACGCTCAGGTTTCGG-3'  
(SEQ ID NO:60) 5'-GCGAGCTCGACGCTGCCCTGATCGAGTTTG-3'

The reaction was run at 94 °C for 1 min, 50 °C for 1 min, and 72 °C for 3 min for 35 cycles followed by a final extension at 72 °C for 5 min. The resulting 3.7 Kb DNA fragment was purified, digested with *SacI* and *KpnI* and ligated to similarly digested pBluescriptII KS(+) (Strategene) for 16 h at 16 °C. The ligated DNA 5 was used to transform *E. coli* DH5 $\alpha$  (Gibco/BRL) and the expected plasmid, pJSP29, was isolated from a transformant demonstrating white colony color on LB agar (Difco) containing X-gal (40  $\mu$ g/mL) and ampicillin (100  $\mu$ g/mL). Plasmid pJSP29 was digested with *AflII* and *NdeI* to liberate a 409 bp DNA 10 fragment comprising 363 bp of the *yqhD* gene and 46 bp of 3'-flanking DNA sequence. The remaining 5,350 bp DNA fragment was purified and ligated to the 1,374 bp *AflII/NdeI* DNA fragment containing the kanamycin resistance gene 15 from pLoxKan2 (Genencor International, Palo Alto, CA) for 16 h at 16 °C. The ligated DNA was used to transform *E. coli* DH5 $\alpha$  and the expected plasmid, pJSP32-Blue, was isolated from a transformant selected on LB agar media containing kanamycin (50  $\mu$ g/mL). Plasmid pJSP32-Blue was digested with *KpnI* 20 and *SacI* and the 3,865 bp *yqhD* disruption cassette was purified and ligated to similarly digested pGP704 (Miller and Mekalanos, *J. Bacteriol.* 170:2575-2583 (1988)) for 16 h at 16 °C. The ligated DNA was used to transform *E. coli* SY327 (Miller and Mekalanos, *J. Bacteriol.* 170:2575-2583 (1988)) and the expected 25 plasmid, pJSP32, was isolated from a transformant selected on LB agar media containing kanamycin (50  $\mu$ g/mL). Plasmid pJSP32 was transformed into *E. coli* KLP23 and transformants were selected on LB agar containing kanamycin (50  $\mu$ g/mL). Of the 200 kanamycin-resistant transformants screened, two demonstrated the ampicillin-sensitive phenotype expected for a double-crossover 30 recombination event resulting in replacement of the *yqhD* gene with the *yqhD* disruption cassette.

The disruption of the *yqhD* gene was confirmed by PCR using genomic DNA isolated from these two transformants as the template and the following sets of primer pairs:

30 Set #1:

(SEQ ID NO:61) 5'-GCGAGCTCGACGCTTGCCTGATCGAGTTTG-3'  
(SEQ ID NO:62) 5'-CAGCTGGCAATTCCGGTTCG-3'

Set #2:

(SEQ ID NO:63) 5'-CCCAGCTGGCAATTCCGGTTCGCTTGCTGT-3'

35 (SEQ ID NO:64) 5'-GGCGACCCGACGCTCCAGACGGAAGCTGGT-3'

Set #3:

(SEQ ID NO:65) 5'-CCGCAAGATTCACGGATGCATCGTGAAGGG-3'

(SEQ ID NO:66) 5'-CGCCTTCTTGACGAGTTCTGAGCGGGA-3'

Set #4:

(SEQ ID NO:67) 5'-GGAATTCATGAACAACTTTAATCTGCACAC-3'

(SEQ ID NO:68) 5'-GTTTGAGGCGTAAAAAGCTTAGCAGGGCGGC-3'

5 The reactions were run using either *Expand High Fidelity Polymerase* (Boehringer Manheim) or *Platinum PCR Supermix* containing *Taq polymerase* (Gibco/BRL) at 94 °C for 1 min, 50 °C for 1 min, and 72 °C for 2 min for 35 cycles followed by a final extension at 72 °C for 5 min. The resulting PCR products were analyzed by gel electrophoresis in 1.0 % (w/v) agarose. The results summarized in Table 8

10 confirmed disruption of the *yqhD* gene in both transformants.

TABLE 8

Primer Set	Expected Size (bp)		Observed Size (bp)
	<i>yqhD</i> disruption	<i>yqhD</i> wild-type	
1	1,200	no product	~1,200
2	1,266	no product	~1,266
3	2,594	no product	~2,594
4	no product	1,189	~900

The *yqhD* disruption deletes the 3' end of *yqhD*, including 46 bp of 3'-flanking intergenic DNA sequence. The deletion removes 363 bp of 3' *yqhD* coding sequence corresponding to 121 amino acids. A stop codon is present 15 bp downstream of the remaining *yqhD* coding sequence in the kanamycin resistance cassette.

15 Plasmids pAH48 and pKP32 were co-transformed into *E. coli* KLP23 (*yqhD*-) and transformants containing both plasmids were selected on LB agar containing ampicillin (100 µg/mL) and spectinomycin (50 µg/mL). A representative transformant was tested for its ability to convert glucose to 1,3-propanediol in 10 L fermentations either in the presence or absence of vitamin B<sub>12</sub>.

20 Demonstration that *yqhD* is required for significant 1,3-propanediol production in *E. coli* strain KLP23/pAH48/pKP32:

Fermentations for the production of 1,3-propanediol were performed, essentially as described in Example 7, with the *E. coli* strain KLP23 (*yqhD*-)/pAH48/pKP32 in order to test for the effect of the *yqhD* disruption on 1,3-propanediol production.

25 A representative 10-L fermentation using the knockout of the non-specific catalytic activity, *E. coli* strain KLP23 (*yqhD*-)/pAH48/pKP32, is shown in Table

9. The organism steadily accumulated cell mass and glycerol until the addition of vitamin B<sub>12</sub> when the OD<sub>550</sub> exceeded 30 A (10.4 h). Vitamin B<sub>12</sub> was added as a bolus addition of 8 mg at 10.4 h and thereafter vitamin B<sub>12</sub> was continuously fed at a rate of 1.32 mg/h. In the 4 h that followed B<sub>12</sub> addition, glucose consumption  
 5 slowed, the oxygen utilization rate dropped and there was no further increase in optical density. Fermentation of glucose ceased and the glucose concentration in the tank accumulated. The highest titer of 1,3-propanediol obtained was 0.41 g/L. The organism was checked for its viability by plating a dilution series of the cells on agar plates containing ampicillin and spectinomycin. The plates were  
 10 incubated for 24 h in a 30 °C incubator. There were no viable colonies on the plate from the fermentation of *E. coli* KLP23 (*yqhD*<sup>-</sup>)/pAH48/pKP32, Table 11.

By contrast, the cell suspension from a control tank to which no vitamin B<sub>12</sub> was added continued to accrue cell mass and glycerol until the 10-L tank was full due to the complete addition of the glucose feed solution (Table 10). An agar  
 15 plate viability determination by dilution series of the cell suspension at the end of this fermentation showed a viable cell count that was consistent with the total cell number estimated by the optical density value (Table 11).

**TABLE 9**

Representative fermentation summary of the failed conversion of glucose to 1,3-  
 20 propanediol (1,3-PD) using *E. coli* strain KLP23 (*yqhD*<sup>-</sup>)/pAH48/pKP32.

time (h)	OD <sub>550</sub> (AU)	DO (%)	glucose (g/L)	glycerol (g/L)	1,3-PD (g/L)
0	0.4	150	11.3	0.05	0
2.3	3.0	134	10.7	0.13	0
4.3	10.8	85.0	8.2	1.41	0
8.3	23.1	81.8	0.9	10.0	0
16.3	37.2	149	13.1	21.4	0.41
18.3	47.6	149	18.9	21.6	0.39
20.3	39.6	149	24.4	22.3	0.42
23.8	33.6	149	25.4	22.0	0.41

TABLE 10

Representative fermentation summary of the conversion of glucose to glycerol using *E. coli* strain KLP23 (*yqhD*<sup>-</sup>)/pAH48/pKP32.

Time (h)	OD <sub>550</sub> (AU)	DO (%)	glucose (g/L)	glycerol (g/L)
0	0.2	148	9.5	0.06
2.2	2.8	128	8.9	0.13
4.2	10.4	58.5	7.0	1.4
8.2	21.6	57.6	2.7	11.2
16.2	76.8	10.7	0	40.5
20.2	117	10.2	0	52.9
23.7	154	8.5	0	63.9
36.2	239	10.1	0.1	122

5

TABLE 11

Representative summary of viability plate counts from endpoints of fermentations of glucose using *E. coli* strain KLP23(*yqhD*<sup>-</sup>)/pAH48/pKP32 in the absence and presence of vitamin B<sub>12</sub>.

vitamin B <sub>12</sub>	time (h) at endpoint	OD <sub>550</sub> (AU)	viable counts (cfu/mL)
no	36.2	239	2.1E11
yes	23.8	33.6	0
yes	23.8	41.2	0

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A. The indications made below relate to the microorganism referred to in the description</b> on page <u>12</u> , line <u>18</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b>	
Name of depositary institution <b>AMERICAN TYPE CULTURE COLLECTION</b>	
Address of depositary institution ( <i>including postal code and country</i> ) <b>10801 University Blvd. Manassas, Virginia 20110-2209 USA</b>	
Date of deposit <b>18 April 1995</b>	Accession Number <b>ATCC 69789</b>
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )      This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> ) The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )	
For receiving Office use only	
<input type="checkbox"/> This sheet was received with the international application	
Authorized officer	
For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A. The indications made below relate to the microorganism referred to in the description on page <u>12</u>, line <u>22</u></b>	
<b>B. IDENTIFICATION OF DEPOSIT</b>	
Name of depositary institution <b>AMERICAN TYPE CULTURE COLLECTION</b>	
Address of depositary institution ( <i>including postal code and country</i> ) 10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit <b>18 April 1995</b>	Accession Number <b>ATCC 69790</b>
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )      This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> ) The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )	
For receiving Office use only	
<input type="checkbox"/> This sheet was received with the international application	For International Bureau use only
Authorized officer	Authorized officer

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A. The indications made below relate to the microorganism referred to in the description</b> on page <u>12</u> , line <u>30</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b>	
Name of depositary institution <b>AMERICAN TYPE CULTURE COLLECTION</b>	
Address of depositary institution ( <i>including postal code and country</i> ) <b>10801 University Blvd. Manassas, Virginia 20110-2209 USA</b>	
Date of deposit <b>25 November 1997</b>	Accession Number <b>ATCC 98597</b>
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )	
This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> )	
The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g. "Accession Number of Deposit"</i> )	
<b>For receiving Office use only</b>	
<input type="checkbox"/> This sheet was received with the international application	<b>For International Bureau use only</b>
Authorized officer	<input type="checkbox"/> This sheet was received by the International Bureau on:
	Authorized officer

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A. The indications made below relate to the microorganism referred to in the description on page <u>12</u>, line <u>27</u></b>							
<b>B. IDENTIFICATION OF DEPOSIT</b>							
Name of depositary institution <b>AMERICAN TYPE CULTURE COLLECTION</b>							
Address of depositary institution ( <i>including postal code and country</i> ) 10801 University Blvd. Manassas, Virginia 20110-2209 USA							
Date of deposit 25 November 1997	Accession Number ATCC 98598						
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )      This information is continued on an additional sheet <input type="checkbox"/>							
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)							
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )							
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> ) The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )							
<table border="0"> <tr> <td style="text-align: center;">For receiving Office use only</td> <td style="text-align: center;">For International Bureau use only</td> </tr> <tr> <td><input type="checkbox"/> This sheet was received with the international application</td> <td><input type="checkbox"/> This sheet was received by the International Bureau on:</td> </tr> <tr> <td>Authorized officer</td> <td>Authorized officer</td> </tr> </table>		For receiving Office use only	For International Bureau use only	<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:	Authorized officer	Authorized officer
For receiving Office use only	For International Bureau use only						
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:						
Authorized officer	Authorized officer						

CLAIMS

What is claimed is:

1. An isolated nucleic acid fragment encoding a non-specific catalytic activity for the conversion of 3-hydroxypropionaldehyde to 1,3-propanediol and  
5 selected from the group consisting of:
  - (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence of SEQ ID NO:57;
  - (e) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence of SEQ ID NO:57;
  - 10 (f) an isolated nucleic acid fragment encoding a polypeptide of at least 387 amino acids having at least 80% with the amino acid sequence of SEQ ID NO:57;
  - (d) an isolated nucleic acid fragment that hybridizes with (a) under hybridization conditions of 0.1X SSC, 0.1% SDS, 65 °C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS; and
  - (e) an isolated nucleic acid fragment that is complementary to (a), (b), (c), or (d).
- 20 2. The isolated nucleic acid fragment as set out in SEQ ID NO:58.
3. A polypeptide encoded by the isolated nucleic acid fragment of

Claim 1.

4. The polypeptide of Claim 3 as set out in SEQ ID NO:57.
5. A chimeric gene comprising the isolated nucleic acid fragment of

25 Claim 1 operably linked to suitable regulatory sequences.

6. A microorganism transformed with the chimeric gene of Claim 5 wherein the microorganism is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*,

30 *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Salmonella*, *Bacillus*, *Aerobacter*, *Streptomyces* and *Pseudomonas*.

  7. A recombinant microorganism, useful for the production of 1,3-propanediol, comprising:
    - (a) at least one gene encoding a polypeptide having a dehydratase activity;
    - (b) at least one gene encoding a dehydratase reactivation factor; and

(c) at least one exogenous gene encoding an non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol;

wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant microorganism and the microorganism is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Salmonella*, *Bacillus*, *Aerobacter*, *Streptomyces* and *Pseudomonas*.

8. The recombinant microorganism of Claim 7 further comprising:

- at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity; and
- at least one gene encoding a polypeptide having glycerol-3-phosphatase activity;

9. The recombinant microorganism of Claim 7 or 8 wherein the dehydratase reactivation factor is encoded by *orfX* and *orfZ*, isolated from a *dha* regulon.

10. The recombinant microorganism of Claim 9 wherein *orfX* and *orfZ* are independently isolated from *Klebsiella sp.*, *Citrobacter sp.*, or *Clostridium sp.*

11. The recombinant microorganism of Claim 8, further comprising a set of endogenous genes, each having a mutation inactivating the gene, the set consisting of:

- a first gene encoding a polypeptide having glycerol kinase activity;
- a second gene encoding a polypeptide having glycerol dehydrogenase activity; and
- a third gene encoding a polypeptide having triosephosphate isomerase activity.

12. The recombinant microorganism of Claims 8 or 11 wherein the recombinant microorganism converts a carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates to 1,3-propanediol.

13. The recombinant microorganism of Claim 7 wherein the recombinant microorganism converts a carbon source selected from the group consisting of glycerol and dihydroxyacetone to 1,3-propanediol.

14. The recombinant microorganism of Claims 8 or 11 wherein the gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity is selected from the group consisting of GPD1, GPD2, GPD3, DAR1, *gpsA*, GUT2, *glpD*, and *glpABC*.

5 15. The recombinant microorganism of Claims 8 or 11 wherein the gene encoding a polypeptide having glycerol-3-phosphatase activity is selected from the group consisting of GPP1 and GPP2.

10 16. The recombinant microorganism of Claims 7, 8 or 11 wherein the gene encoding a polypeptide having a dehydratase activity is selected from the group consisting of a glycerol dehydratase and a diol dehydratase.

17. The recombinant microorganism of Claims 7, 8 and 11 wherein the gene encoding a polypeptide having a dehydratase activity is isolated from *Klebsiella sp.*, *Citrobacter sp.*, or *Clostridium sp.*

18. A recombinant *E. coli* comprising:

15 (a) a set of exogenous genes consisting of:  
(i) at least one gene encoding a polypeptide having a dehydratase activity;  
(ii) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity;  
20 (iii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and  
(iv) at least one gene encoding a dehydratase reactivation factor; and  
(b) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol; wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli*.

25 19. A recombinant *E. coli* comprising:

30 (a) a set of exogenous genes consisting of  
(i) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity;  
(ii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and  
35 (iii) at least one subset of genes encoding the gene products of *dhaR*, *orfY*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3* and *orfZ*, and

(b) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxypropionaldehyde to 1,3-propanediol,

5 wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli*.

20. The recombinant *E. coli* of Claim 19 further comprising a set of endogenous genes, each gene having a mutation inactivating the gene, the set consisting of:

10 (a) a gene encoding a polypeptide having glycerol kinase activity;

(b) a gene encoding a polypeptide having glycerol dehydrogenase activity; and

(c) a gene encoding a polypeptide having triosephosphate isomerase activity.

21. A process for the bioproduction of 1,3-propanediol comprising:

15 (a) contacting under suitable conditions the recombinant *E. coli* of either Claim 19 or Claim 20 with at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and

(b) optionally recovering the 1,3-propanediol produced in (a).

20. 22. A process for the bioproduction of 1,3-propanediol comprising:

25 (a) contacting the recombinant *E. coli* of Claims 19 or 20 or the recombinant *E. coli* of Claims 19 or 20 further comprising:

(i) at least one exogenous gene encoding a polypeptide having a dehydratase activity;

(ii) at least one exogenous gene encoding a dehydratase reactivation factor;

(iii) at least one endogenous gene encoding a non-specific catalytic activity to convert 3-hydroxy-

30 propionaldehyde to 1,3-propanediol,

with at least one carbon source selected from the group consisting of glycerol and dihydroxyacetone, and

(b) optionally recovering the 1,3-propanediol produced in (a).

23. A process for the production of 1,3-propanediol comprising:

35 (a) contacting a recombinant *E. coli* with a first source of carbon and with a second source of carbon, the recombinant *E. coli* comprising:

(i) at least one exogenous gene encoding a polypeptide having a dehydratase activity;

(ii) at least one exogenous gene encoding a dehydratase reactivation factor;

5 (iii) at least one endogenous gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol, wherein no functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity is present in the recombinant *E. coli* and wherein the first carbon source is selected from the group consisting of glycerol and dihydroxyacetone, and the second carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates; and

10 (b) optionally recovering the 1,3-propanediol produced in (a).

15 24. The process of Claim 23 wherein the recombinant *E. coli* further comprises

(a) a set of exogenous genes consisting of

20 (i) at least one gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity;

(ii) at least one gene encoding a polypeptide having glycerol-3-phosphatase activity; and

(iii) at least one subset of genes encoding the gene products of *dhaR*, *orfY*, *orfX*, *orfW*, *dhaB1*, *dhaB2*,  
25 *dhaB3* and *orfZ*, and

(b) a set of endogenous genes, each gene having a mutation inactivating the gene, the set consisting of:

30 (i) a gene encoding a polypeptide having glycerol kinase activity;

(ii) a gene encoding a polypeptide having glycerol dehydrogenase activity; and

(iii) a gene encoding a polypeptide having triosephosphate isomerase activity.

35 25. Vector pDT29 comprising a set of genes *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3*, and *orfZ* as set forth in SEQ ID NO:1.

26. Vector pKP32 comprising *dhaR*, *orfY*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3* and *orfZ* as set forth in SEQ ID NO:1.

27. A recombinant *E. coli* strain KLP23 comprising:

- (a) a set of two endogenous genes, each gene having a mutation inactivating the gene, the set consisting of
  - (i) a gene encoding a polypeptide having a glycerol kinase activity; and
  - (ii) a gene encoding a polypeptide having a glycerol dehydrogenase activity;
- 5 (b) at least one exogenous gene encoding a polypeptide having glycerol-3-phosphate dehydrogenase activity;
- 10 (c) at least one exogenous gene encoding a polypeptide having glycerol-3-phosphatase activity; and
- (d) a plasmid pKP32.

28. A recombinant *E. coli* strain RJ8 comprising:

- (a) set of three endogenous genes, each gene having a mutation inactivating the gene, the set consisting of:
  - (i) a gene encoding a polypeptide having a glycerol kinase activity;
  - (ii) a gene encoding a polypeptide having a glycerol dehydrogenase activity; and
  - 15 (iii) a gene encoding a polypeptide having a triosephosphate isomerase activity.

29. A process for the production of 1,3-propanediol comprising:

- (a) contacting, under suitable conditions, a recombinant *E. coli* comprising a *dha* regulon and lacking a functional *dhaT* gene encoding a 1,3-propanediol oxidoreductase activity with at least one carbon source, wherein the carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates; and
- 25 (b) optionally recovering the 1,3-propanediol produced in (a).

30

1/6




FIG. 1

2/6




FIG. 2

3/6




FIG. 3

4/6




FIG. 4

5/6




FIG. 5

6/6




FIG. 6

SEQUENCE LISTING

<110> E.I. du Pont de Nemours and Company  
<120> Improved Process for the Biological Production of 1,3-Propanediol with High Titer  
<130> BC1020 PCT  
<140>  
<141>  
<150> 60/149,534  
<151> 1999-08-08  
<160> 68  
<170> Microsoft Office 97  
<210> 1  
<211> 12145  
<212> DNA  
<213> Klebsiella pneumoniae  
<400> 1  
gtcgaccacc acgggtggta cttaatgcc gctctcatgc agcagctgg tggcggtctc 60  
aaaattcagg atgtcgccgg tatagtttt gataatcage aagacgcctt cgccgcccgtc 120  
aatttgcattcgcgcattcaa acatTTTgc cggcgccgg gaggtgaata ttccccccgg 180  
acaggcgccg gagagcatgc cctggccat atagccgcag tgcatcggtt catgtccgct 240  
gccggccggc gagagcaggg ccacccgtcc agccaccggc gcgtcggtgc gggtcacata 300  
cagcggtcc ttagtgcaggg tcagctgcgg atgggctta gccagccccct gtaattgttc 360  
attcagtaca tcttcaacac ggttaatcag cttttcatt attcagtgtt ccgttgaga 420  
aggttcgatg ccgcctctt gctggcgag gcggtcatcg cgtagggta tcgtctgacg 480  
gtggagcgtg cctggcgata ttagtattct ggctgagcgg acgaaaaaaa gaatgccccg 540  
acgatcggtt ttcattacga aacattgtt cctgattttt tttctttatg gaacgtttt 600  
gctgaggatg tggtaaaat gcgagctggc gcgcgtttt tcttcgtccaa taagcgccgg 660  
tcagatagc cggcgaagcg ggtggaaaaa aatttttgc tgattttctg ccgactgccc 720  
gagaaaaggc ggtcaaacac ggagattgt aaggcattt tgccgaaag gagcgatcg 780  
ggatcgcaat cctgacagag actagggtt tttgttccaa tatgaaacgt aaaaaattaa 840  
cctgtgttcc atatcagaac aaaaaggcga aagattttt tggccctgc cggccctaca 900  
gtgatcgac tggccggta cgctccgttc aggccgcgt tcactggccg gcgcggataa 960  
cgccagggtc catcatgtct acatgcgcac ttatttgagg gtgaaaggaa tgctaaaagt 1020  
tattcaatcc ccaagccaaat atcttcaggg tccctgatgtc gctgttctgt tcggtaata 1080  
tgccaaaaac ctggcgaga gcttctcgat catcgctgac gatttcgtaa tgaagctggc 1140  
ggggagaaaaa tgggtgaatg cggctcgagac ccacgatcat ccgtccatgc cggaaacgggt 1200  
taacggcgaa tgcggccatcg cggaaatcaa ccgtctgatg gcgattttgc aaaaacaggg 1260  
ctggccggcgtc gtggcgaga tcggcggtgg taaaaccctc gataccgcga aggcgatcgg 1320  
ttactaccatc aagctgcggg tgggtgtat cccgaccatc gcctcgaccg atgcgccaac 1380  
cagcgctgtc tgggtgatct acaccgaac gggcgagttt gaagagtatc tgatctatcc 1440  
aaaaaaccgg gatatggtgg ttagtggacac ggcgattatc gccaaagcgc cggtacgcct 1500  
gctgtctcc ggcattggcg atgcgtctc cacctgggtc gaggccaaag cttgtctacga 1560  
tgcgcgcgc accagcatgg cgggaggaca gtccaccggag gccgcgtga gcctcgcccc 1620  
cctgtctatc gatacgctgc tggcgagggt cggaaaaggcc cgtctggccgg cgcaggccgg 1680  
ggtagtgacc gaaagcgtgg acgcgcatttccatcg tcaaatccac aacggtttca ccatttttgc 1740  
cttggaaagc agtggcctgg ccgcgtccca agtggccatc cacctgtatc acggtgagaa tgcacatccac aacggttca ccatttttgc 1800  
agagtgcatttccatc acggtgagaa gctacccatcg tggaccctgg cgcagctgg 1860  
gctgcagaac agcccgatgg acggatgtt aacgggtgcag ggcttctgcc agcgcgtccgg 1920  
cctggccgttgc acgctcgccg acatggcgat caaagagggg atcgacgaga aaatcgccgc 1980  
ggtggcgaaa gctacccatcg cggaaaggga aaccatccat aatatgcgtt ttgcgggtgac 2040  
cccgagagc gtccatggcg ctatccatc cggccatctg ttaggcccgc agtggctggc 2100  
gcgttaatttccatcg tgggtggat aaccgtggc ccagggtcgc ggttttttctt tctccctcc 2160  
ggcagtcgtc gccggagggg ttctctatgg tacaacgcgg aaaaggatat gactgtttag 2220  
actcaggata cccggaggc ggttcttccatcg tcaatccac aacggttca ccggccatcc 2280  
aagttagtgc agcgcgaaac ctggcaaacc cccggccctt gacccatccac aacggttca ccggccatcc 2340

tccatctgtc	ggcgtaaaac	cgcgctgctc	accatcgccc	aggccgcgt	ggaagacgcc	2400
tgggagttt	tggacggccg	ccccctgcgc	ctgtttatcc	ttgatgagtc	cgcctgcac	2460
ctgagccgtt	gcggcgagcc	gcaaaccctg	gcccaagctgg	ctgccttggg	atttcgcgac	2520
ggcagctatt	gtgcggagag	cattatcgcc	acctgcgc	tgtcgctggc	cgcgatgcag	2580
ggccagccga	tcaacaccgc	cggcgatcg	cattttaa	aggcgctaca	gccatggagt	2640
ttttgtcga	cgccgggttt	tgataaccac	ggccggctgt	tcggcttat	ctcgcttgc	2700
tgtctggtc	agcaccagtc	cagcggccac	ctctccctga	cgctggccat	cgcggccgag	2760
gtgggtaact	ccctgttac	cgacagcctg	ctggcggaat	ccaaccgtca	cctcaatca	2820
atgtacggcc	tgctggagag	catggacgat	gggggtgatgg	cgtaaacgca	acagggcg	2880
ctgcagttt	tcaatgttca	ggcgccgaga	ctgctgcac	ttgtatgtca	ggccagccag	2940
gggaaaata	tcggcgatct	ggtgaccctc	ccggcgctgc	tgcggccg	catcaaaacac	3000
gcccggcc	tgaatcacgt	cgaatgtacc	tttggaaatgc	agcatcagt	tgtcgatgc	3060
gtgatcacct	aaaaaccgt	tgtcgaggcg	caaggcaaca	gttttattct	gctgctgc	3120
ccggggagc	agatgcggca	gctgatgacc	agccagctcg	gttaaagtca	ccacacctt	3180
gagcagatgt	ctgcccacga	tccgaaacc	cgacgcctga	tccacttgg	ccggccaggcg	3240
gcccggccg	gcttcccggt	gctactgtgc	ggcgaagagg	gggtcgggaa	agagctgc	3300
agccaggcta	ttcacaaatga	aagcgaacgg	gccccggccc	cctacatctc	cgtcaactgc	3360
cagctatatg	ccgacagcgt	gctggccag	gactttatgg	gcagcgcccc	taccgacgat	3420
gaaaatggtc	gcctgagccg	cctttagctg	gccaacggcg	gcacccctgtt	tctggaaaag	3480
atcgagttt	ttggccggca	gctgcagtcg	gctctgtgc	aggtgat	gcagggcg	3540
ctcacccgcc	tcgacggcc	gcccgtatc	ccgggtggat	tgaaggat	tgccaccacc	3600
accgtcgatc	ttggcaat	ggtgaaacag	aaccgc	gcccagct	gtactatgc	3660
ctgcacttct	tttagatgt	catcccgc	ctgcgc	gaccaacag	tattccgtcg	3720
ctgggtcata	accgggttga	gagcctggag	aagcgttct	cttcgc	gaaagtggac	3780
gatgacgcgc	tggcacagct	ggtggctac	tcgtggccgg	ggaatgattt	tgagctca	3840
agcgtcattt	agaatatcgc	catcagcagc	gacaacggcc	acattcg	gagtaatctg	3900
ccggaatatac	tctttccga	gccccgggc	ggggatagcg	cgatcgatcg	gtgcgggccc	3960
agcctgactt	tttagccat	cgaaaaggaa	gcttatttcc	acgcgc	ggtagcc	4020
ggccgggtgc	aggagatgtc	gcagctgc	aatatcg	gcacccctt	tgggcg	4080
atgaagcagt	agcatatttga	cgccagccag	ttcaagcga	agcatcag	ctagtctt	4140
cgattcgcgc	catggagaac	agggatccg	acaggcatt	gctgtagc	ttagcgc	4200
cgcgcagcgg	atgcgcg	tccatggcc	tcagcaggcg	ttcgagcc	cgggacttgg	4260
tgcgcgcac	gtcagctgg	gcagaggcg	gattcctcc	cggtatc	aactgttta	4320
acggccgcet	ctcgccata	ttgcgtc	taagccgtc	caggccgt	atctccctt	4380
cgccgatcgt	ctggctcagg	cggtcaggc	cccgccat	gctgtcc	tcagccccca	4440
gcacaaacag	ctgtctgtca	atatgttca	ggcttcccg	caggccgg	tcgcgggt	4500
tggcgttag	gacgccc	ttggatata	tttcatcg	ggtggcgt	gcctcgac	4560
gaatatggtc	tttctcgat	cggtcgcc	cgtagggc	ggtggcgt	ttatccccgg	4620
tgcgggtata	gatacgatac	attcgtt	tctca	cgccaggact	ttaaccagct	4680
gccccggcgtt	ggcggccgagc	gtacgc	gatcg	atcgttgc	tgtccgg	4740
ccagccgcgc	gtccgccc	agctggc	gagtgg	tatctcg	gacgcgt	4800
gcccatacc	cacccgc	ggcga	ggcc	ggc	gcagccgc	4860
cacccctcc	gtcatagg	atgtctgg	aggggac	ctgc	agcccccc	4920
acagctcatt	gtggcgc	gtatgttgc	cgcgc	gtaaaac	cgtacgc	4980
gcccgtt	ggcggccgag	gtacgc	gatcg	atcgttgc	tgtccgg	5040
ccagccgcgc	gtccgccc	agctggc	gagtgg	tatctcg	gacgcgt	5100
catctccgc	atgtaggg	agtcggc	tttaccc	agatcg	gatgtgc	5160
aataccgata	tccatcgaca	gacgcgt	agcggc	gttttcc	ccgcgtcg	5220
agtggacagt	ccgg	tttgc	cagttc	atatcg	atttctcc	5280
gttggcgtatc	agggtgt	gcccacat	cg	cg	ccacgc	5340
cgccatgtcg	tacaggcc	ccagctgg	cc	cg	cgagggtt	5400
gttattgtt	ggccatccc	ccagc	cc	cg	cgccctgc	5460
attgtcgcc	aggggccac	cttgc	cg	cg	cgccctgc	5520
ggcggccgc	tccgtc	ggtagc	tttgc	cg	cgccgtgg	5580
cagggcatcc	atcccgtc	ccgcgtc	ggcc	cg	ccacgc	5640
atcggtata	gagaccg	gcagtt	ccag	cg	cgactttt	5700
ttcgggtt	gtcaggac	agtgg	cc	cg	cggtgtt	5760
gaccgcac	ataggcgg	gcccgtt	cagg	cg	actgttac	5820
atcgccctca	tgggtgg	cgatgc	gccttgc	caatcg	ggctgc	5880
gcccacgg	acgtatgt	cgca	cc	cg	cgccgc	5940
gttgggtt	ttcgggtt	gtcgc	gc	cg	ccacact	6000
ccgcagataa	tgcagg	tttgc	ccat	cg	tccggc	6060
ggtgacc	agggtttt	tccccc	cagtc	cg	ctacggaa	6120
ggcgttgggg	ccaaaaa	taacgttgg	cacc	cg	tcaaacata	6180

aataatacctt	ctcgcttcag	gttataatgc	ggaaaaacaa	tccaggcg	actgggctaa	6240	
taattgtatcc	tgctcgaccg	taccgcgc	aacgcgc	gcgcattt	ttctgctcatt	6300	
aaaaataact	ggcaggccgc	cgccaaaat	aataattcg	tgttggttgg	tttagctgcag	6360	
accgtacaga	gattgtcttg	gctggaccgc	tgacgtatt	tcatgggtac	cttgcttcag	6420	
gctgcaggcg	ctccaggcgtt	tattcaggg	aatatcg	ctggagacga	aggcctcg	6480	
catccgtctgg	ataagcagcg	tgttgctcc	gccccact	acggaaaaca	ccaccgccc	6540	
gttgatctca	gtggctttt	tttccaccgc	cggccatt	tgctggccgg	cggccagggt	6600	
gattgtctga	acttgtggc	tcttgtcat	cattctctcc	cgcaccagg	taacgctggc	6660	
gccaatagtgc	agtagggggc	gatagtaaaa	aactattacc	attcggttgg	cttgctgtgg	6720	
ttttgtcagc	gttattttgt	cgccccccat	gatttagtca	atagggtttaa	aatagctcg	6780	
gaaaaacgta	attaaggcgc	ttttttatta	attgatttat	atattgcgg	gcgatcacat	6840	
tttttatttt	tgccgcgg	gtaaagttt	atagtgaac	tgtcggtaga	tttcgtgtgc	6900	
caaattgaaa	cgaaaattaaa	tttattttt	tcaccactgg	ctcatttaaa	gttccgctat	6960	
tgccggtaat	ggccggggcgg	caacgcgc	ggcccg	attcgctacc	gtctgcggat	7020	
ttcaccttt	gagccgatga	acaatgaaa	gatcaaaac	atttgcagta	ctggccc	7080	
gccccgtcaa	tcaggacggg	ctgattggc	agtgcc	agaggggtcg	atcgccatgg	7140	
acagccccct	tgacccggc	tcttcagtaa	aagtggaca	cggtctgatc	gtcgaactgg	7200	
acggcaaaac	ccgggaccag	tttgcacatg	tcgaccgatt	tatcgccat	taacgcgat	7260	
acgttgacg	cacagagcc	gcaatgc	ttgaggcggt	gaaatagcc	cgtatgtgg	7320	
ttgatattca	cgtcagccgg	gaggatca	ttgcccattac	taccgc	acgcggccca	7380	
aagcggtcga	ggtgatggcg	cagatgaac	tggtgagat	gatgtggcg	ctgcagaaga	7440	
tgcgtgccc	ccgacccccc	tccaacc	gccacgtc	caatctaaa	gataatccgg	7500	
tgcagattgc	cgctgacgc	gccgaggcc	ggatccgc	tttctcagaa	caggagacca	7560	
cggtcggtat	cgcgcgctac	gcccgtt	acgcctgg	gtctgtggc	gttgcgc	7620	
gcggccgccc	cgcggttgg	acgcagtgc	cggtggaa	gcccaccc	ctggagctgg	7680	
gcatgcgtgg	cttaaccagc	taagccgaga	cggtgtcg	ctacggcacc	gaagcggat	7740	
ttaccgcacgg	cgatgatacg	ccgtggtaa	aggcgttcc	cgccctgg	tacgcctccc	7800	
gcgggttggaa	aatgcgtcac	acccccc	ccggatccg	agcgcgtat	ggcttattcg	7860	
agagcaatgc	gatgcgtctac	ctcgaatgc	gtctgcattt	cattactaaa	ggcgcgggg	7920	
ttcagggact	gcaaaacggc	gcggtgagct	gtatcgccat	gaccggcg	gtgcgcgtcg	7980	
gcattcgccc	ggtgctggcg	gaaaacctg	tcgcctctat	gtcgcac	gaagtggcg	8040	
ccgccaacga	ccagactttc	tcccactcg	atattcgcc	caccgcgc	accctgatgc	8100	
agatgtgc	gggcaccgac	tttattttct	ccggctacag	cgcgg	ccgcgc	8160	
acatgttcgc	cggtcgaaac	ttcgc	aagatttga	tgattacaac	atctgcagc	8220	
gtgacctgtat	ggtgacggc	gcctcg	cggtaccg	ggcgaaacc	attgcattc	8280	
gccaagaaagc	ggcgccgggc	atccaggc	tttccgcg	gtctggcg	ccgc	8340	
cccgacgagga	ggtgaggggc	gccac	ccgcaccc	caacgagat	ccgcgcgt	8400	
acgtgggtga	ggatctgagt	gcggtgaa	agatgtgaa	g	gcacacatc	accggcc	8460
atattgtcg	cgcgtcgac	cgcac	ttgaggat	cgcc	cgcaaat	attctcaata	8520
tgcgtgc	gggggtcacc	ggcgattacc	tgacgac	cc	ggcattctc	gatcg	8580
tcgaggttgt	gagtgcgtc	aacgacatc	atgactatc	ggggccgg	accggctatc	8640	
gcatctctgc	cgAACGCTGG	cgggagatc	aaaatattcc	ggcgtgg	cagccc	8700	
ccattgaata	aggcggtatt	cctgtgcac	agacaaccc	aattcag	cccttttaccc	8760	
tggaaaacc	cgaggcgccgg	gtactctcg	ccgtatgc	cgccgtat	gggtgtatcg	8820	
cgctcgcccc	tgccttcgat	aaacacc	atcacactc	gatcgat	cccatggc	8880	
cgatcctcaa	agagctgatt	gccgggtgg	aagaagagg	gttca	cggtgttgc	8940	
gcattctcg	cacgtccgac	gtctc	tttgcctgg	tgccgc	ac	9000	
cggggatcgg	catcggtatc	cagtc	ggaccac	catcc	cg	9060	
tgccgctcag	caacctggag	ctgtt	cccg	gac	ctgc	9120	
ggcagattgg	caaaaacgct	g	cg	gtc	ccgt	9180	
ttgtgaacga	tcagatggtg	cgcc	ccaa	acc	gtcc	9240	
aagagaccaa	acatgtggtg	ttatgg	ttt	at	gg	9300	
gggagtgtacc	atgagcgaga	cg	cc	cc	gg	9360	
cccgagacat	atccgtacgc	aaacat	cg	at	cc	9420	
gctctctggc	gaggtggggc	cg	cc	cc	gg	9480	
ggcgcagatt	gccgagcaga	cg	cc	cc	gg	9540	
ggagcttatac	gccattcttg	ac	cc	cc	gg	9600	
ccgctctcg	caggcggagc	tg	cc	cc	gg	9660	
gacagtgaat	gccgccttt	cg	cc	cc	gg	9720	
gctaaagga	agctaagcg	cg	cc	cc	gg	9780	
cgccaccacc	gaggtggccg	tg	cc	cc	gg	9840	
cgggatcgtc	gcgacgacgg	cg	cc	cc	gg	9900	
cgcgctggag	caggccctgg	cg	cc	cc	gg	9960	
tcttaacgaa	gccgcgcgg	tg	cc	cc	gg	10020	

tatcaccgaa tcgaccatga tcggtcataa cccgcagacg ccgggcgggg tgggcgttgg 10080  
 cgtggggacg actatcgccc tcgggcggct ggcgacgctg ccggcggcgc agtatgcgca 10140  
 ggggtggatc gtactgattt acgacgcccgt cgatttcctt gacgccgtgt ggtggctcaa 10200  
 tgaggcgctc gaccggggtaa tcaacgtgtt ggcggcgatc ctcaaaaagg acgacggcgt 10260  
 gctggtaac aaccgcctgc gtaaaaacctt gccgggtggtg gatgaagtga cgctgctgga 10320  
 gcaggtcccc gagggggtaa tggcggcggtt ggaagtggcc gcgcggggcc aggtggtgcg 10380  
 gatcctgtcg aatccctacg ggatcgccac cttcttcggg ctaagccccg aagagaccca 10440  
 ggccatcgtc cccatcgccc ggcgcctgtat tggcaaccgt tccgcgggtgg tgctcaagac 10500  
 cccgcagggg gatgtgcagt cgcgggtgtat cccggcgggc aacctctaca ttagcggcga 10560  
 aaagcgcgc gggagggccg atgtcgccga gggcgcggaa gccatcatgc aggcatgag 10620  
 cgcctgcgtc cccgtacgcg acatccgcgg cgaaccgggc acccacgcgc gccgcgtct 10680  
 tgagcgggtg cgcaaggtaa tggcgttccct gaccggccat gagatgagcg cgatatacat 10740  
 ccagggatctg ctggcggtgg atacgtttat tccgcgcgaag gtgcaggggcg gatggccgg 10800  
 cgagtgcgc atggagaatg cccgtcggtat ggcggcgatc gtggaaaggcg atcgtctgca 10860  
 aatgcagggtt atgcggccgc aactgagcgc cccgactgcg accggagggtt tggtggccgg 10920  
 cgtggaggcc aacatggcca tcggcggggc gttAACACT cccggctgtg cggcggccct 10980  
 ggcgatcctc gacctcgccg cccgctcgac ggatgcggcg atcgtcaacg cggaggggca 11040  
 gataacggcg gtccatctcg cggggcgccc gaatatggtc agcctgttga taaaaccga 11100  
 gctgggcctc gaggatctt cgcgtggcgga agcgataaaa aaataccgc tggccaaagt 11160  
 ggaaggctg ttcaagtattt gtcacagagaa tggcgcgggt gaggttttc gggaaaggccct 11220  
 cagcccgccg gtgttcggca aagtgggtta catcaaggag ggcgaaactgg tgccgatcga 11280  
 taacggccage cccgtggaaa aaatctgtct cgtgcgcggc caggcgaaag agaaagtgtt 11340  
 tgtcaccac tgcgtgcgc cgcgtcgcca ggtctcaccc ggcggttcca ttgcgcgat 11400  
 cgcctttgtg gtgctgggtt gcggtctatc gctggactt gagatcccgc agtttatcac 11460  
 ggaaggcttgc tcgactatg gctgggtcgcc cgggcaggcc aatattcggg gaacagaagg 11520  
 gccgcgcaat gcggtcgcca cccggctgtat actggccgtt caggcgaatt aaacgggcgc 11580  
 tcgcgcgcagc ctctctttt aacgtgttat ttcaggatgc cgataatgaa ccagacttct 11640  
 acctaaccg ggcagtgcgt ggccgagttt cttggcaccc gattgtctcat tttcttcggc 11700  
 gcggtctgcg tcgctgcgcg ggggtcgcc ggggcagct ttggtcagtg ggagatcagt 11760  
 attatctggg gcttgggtt cgcctatggcc atctacatcga cggccgggtt ctccggcgcg 11820  
 caccataaaat cggcggtgac cattggccctg tggctgttcg cctgttttga acggcgaag 11880  
 gtgctggcggtt ttattgttgc ccagacggcc ggggccttct ggcggccgc gctgggttat 11940  
 gggctctatc gccagctgtt tctcgatctt gaacagagtc agcatatcgt ggcggcact 12000  
 gcccgcagtc ttaacctggc cggggctttt tccacgtacc cgcattccaca tatcacttt 12060  
 atacaaggctt tgccgttga gaccaccatc acggcaatcc tgatggcgat 12120  
 ctgacccgacg acggcaacgg aattc 12145

&lt;210&gt; 2

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Unknown

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;220&gt;

&lt;223&gt; primer

&lt;400&gt; 2

gctttctgtg ctgcggcttt ag

22

&lt;210&gt; 3

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;220&gt;

&lt;223&gt; primer

&lt;400&gt; 3

tggtcgagga tccacttcac ttt

23

<210> 4  
<211> 51  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 4  
aaagtgaagt ggatcctcga ccaattggat ggtggcgca tagcaaacaa t 51

<210> 5  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 5  
ggatcaccgc cgccagaaact acg 23

<210> 6  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 6  
ctgtcagccg ttaagtgttc ctgtg 25

<210> 7  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 7  
cagttcaacc tgttgatagt acg 23

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

```
<220>
<223> primer

<400> 8
atgagtcaaaa catcaacacctt 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 9
atggagaaaaaa aaatcactgg 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 10
ttacgcccccg ccctgccact 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 11
tcagaggatg tgcacacctgca 20

<210> 12
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 12
cgagcatgcc gcattttggca ctactc 26
```

<210> 13  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 13  
gcgtctagag taggttattc ccactcttg 29

<210> 14  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 14  
gaagtcgacc gctgcgcctt atccgg 26

<210> 15  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 15  
cgctcgacg tttacaattt caggtggc 28

<210> 16  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 16  
gcagcatgct ggactggtag tag 23

<210> 17  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer  
  
<400> 17  
cagtctagag ttattggcaa acctacc 27  
  
<210> 18  
<211> 25  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<220>  
<223> primer  
  
<400> 18  
gatgcattgcc cagggcgagg acggc 25  
  
<210> 19  
<211> 29  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<220>  
<223> primer  
  
<400> 19  
ctaacgattt ttctcttagag aaaatgtcc 29  
  
<210> 20  
<211> 30  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<220>  
<223> primer  
  
<400> 20  
cacgcattgc gttcaacctt ttgatagttac 30  
  
<210> 21  
<211> 28  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<220>  
<223> primer  
  
<400> 21  
gcgtcttagat ccttttaaat taaaaatg 28  
  
<210> 22  
<211> 51

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 22  
gcgcggatcc aggagtctag aattatggga ttgactacta aacctctatc t 51

<210> 23  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 23  
gatacgcccg ggttaccatt tcaacagatc gtcctt 36

<210> 24  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 24  
ttgataatat aaccatggct gctgctgctg atag 34

<210> 25  
<211> 39  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 25  
gtatgatatg ttatcttggaa tccaaataat ctaatcttc 39

<210> 26  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 26  
catgactagt aaggaggaca attc 24

<210> 27  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 27  
catggaattg tcctccttac tagt 24

<210> 28  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 28  
ctagtaagga ggacaattc 19

<210> 29  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 29  
catggaattg tcctcctta 19

<210> 30  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 30  
gatccaggaa acaga 15

<210> 31  
<211> 15  
<212> DNA  
<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 31
ctagtctgtt tcctg 15

<210> 32
<211> 94
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: terminator
sequence

<220>
<223> terminator sequence

<400> 32
agcttaggag tctagaatat tgagctcgaa ttcccgggca tgccgtaccg gatccagaaa 60
aaagcccgca cctgacagtg cgggctttt tttt 94

<210> 33
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 33
ggaattcaga tctcagcaat gagcgagaaa accatgc 37

<210> 34
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer

<400> 34
gctctagatt agttccctt acgcagc 27

<210> 35
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<223> primer
```

<400> 35  
ggccaaagctt aaggaggtta attaaatgaa aag 33

<210> 36  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 36  
gctcttagatt attcaatggc gtcggg 26

<210> 37  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 37  
gcgcgcgtcta gaattatgag ctatcgatg tttgattatc tg 42

<210> 38  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 38  
tctgatacgg gatcctcaga atgcctggcg gaaaat 36

<210> 39  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: linker

<220>  
<223> linker

<400> 39  
tcgacgaatt caggagga 18

<210> 40  
<211> 18  
<212> DNA  
<213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence: linker

<220>
<223> linker

<400> 40
ctagtccctcc tgaattcg 18

<210> 41
<211> 4549
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: pCL1920

<220>
<223> plasmid

<400> 41
agctcgtcag cgggtgttgg cgggtgtcgg ggctggctta actatgcggc atcagagcag 60
attgtactga gagggtccacca tatgcgtgt gaaataccgc acagatgcgt aaggagaaaa 120
taccgcacca ggcgcattc gccattcagg ctgcgcacaact gttggaaagg gcgatcggtg 180
cgggccttc cgttattacg ccagctggc aaaggggat gtgctgcaag gcgattaagt 240
tgggttaacgc cagggtttc ccagtcaacg cgttgtaaaaa cgacggccag tgaattcgag 300
ctcggttaccc gggatcctc tagagtgcac ctgcaggcat gcaagcttgg cgtaatcatg 360
gtcatagctg ttccctgtgt gaaatttta tccgctcaca attccacaca acatacgagc 420
cggaagcata aagtgtaaaag cctggggtgc ctaatgatgt agctaactca cattaattgc 480
gttgcgtca ctgcccgett tccagtcggg aaacctgtcg tgccagctgc attaatgaat 540
cgggcaacgc gaattccccga cagtaagacg ggttaagcctg ttgatgatac cgctgcctta 600
ctgggtgcac taggcagtcgtaatgacccctg tcacgggata atccgaatgt gtcagactgg 660
aaaatcacag ggcaggaaact gctgaacacg aaaaatgtcg atagcaccac atagcagacc 720
cgccataaaa cggccctgaga agccctgtac gggctttct ttttattatgg tgatttct 780
tgcattgaatc cataaaaaggc gctctgtatgc cattttaccc catttactg ccagagccgt 840
gagcgcagcg aactgaatgt cacgaaaaag acagcgactc aggtgcctga tggtcggaga 900
caaaaggaat attcagcgat ttggccggc ttgcgggggt gctacttaag cctttaggg 960
tttaaggctt gttttgtaga ggagcaaca gcgttgcga catcctttt taatactgcg 1020
gaactgacta aagtagtgag ttatacacag ggctgggatc tattctttt atctttttt 1080
attctttctt tattctataa attataacca cttgaatata aacaaaaaaaaa acacacaaaag 1140
gtcttagcgga attacacag ggtctacgat aatttacaag tttccacca aaggtagtcg 1200
agaatttaca gataccacaa actcaaaggaa aaggactatg taattatcat tgatagccc 1260
atctcaattt gtagatgtat taaaatcacc tagaccatg gagatgtatg tctgaattag 1320
ttgtttcaaa agcaaatgaa ctagcgat gtcgctatga cttaaaggag catgaaacca 1380
agctaattttt atgctgtgtg gcactactca accccacgat tggaaaccct acaaggaaag 1440
aacggacgggt atcggtact tataaccaat acgctcagat gatgaacatc agtagggaaa 1500
atgcttatgg tttttagtgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1560
ggatccctt ggttaaaggc ttttagtgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1620
gcaaaaaattt agaattatgtt ttttagtgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1680
aattcataaa atataatctg gaacatgttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1740
tttatgatgtt gttttagtgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1800
tttagcttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1860
ggcttaacca atgggttttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1920
aattgggttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 1980
atagacaatggatctcgatccgaaacttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2040
aaatccaac aaccattacatccgaaacttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2100
acgatgttttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2160
tgcggaaatggatctcgatccgaaacttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2220
cactagagaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2280
atcgtgttgcgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2340
aaggaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2400
ctttacgatccgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2460
gatgaacacgcgatccgaaatccctt ggttaaaggc tttgagattt tccagtgacaaactatgcc aagttctcaa 2520

```

catgaaaattg aacacacctgag acaacttggta acagctcaac agtcacacat agacagccgt 2580  
 aaacaggcga tgctgcttat cgaatcaaag ctgccgacaa cacgggagcc agtgacgcct 2640  
 cccgtgggaa aaaaatcatg gcaattctgg aagaaatagc gcttcagcc ggcaaaccgg 2700  
 ctgaagccgg atctcgatt ctgataacaa actagcaaca ccagaacacg ccgtttgcgg 2760  
 gcagaaaaac ccgtggaat taattccccct gctcgccgag gctgggtgcc aagctctcg 2820  
 gtaacatcaa gccccgatcc ttggagccct tgccctcccg cacgatgatc gtgcccgtat 2880  
 cgaatcccg atccctgacc cgcaattgc aaccctcaact gatccgcgt cccgttccat 2940  
 acagaagctg ggcgaacaaa cgatgctcg cttccagaaa accgaggatc cgaaccact 3000  
 catccgggt cagcacccggcgaacggc ggcacggcc aggtttccg atctcctgaa 3060  
 gccagggcag atccgtgac accacccgtc cgtagaagaa cagaaggcc gccaatgcct 3120  
 gacgatgcgt ggagaccgaa accttgcgt cggtcccgcc aggacacaga aatgcctcga 3180  
 cttcgctgct gcccaagggtt gcccgggtgac gcacaccgtg gaaacggatg aaggcacgaa 3240  
 cccagtggac ataagcctgt tcggttcgta agctgtatg caagtagcgt atgcgctcac 3300  
 gcaactggtc cagaacccgt accgaacgcg cgggtggtaa cggccgcgtg gcggttttca 3360  
 tggcttgtta tgactgtttt tttgggtac agtctatgcc tcgggcattcc aagcagcaag 3420  
 cgcgttacgc cgtgggtcga tggttgcgt tatggagcag caacgatgtt acgcagcagg 3480  
 gcagtcgccc taaaacaaag taaaacatca tgagggaaac ggtatgcgc gaagtatcga 3540  
 ctcaactatc agaggtatg ggcgtatcg agcgcattt cgaacccgacg ttgtggccg 3600  
 tacatttgcg cggctccgca gtggatggcg gcctgaagcc acacagtatg attgatttgc 3660  
 tggttacggt gaccgtaaagg cttgtatgaaa caacgcggcg agtccgtatc aacgacattt 3720  
 tggaaacttc ggcttccctt ggagagagcg agattctccg cgctgttagaa gtcaccattt 3780  
 ttgtgcacga cgacatcatt ccgtggcgat atccagctaa ggcgcgaaactt caatttggag 3840  
 aatggcagcg caatgacatt cttgcaggta tcttcgagcc agccacgcgtc gacattgtatc 3900  
 tggctatctt gctgacaaaaa gcaagagaac atagcgttgc cttgttaggt ccagcggccg 3960  
 aggaactctt tgatccgggtt cctgaacagg atctatttgc ggcgtctaat gaaaccttaa 4020  
 cgctatggaa ctcggccggcc gactgggtg gcgatgagcg aaatgtatgtt cttacgttgt 4080  
 cccgcattt gtacagcgcg gtaacccggca aaatcgcggc gaaggatgtc gtcggcact 4140  
 gggcaatggc ggcgcgtccg gcccagtatc agccgcgtcat acttgaagct agacaggctt 4200  
 atcttggaca agaagaagat cgcttggctt cgcgcgcaga tcaggtagaa gaatttgc 4260  
 actacgtgaa aggcgagatc accaaggtag tcggcaataa atgtctaaca attcgttcaa 4320  
 gcccgcgcg cttcgcggcg cggcttaact caagcgttag atgcactaag cacataattt 4380  
 ctcacagcca aactatcagg tcaagtctgc ttttatttt ttaaggctg cataataaagc 4440  
 cctacacaaa ttggagatatacatgaaa ggctggctt ttctgttat cgcaatagtt 4500  
 ggcgaagtaa tcgcaacatc cgcattaaaa tctagcggagg gctttacta 4549

&lt;210&gt; 42

&lt;211&gt; 199

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: glucose isomerase promoter

&lt;220&gt;

&lt;223&gt; promoter

&lt;400&gt; 42

gaatttcacta gtcgatctgt gctgtttgcc acggatgtca gcaccagcgc gagattatgg 60  
 gctcgcacgc tcgactgtcg gacggggggca ctggaaacgg aagtgcggc agccgtcacg 120  
 cccttgcacaa tgccacatcc tgagcaataa attcaaccac taaacaaatc aaccgcgtt 180  
 cccggaggtt accaagctt 199

&lt;210&gt; 43

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;220&gt;

&lt;223&gt; primer

<400> 43  
gacgcaacag tattccgtcg c 21

<210> 44  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 44  
atgagctatc gtatgttccg ccaggcattc tgagtgttaa cg 42

<210> 45  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 45  
gcctggcgga acatacgata gctcataata tac 33

<210> 46  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 46  
cggggcgctg ggccagtact g 21

<210> 47  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<220>  
<223> primer

<400> 47  
tcaaaccgg tggtttctcg cgaccggg 28

<210> 48  
<211> 28

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 48  
ctcagccgga tatcgacggc gcgctggt 28

<210> 49  
<211> 60  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 49  
accagcgcgc cgtcgatatac cggctgagta ctcaaacacct gccagctctt tacgcagggtt 60

<210> 50  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 50  
cagcatgcct gcgaaccaca ggcctatc 28

<210> 51  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 51  
atgaacaagt ggggcgttagg gttaacat 28

<210> 52  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<220>  
<223> primer

<400> 52  
 ttaattactt gatttattgt cggcttta 28

<210> 53  
 <211> 1380  
 <212> DNA  
 <213> *Saccharomyces cerevisiae*

<400> 53  
 cttaattttt cttttatctt actctccatc ataagacatc aagaaacaat tttatattgt 60  
 acacccccc cctccacaaa cacaatatt gataatataa agatgtctgc tgctgctgat 120  
 agattaaact taacttcgg ccacttgaat gctggtagaa agagaagtcc ctcttctgtt 180  
 tctttgaagg ctgccgaaaa gccttcaag ttactgtga ttggatctgg taactgggt 240  
 actactattt ccaaggtggc tgccgaaaat ttttggatc acccagaagt tttcgctcca 300  
 atagtacaaa tttgggtgtt cgaagaagag atcaatggtg aaaaatttgac tgaatcata 360  
 aatactagac atcaaaaacgt gaaatacttgc cctggcatca ctctaccga caatttgggt 420  
 gctaattccag acttgattga ttcaatgttgc gatgtcgaca tcatacggtt caacattcca 480  
 catcaatttt tgccccgtat ttgttgcggc ttgaaagggtc atgttgcattt acacgtcaga 540  
 gctatcttctt gtctaaagggtt ttttggatgttgc ggttgcataa gtttgcattt gctatcttct 600  
 tacatcaactg aggaacttggc tattcaatgttgc ggttgcatttgc ctgggtctaa cattggccacc 660  
 gaagtcgctc aagaacactg gtctgaaaca acagttgtt accacattcc aaaggatttc 720  
 agaggcgagg gcaaggacgt cgaccataag gtttgcatttgc ctttgttcca cagacccatc 780  
 ttccacgttta gtgtcatcga agatgttgc ggttgcatttgc tctgtggc ttttggaaac 840  
 gtttgcctt tagttgtgg ttctgttgc ggttgcatttgc gggtaacaa cgcttctgtt 900  
 gccatccaaa gatgtcggtt gggtgatc atcagatttc gtttgcatttgc ttttgcatttgc 960  
 tcttagagaa aacataacta ccaagatgttgc gtttgcatttgc ctgttgcatttgc caccacgtc 1020  
 gtttgcatttgc gaaacgttca ggttgcatttgc ctttgttcca ggacgcctgg 1080  
 gaatgtgaaa aggagttgtt gatggccaa tccgctcaag gtttgcatttgc ctgcaaaagaa 1140  
 gttcacaatgtt gtttgcatttgc atgttgcatttgc gtttgcatttgc tccatttgc tgaagccgtt 1200  
 taccaaatacg ttacaacaa ctacccatgtt gtttgcatttgc cggacatgtt gtttgcatttgc 1260  
 gatctacatg aagatttagat ttattggat gtttgcatttgc aagataacat atcatacttcc ccccaactttt 1320  
 ttcgaggctc ttctatatca tattcataaa ttagcatttgc ttcatttgc ataaactactt 1380

<210> 54  
 <211> 391  
 <212> PRT  
 <213> *Saccharomyces cerevisiae*

<400> 54  
 Met Ser Ala Ala Ala Asp Arg Leu Asn Leu Thr Ser Gly His Leu Asn 1  
 1 5 10 15

Ala Gly Arg Lys Arg Ser Ser Ser Val Ser Leu Lys Ala Ala Glu 20 25 30

Lys Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr Thr 35 40 45

Ile Ala Lys Val Val Ala Glu Asn Cys Lys Gly Tyr Pro Glu Val Phe 50 55 60

Ala Pro Ile Val Gln Met Trp Val Phe Glu Glu Ile Asn Gly Glu 65 70 75 80

Lys Leu Thr Glu Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr Leu 85 90 95

Pro Gly Ile Thr Leu Pro Asp Asn Leu Val Ala Asn Pro Asp Leu Ile 100 105 110

Asp Ser Val Lys Asp Val Asp Ile Ile Val Phe Asn Ile Pro His Gln 115 120 125

Phe Leu Pro Arg Ile Cys Ser Gln Leu Lys Gly His Val Asp Ser His  
 130 135 140

Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Val Gly Ala Lys Gly  
 145 150 155 160

Val Gln Leu Leu Ser Ser Tyr Ile Thr Glu Glu Leu Gly Ile Gln Cys  
 165 170 175

Gly Ala Leu Ser Gly Ala Asn Ile Ala Thr Glu Val Ala Gln Glu His  
 180 185 190

Trp Ser Glu Thr Thr Val Ala Tyr His Ile Pro Lys Asp Phe Arg Gly  
 195 200 205

Glu Gly Lys Asp Val Asp His Lys Val Leu Lys Ala Leu Phe His Arg  
 210 215 220

Pro Tyr Phe His Val Ser Val Ile Glu Asp Val Ala Gly Ile Ser Ile  
 225 230 235 240

Cys Gly Ala Leu Lys Asn Val Val Ala Leu Gly Cys Gly Phe Val Glu  
 245 250 255

Gly Leu Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Val Gly  
 260 265 270

Leu Gly Glu Ile Ile Arg Phe Gly Gln Met Phe Phe Pro Glu Ser Arg  
 275 280 285

Glu Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile Thr  
 290 295 300

Thr Cys Ala Gly Gly Arg Asn Val Lys Val Ala Arg Leu Met Ala Thr  
 305 310 315 320

Ser Gly Lys Asp Ala Trp Glu Cys Glu Lys Glu Leu Leu Asn Gly Gln  
 325 330 335

Ser Ala Gln Gly Leu Ile Thr Cys Lys Glu Val His Glu Trp Leu Glu  
 340 345 350

Thr Cys Gly Ser Val Glu Asp Phe Pro Leu Phe Glu Ala Val Tyr Gln  
 355 360 365

Ile Val Tyr Asn Asn Tyr Pro Met Lys Asn Leu Pro Asp Met Ile Glu  
 370 375 380

Glu Leu Asp Leu His Glu Asp  
 385 390

<210> 55

<211> 753

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 55

atgggattga ctactaaacc tctatcttg aaagttaacg ccgtttgtt cgacgtcgac 60

ggtaccatta tcatacctca accagccatt gctgcattt ggagggattt cggtaaggac 120

aaacacctt tcgatgtcga acacgttac caagtctcgcc atggttggag aacgtttgat 180

gccattgcta agttcgctcc agactttgcc aatgaagagt atgttaacaa attagaagct 240

gaaattccgg tcaagtacgg tgaaaaatcc attgaagtcc caggtgcagt taagctgtgc 300

aacgctttga acgctctacc aaaagagaaa tgggctgtgg caacttccgg taccctgttat 360

atggcacaaa aatggttcga gcatctggga atcaggagac caaagtactt cattaccgct 420

aatgatgtca aacaggtaa gcctcatcca gaaccatac tgaagggcag gaatggctta 480  
 gatatccga tcaatgagca agacccttcc aaatctaagg tagtagtatt tgaagacgct 540  
 ccagcaggtt ttgcgcggg aaaagccgcc gggtgttgcgaa tcatttttgat tgccactact 600  
 ttcgacttgg acttcctaaa ggaaaaaggc tgcacatca ttgtcaaaaa ccacgaatcc 660  
 atcagagttg gcggctacaa tgccgaaaca gacgaagttt aattcatttt tgacgactac 720  
 ttatatgcta aggacgatct gttgaaatgg taa 753

<210> 56  
 <211> 250  
 <212> PRT  
 <213> *Saccharomyces cerevisiae*

<400> 56  
 Met Gly Leu Thr Thr Lys Pro Leu Ser Leu Lys Val Asn Ala Ala Leu  
 1 5 10 15  
 Phe Asp Val Asp Gly Thr Ile Ile Ser Gln Pro Ala Ile Ala Ala  
 20 25 30  
 Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr Phe Asp Ala Glu His  
 35 40 45  
 Val Ile Gln Val Ser His Gly Trp Arg Thr Phe Asp Ala Ile Ala Lys  
 50 55 60  
 Phe Ala Pro Asp Phe Ala Asn Glu Glu Tyr Val Asn Lys Leu Glu Ala  
 65 70 75 80  
 Glu Ile Pro Val Lys Tyr Gly Glu Lys Ser Ile Glu Val Pro Gly Ala  
 85 90 95  
 Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro Lys Glu Lys Trp Ala  
 100 105 110  
 Val Ala Thr Ser Gly Thr Arg Asp Met Ala Gln Lys Trp Phe Glu His  
 115 120 125  
 Leu Gly Ile Arg Arg Pro Lys Tyr Phe Ile Thr Ala Asn Asp Val Lys  
 130 135 140  
 Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys Gly Arg Asn Gly Leu  
 145 150 155 160  
 Gly Tyr Pro Ile Asn Glu Gln Asp Pro Ser Lys Ser Lys Val Val Val  
 165 170 175  
 Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly Lys Ala Ala Gly Cys  
 180 185 190  
 Lys Ile Ile Gly Ile Ala Thr Thr Phe Asp Leu Asp Phe Leu Lys Glu  
 195 200 205  
 Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu Ser Ile Arg Val Gly  
 210 215 220  
 Gly Tyr Asn Ala Glu Thr Asp Glu Val Glu Phe Ile Phe Asp Asp Tyr  
 225 230 235 240  
 Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp  
 245 250  
 <210> 57  
 <211> 387

<212> PRT  
<213> E. coli

<400> 57  
Met Asn Asn Phe Asn Leu His Thr Pro Thr Arg Ile Leu Phe Gly Lys  
1 5 10 15  
Gly Ala Ile Ala Gly Leu Arg Glu Gln Ile Pro His Asp Ala Arg Val  
20 25 30  
Leu Ile Thr Tyr Gly Gly Ser Val Lys Lys Thr Gly Val Leu Asp  
35 40 45  
Gln Val Leu Asp Ala Leu Lys Gly Met Asp Val Leu Glu Phe Gly Gly  
50 55 60  
Ile Glu Pro Asn Pro Ala Tyr Glu Thr Leu Met Asn Ala Val Lys Leu  
65 70 75 80  
Val Arg Glu Gln Lys Val Thr Phe Leu Leu Ala Val Gly Gly Ser  
85 90 95  
Val Leu Asp Gly Thr Lys Phe Ile Ala Ala Ala Asn Tyr Pro Glu  
100 105 110  
Asn Ile Asp Pro Trp His Ile Leu Gln Thr Gly Gly Lys Glu Ile Lys  
115 120 125  
Ser Ala Ile Pro Met Gly Cys Val Leu Thr Leu Pro Ala Thr Gly Ser  
130 135 140  
Glu Ser Asn Ala Gly Ala Val Ile Ser Arg Lys Thr Thr Gly Asp Lys  
145 150 155 160  
Gln Ala Phe His Ser Ala His Val Gln Pro Val Phe Ala Val Leu Asp  
165 170 175  
Pro Val Tyr Thr Tyr Thr Leu Pro Pro Arg Gln Val Ala Asn Gly Val  
180 185 190  
Val Asp Ala Phe Val His Thr Val Glu Gln Tyr Val Thr Lys Pro Val  
195 200 205  
Asp Ala Lys Ile Gln Asp Arg Phe Ala Glu Gly Ile Leu Leu Thr Leu  
210 215 220  
Ile Glu Asp Gly Pro Lys Ala Leu Lys Glu Pro Glu Asn Tyr Asp Val  
225 230 235 240  
Arg Ala Asn Val Met Trp Ala Ala Thr Gln Ala Leu Asn Gly Leu Ile  
245 250 255  
Gly Ala Gly Val Pro Gln Asp Trp Ala Thr His Met Leu Gly His Glu  
260 265 270  
Leu Thr Ala Met His Gly Leu Asp His Ala Gln Thr Leu Ala Ile Val  
275 280 285  
Leu Pro Ala Leu Trp Asn Glu Lys Arg Asp Thr Lys Arg Ala Lys Leu  
290 295 300  
Leu Gln Tyr Ala Glu Arg Val Trp Asn Ile Thr Glu Gly Ser Asp Asp  
305 310 315 320

Glu Arg Ile Asp Ala Ala Ile Ala Ala Thr Arg Asn Phe Phe Glu Gln  
325 330 335

Leu Gly Val Pro Thr His Leu Ser Asp Tyr Gly Leu Asp Gly Ser Ser  
340 345 350

Ile Pro Ala Leu Leu Lys Lys Leu Glu Glu His Gly Met Thr Gln Leu  
355 360 365

Gly Glu Asn His Asp Ile Thr Leu Asp Val Ser Arg Arg Ile Tyr Glu  
370 375 380

Ala Ala Arg  
385

<210> 58  
<211> 1164  
<212> DNA  
<213> *E. coli*

<210> 59  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Primer

<400> 59  
qcggtaccgt tgctcgacgc tcaggttttc gg 32

<210> 60  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Primer

<400> 60	
gcgagctcga cgcttgcctt gatcgagttt tgc	33
<210> 61	
<211> 33	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Primer	
<400> 61	
gcgagctcga cgcttgcctt gatcgagttt tgc	33
<210> 62	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Primer	
<400> 62	
cagctggcaa ttccgggtcg	20
<210> 63	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Primer	
<400> 63	
cccagctggc aattccggtt cgcttgctgt	30
<210> 64	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Primer	
<400> 64	
ggcgacccga cgctccagac ggaagctgg	30
<210> 65	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
?	
<220>	
<223> Description of Artificial Sequence:Primer	
<400> 65	
ccgcaagatt cacggatgca tcgtgaaggg	30

<210> 66  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Primer

<400> 66  
cgccttcttg acgagttctg agcggga 27

<210> 67  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Primer

<400> 67  
ggaattcatg aacaacttta atctgcacac 30

<210> 68  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Primer

<400> 68  
gtttgaggcg taaaaagctt agcgggcggc 30

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12833 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/52, 15/70, C12P 7/18, C12N 9/04, 1/21 // (C12N 1/21, C12R 1:19)

(US). HAYNIE, Sharon [US/US]; 529 Spruce Street, Philadelphia, PA 19106 (US). LAFFEND, Lisa [US/US]; 2 Mount Vernon Drive, Claymont, DE 19703 (US). PUCCI, Jeff [US/US]; 925 Page Mill Road, Palo Alto, CA 94303 (US). WHITED, Greg [US/US]; 304 South Road, Belmont, CA 94002 (US).

(21) International Application Number: PCT/US00/22874

(74) Agent: FLOYD, Linda, Axamethy; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(22) International Filing Date: 18 August 2000 (18.08.2000)

(81) Designated States (national): BR, CA, CN, ID, IN, JP, KR, MX, SG, US.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data:  
60/149,534 18 August 1999 (18.08.1999) US

(88) Date of publication of the international search report:  
30 August 2001


(71) Applicants (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94303 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EMPTAGE, Mark [US/US]; 2822 Landon Drive, Wilmington, DE 19810

[Continued on next page]

(54) Title: PROCESS FOR THE BIOLOGICAL PRODUCTION OF 1,3-PROPANEDIOL



A3

WO 01/12833

(57) Abstract: The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an *E. coli* transformed with the *Klebsiella pneumoniae* *dha* regulon genes *dhaR*, *orfY*, *dhaT*, *orfX*, *orfW*, *dhaB1*, *dhaB2*, *dhaB3*, and *orfZ*, all these genes arranged in the same genetic organization as found in wild type *Klebsiella pneumoniae*. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant *E. coli* containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (*dhaT*). The dramatically improved process relies on the presence in *E. Coli* of a gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol.

**WO 01/12833 A3**



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**INTERNATIONAL SEARCH REPORT**

Int. Application No PCT/US 00/22874
--

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>
IPC 7 C12N15/52 C12N15/70 C12P7/18 C12N9/04 C12N1/21 //(C12N1/21,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL, BIOSIS, CHEM ABS Data, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! Accession AE000383, 29 January 1997 (1997-01-29) BLATTNER F R ET AL: "Escherichia coli K-12 MG1655 section 273 of 400 of the complete genome." XP002162541 100% identity in a 1164 BP overlap between SEQ ID NO 58 (full length) and positions 5818-6981 of AE000383. The predicted amino acid sequences are identical.</p> <p style="text-align: center;">-/-</p>	1-6

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

9 March 2001

22/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lejeune, R

**INTERNATIONAL SEARCH REPORT**

International Application No	
PCT/US 00/22874	

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BOUVET O M M ET AL: "Taxonomic diversity of anaerobic glycerol dissimilation in the Enterobacteriaceae." RESEARCH IN MICROBIOLOGY, vol. 146, no. 4, 1995, pages 279-290, XP000982719 ISSN: 0923-2508 the whole document	
A	SKRALY F A ET AL: "Construction and characterization of a 1,3-propanediol operon" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, US, WASHINGTON, DC, vol. 64, no. 1, January 1998 (1998-01), pages 98-105, XP002134649 ISSN: 0099-2240 the whole document	
X	WO 98 21341 A (DIAZ TORRES MARIA ;CHASE MATTHEW W (US); GENENCOR INT (US); TRIMBU) 22 May 1998 (1998-05-22) cited in the application examples 1-10 figure 1	25
Y	WO 99 28480 A (DU PONT ;NAIR RAMESH V (US); GENECOR INT INC (US); PAYNE MARK S (U) 10 June 1999 (1999-06-10) cited in the application abstract	28
Y	WO 98 21339 A (DIAS TORRES MARIA ;HAYNIE SHARON LORETTA (US); HSU AMY KUANG HUA () 22 May 1998 (1998-05-22) cited in the application examples 1,2 page 23 page 27	28

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Int'l. Jonal Application No

PCT/US 00/22874

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9821341	A 22-05-1998	AU	5248498 A	03-06-1998
		AU	5507698 A	03-06-1998
		BR	9712761 A	26-10-1999
		CN	1239511 A	22-12-1999
		CN	1244217 A	09-02-2000
		EP	0942989 A	22-09-1999
		EP	0946732 A	06-10-1999
		WO	9821339 A	22-05-1998
		US	6013494 A	11-01-2000
		US	6136576 A	24-10-2000
		ZA	9710194 A	12-05-1999
-----	-----	-----	-----	-----
WO 9928480	A 10-06-1999	AU	1619199 A	16-06-1999
		BR	9815361 A	21-11-2000
		CN	1284132 T	14-02-2001
		EP	1034278 A	13-09-2000
-----	-----	-----	-----	-----
WO 9821339	A 22-05-1998	AU	5248498 A	03-06-1998
		AU	5507698 A	03-06-1998
		BR	9712761 A	26-10-1999
		CN	1239511 A	22-12-1999
		CN	1244217 A	09-02-2000
		EP	0942989 A	22-09-1999
		EP	0946732 A	06-10-1999
		WO	9821341 A	22-05-1998
		US	6013494 A	11-01-2000
		US	6136576 A	24-10-2000
		ZA	9710194 A	12-05-1999
-----	-----	-----	-----	-----